0001615774-16-008049.txt : 20161104 0001615774-16-008049.hdr.sgml : 20161104 20161104172838 ACCESSION NUMBER: 0001615774-16-008049 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161104 DATE AS OF CHANGE: 20161104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SECOND SIGHT MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0001266806 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 000000000 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36747 FILM NUMBER: 161976075 BUSINESS ADDRESS: STREET 1: 12744 SAN FERNANDO ROAD, BLDG. 3 CITY: SYLMAR STATE: CA ZIP: 91342 BUSINESS PHONE: 818-833-5000 MAIL ADDRESS: STREET 1: 12744 SAN FERNANDO ROAD, BLDG. 3 CITY: SYLMAR STATE: CA ZIP: 91342 10-Q 1 s104460_10q.htm 10-Q

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

OR 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

 

Commission File Number 333-198073 

Second Sight Medical Products, Inc.

(Exact name of Registrant as specified in its charter)

  

California   02-0692322
(State or other jurisdiction of
incorporation or organization)
 

(I.R.S. Employer Identification No.)

 

 

12744 San Fernando Road, Suite 400, Sylmar, CA 91342
(Address of principal executive offices, including zip code)

 

(818) 833-5000
(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨   Accelerated filer x
Non-accelerated filer ¨ (Do not check if a smaller reporting company)  Smaller reporting company ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).      Yes ¨ No x

 

As of November 2, 2016, the issuer had 42,246,954 shares of common stock issued and outstanding.

 

 

 

 

 

 

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

 

INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

PART I FINANCIAL INFORMATION  
     
Item 1. Financial Statements  
     
  Condensed Consolidated Balance Sheets as of September 30, 2016 (Unaudited) and December 31, 2015 3
  Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and 2015 (Unaudited) 4
  Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2016 and 2015 (Unaudited) 5
  Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and 2015 (Unaudited) 6
  Notes to Condensed Consolidated Financial Statements (Unaudited) 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 25
     
Item 4. Controls and Procedures 25
     
PART II OTHER INFORMATION  
     
Item 1. Legal Proceedings 26
     
Item 1A. Risk Factors 27
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29
     
Item 3. Defaults Upon Senior Securities 29
     
Item 4. Mine Safety Disclosures 29
     
Item 5. Other Information 29
     
Item 6. Exhibits 29
     
SIGNATURES 30

 

 2 

 

 

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

 

Condensed Consolidated Balance Sheets

(In thousands)

 

   September 30,   December 31, 
   2016   2015 
   (Unaudited)     
ASSETS          
Current assets:          
Cash  $277   $239 
Money market funds   17,546    15,721 
Accounts receivable, net   447    1,501 
Inventories, net   5,810    8,209 
Prepaid expenses and other current assets   603    1,094 
Total current assets   24,683    26,764 
           
Property and equipment, net   1,527    1,432 
Deposits and other assets   55    49 
Total assets  $26,265   $28,245 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current liabilities:          
Accounts payable  $694   $710 
Accrued expenses   1,711    2,068 
Accrued compensation expenses   2,055    2,069 
Accrued clinical trial expenses   555    616 
Deferred revenue   195    322 
Deferred grant revenue   456    2,197 
Total current liabilities   5,666    7,982 
           
Commitments and contingencies          
           
Stockholders' equity:          
Preferred stock, no par value, 10,000 shares authorized; none outstanding   -    - 
Common stock, no par value, 200,000 shares authorized; shares issued and outstanding: 42,247 and 35,942 at September 30, 2016 and December 31, 2015, respectively   186,618    166,049 
Common stock to be issued   87    205 
Additional paid-in capital   29,911    27,277 
Notes receivable to finance stock option exercises   (2)   (5)
Accumulated other comprehensive loss   (524)   (581)
Accumulated deficit   (195,491)   (172,682)
Total stockholders' equity   20,599    20,263 
           
Total liabilities and stockholders' equity  $26,265   $28,245 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 3 

 

 

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

 

Condensed Consolidated Statements of Operations (unaudited)

(In thousands, except per share data)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2016   2015   2016   2015 
         
Net sales  $1,180   $2,227   $3,270   $6,588 
Cost of sales   2,615    757    6,768    3,622 
Gross profit (loss)   (1,435)   1,470    (3,498)   2,966 
                     
Operating expenses:                    
Research and development, net of grants   1,588    593    3,266    2,490 
Clinical and regulatory   609    984    1,955    2,543 
Selling and marketing   2,262    2,132    6,473    6,425 
General and administrative   2,605    2,423    7,635    6,079 
Total operating expenses   7,064    6,132    19,329    17,537 
                     
Loss from operations   (8,499)   (4,662)   (22,827)   (14,571)
                     
Interest income   11    -    19    1 
Other income (expense), net   (1)   (4)   (1)   25 
                     
Net loss  $(8,489)  $(4,666)  $(22,809)  $(14,545)
                     
Net loss per common share - basic and diluted  $(0.20)  $(0.13)  $(0.57)  $(0.41)
                     
Weighted average common shares outstanding - basic and diluted   42,220    35,836    39,929    35,555 

 

The accompanying notes are an integral part of these condensed consolidated financial statements 

 

 4 

 

 

 

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

 

Condensed Consolidated Statements of Comprehensive Loss (unaudited)

 

   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2016   2015   2016   2015 
         
Net loss  $(8,489)  $(4,666)  $(22,809)  $(14,545)
                     
Other comprehensive income (loss):                    
Foreign currency translation adjustments   34    (70)   57    (72)
Comprehensive loss  $(8,455)  $(4,736)  $(22,752)  $(14,617)

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

 5 

 

 

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

 

Condensed Consolidated Statements of Cash Flows (unaudited)

 (In thousands)

 

   Nine Months Ended 
   September 30, 
   2016   2015 
     
Cash flows from operating activities:          
Net loss  $(22,809)  $(14,545)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization of property and equipment   311    231 
Stock-based compensation   2,581    1,918 
Bad debt expense   191    - 
Excess inventory reserve   2,611    - 
Common stock issuable for services   206    233 
Changes in operating assets and liabilities:          
Accounts receivable   874    (600)
Inventories   (166)   (2,416)
Prepaid expenses and other assets   492    195 
Accounts payable   (16)   31 
Accrued expenses   (377)   469 
Accrued compensation expenses   (15)   888 
Accrued clinical trial expenses   (61)   68 
Deferred revenue   (135)   184 
Deferred grant revenue   (1,741)   (1,308)
Net cash used in operating activities   (18,054)   (14,652)
           
Cash flows from investing activities:          
Purchases of property and equipment   (406)   (578)
(Investment) proceeds from money market funds   (1,820)   12,599 
Net cash provided by (used) in investing activities   (2,226)   12,021 
           
Cash flows from financing activities:          
Net proceeds from rights offering   19,483    - 
Proceeds from the exercise of options, warrants and employee stock purchase plan options   816    2,476 
Payment of employment taxes related to stock option exercises   -    (124)
Net cash provided by financing activities   20,299    2,352 
           
Effect of exchange rate changes on cash   19    (72)
Cash:          
Net increase (decrease)   38    (351)
Balance at beginning of period   239    619 
Balance at end of period  $277   $268 
           
Supplemental cash flow information:          
Non-cash financing and investing activities:          
Fair value of stock options issued for services rendered in connection with rights offering  $53   $- 

 

The accompanying notes are integral part of these condensed consolidated financial statements.

 

 6 

 

 

SECOND SIGHT MEDICAL PRODUCTS, INC.

AND SUBSIDIARY

Notes to Condensed Consolidated Financial Statements (unaudited)

 

Three Months and Nine Months Ended September 30, 2016 and 2015

 

1.  Organization and Business Operations

 

Second Sight Medical Products, Inc. (“Second Sight” or “the Company”), was founded in 1998 as a limited liability company and was subsequently incorporated in the State of California in 2003. Second Sight develops, manufactures and markets implantable prosthetic devices that can restore some functional vision to patients blinded by outer retinal degenerations, such as Retinitis Pigmentosa. 

 

In 2007, Second Sight formed Second Sight (Switzerland) Sarl, initially to manage clinical trials for its products in Europe, and later to manage sales and marketing in Europe and the Middle East. As the laws of Switzerland require at least two corporate stockholders, Second Sight (Switzerland) Sarl is 99.5% owned directly by the Company and 0.5% owned by an executive of Second Sight, who is acting as a nominee of the Company. Accordingly, Second Sight (Switzerland) Sarl is considered 100% owned for financial statement purposes and is consolidated with Second Sight for all periods presented.

 

Since its inception, the Company has generated limited revenues from the sale of products and has financed its operations primarily through the issuance of common stock, convertible debt (which has been converted into common stock), and grants primarily from government agencies.

 

The Company’s financial statements have been presented on the basis that its business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is subject to the risks and uncertainties associated with a business with one product line and limited commercial product revenues, including limitations on the Company’s operating capital resources and uncertain demand for its products. The Company has incurred recurring operating losses and negative operating cash flows since inception, and it expects to continue to incur operating losses and negative operating cash flows for at least the next few years. The Company’s independent registered public accounting firm, in its report on the Company’s 2015 consolidated financial statements, raised substantial doubt about the Company’s ability to continue as a going concern.

 

In June 2016, the Company successfully completed a Rights Offering to existing stockholders, raising proceeds of $19.5 million net of cash offering costs, and selling 5,978,465 shares of common stock at $3.315 per share, representing 85% of the Company’s stock price at the close of the rights offering. The Company believes that it has sufficient funds to last through the end of the second quarter of 2017. In order to continue business operations past that point, the Company currently anticipates that it will need to raise additional debt and/or equity capital during the next several months. However, there can be no assurances that the Company will be able to secure any such additional financing on acceptable terms and conditions, or at all. If cash resources become insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale back or discontinue its technology and product development programs and/or clinical trials, or obtain funds, if available (although there can be no certainty), through strategic alliances that may require the Company to relinquish rights to its products, or to discontinue its operations entirely.

 

2.   Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for Form 10-Q. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2015 has been derived from the Company’s audited consolidated financial statements.

 

 7 

 

 

In the opinion of management, these financial statements reflect all normal recurring and other adjustments necessary for a fair presentation. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year or any other future periods.

 

Significant Accounting Policies

 

The Company’s significant accounting policies are set forth in Note 2 of the financial statements in its Annual Report on Form 10-K for the year ended December 31, 2015.

 

Recent Accounting Pronouncements

 

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230), which updates the guidance as to how certain cash receipts and cash payments should be presented and classified. The update is intended to reduce the existing diversity in practice. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted, including adoption in an interim period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires measurement and recognition of expected versus incurred credit losses for financial assets held. ASU 2016-13 is effective for the Company in the first quarter of fiscal 2020 with early adoption permitted beginning in the first quarter of fiscal 2019. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.

 

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), a new standard that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. The standard also allows the Company to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting, clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on the cash flow statement, and provides an accounting policy election to account for forfeitures as they occur. The new standard is effective for the annual periods beginning after December 15, 2016, and interim periods within those annual periods with early adoption permitted. The Company is currently evaluating the impact of the standard on the Company’s financial statements.

 

Management does not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

 

3. Concentration of Risk

 

Credit Risk

 

Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash, money market funds, and trade accounts receivable. The Company maintains cash and money market funds with financial institutions that management deems reputable, and at times, cash balances may be in excess of Federal Deposit Insurance Corporation and Securities Investor Protection Corporation insurance limits. The Company extends differing levels of credit to customers, and typically does not require collateral.

 

The Company also maintains a cash balance at a bank in Switzerland, which is insured up to an amount specified by the deposit insurance agency of Switzerland.

 

 8 

 

 

Customer Concentration

 

During the three and nine months ended September 30, 2016 and 2015 (unaudited), the following customers comprised more than 10% of revenues:

 

   Three Months   Three Months   Nine Months   Nine Months 
   Ended   Ended   Ended   Ended 
   September 30, 2016   September 30, 2015   September 30, 2016   September 30, 2015 
                 
Customer 1   21%   0%   8%   1%
Customer 2   12%   6%   3%   2%
Customer 3   11%   12%   16%   15%
Customer 4   7%   13%   5%   8%
Customer 5   0%   13%   3%   10%
Customer 6   0%   0%   10%   1%

 

As of September 30, 2016 and December 31, 2015, the following customers comprised more than 10% of accounts receivable:

 

   September 30,   December31, 
   2016   2015 
   (unaudited)     
Customer 1   37%   0%
Customer 2   29%   17%
Customer 3   21%   0%
Customer 4   15%   3%
Customer 5   0%   19%
Customer 6   0%   10%
Customer 7   0%   10%
Customer 8   0%   10%

 

Geographic Concentration

 

During the three and nine months ended September 30, 2016 and 2015 (unaudited), regional revenue, based on customer location, consisted of the following:

 

   Three Months   Three Months   Nine Months   Nine Months 
   Ended   Ended   Ended   Ended 
   September 30, 2016   September 30, 2015   September 30, 2016   September 30, 2015 
                 
United States   47%   56%   47%   46%
Germany   35%   4%   15%   5%
Italy   11%   12%   21%   20%
France   7%   11%   8%   18%
Canada   0%   13%   3%   6%
Turkey   0%   4%   5%   3%

 

 9 

 

 

Sources of Supply

 

Several of the components, materials and services used in the Company’s current Argus II product are available from only one supplier, and substitutes for these items cannot be obtained easily or would require substantial design or manufacturing modifications. Any significant problem experienced by one of the Company’s sole source suppliers could result in a delay or interruption in the supply of components to the Company until that supplier cures the problem or an alternative source of the component is located and qualified. Even where the Company could qualify alternative suppliers, the substitution of suppliers may be at a higher cost and create time delays that impede the commercial production of the Argus II and impact the Company’s abilities to deliver its products as may be timely required to meet demand.

 

Foreign Operations

 

The accompanying condensed consolidated financial statements as of September 30, 2016 (unaudited) and December 31, 2015 include assets amounting to $2,228,000 and $3,041,000, respectively, relating to operations of the Company’s subsidiary based in Switzerland. It is possible that unanticipated events in foreign countries could disrupt the Company’s operations.

  

4. Money Market Funds

 

The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.

 

Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.

 

Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.

 

Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.

 

Money market funds are the only financial instrument measured and recorded at fair value on the Company’s balance sheet, and they are considered Level 1 valuation securities. The following table presents money market funds at their level within the fair value hierarchy at September 30, 2016 and December 31, 2015 (in thousands):

  

   Total   Level 1   Level 2   Level 3 
                 
September 30, 2016 (unaudited):                    
Money market funds  $17,546   $17,546   $   $ 
                     
December 31, 2015:                    
Money market funds  $15,721   $15,721   $   $ 

 

 10 

 

 

5.  Selected Balance Sheet Detail

 

Inventories, net

 

Inventories consisted of the following at (in thousands):

 

   September 30,   December 31, 
   2016   2015 
   (unaudited)     
Raw materials  $470   $575 
Work in process   4,920    5,028 
Finished goods   3,499    3,156 
           
    8,889    8,759 
           
Allowance for excess and obsolescence   (3,079)   (550)
Inventories, net  $5,810   $8,209 

 

Property and equipment, net of accumulated depreciation and amortization

 

Property and equipment consisted of the following at (in thousands):

 

   September 30,   December 31, 
   2016   2015 
   (unaudited)     
Laboratory equipment  $3,594   $3,369 
Computer hardware and software   2,117    1,960 
Leasehold improvements   533    508 
Furniture, fixtures and equipment   135    135 
           
    6,379    5,972 
Accumulated depreciation and amortization   (4,852)   (4,540)
           
Property and equipment, net  $1,527   $1,432 

 

6. Long Term Investor Right

  

Investors who purchased shares in the Company’s IPO, and who complied with certain terms and conditions, such as holding their IPO shares in their name during the twenty-four month period following the closing of the IPO, are entitled under certain conditions to receive up to one additional share for each share they purchased in the IPO. For a more complete discussion of the Long Term Investor Right, see Note 2 in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

 

As of September 30, 2016, the Company identified investors who had perfected and maintained Long Term Investor Rights in 1,181,927 shares of common stock that were acquired as part of the Company’s IPO. The highest average closing price for the Company’s common stock on NASDAQ during any consecutive 90 day period ended on or before September 30, 2016 was $13.96. Based on this average closing stock price, an investor who purchased shares as part of the IPO, and who has perfected its Long Term Investor Right, would be entitled to 0.2894 shares for each share purchased in the IPO, rounded up to the next whole share, which represents an aggregate maximum of 342,089 shares that are potentially issuable by the Company pursuant to the Long Term Investor Right at that date. The actual number of common shares issuable pursuant to the Long Term Investor Right is dependent on the future stock price of the Company over the two year period subsequent to the November 24, 2014 closing date of the IPO, and could be as high as 342,089 shares and as low as zero shares.

 

 11 

 

 

The Long Term Investor Right is an equity instrument that will be accounted for as a component of the actual price per common share paid by the investor in the IPO. For basic earnings per share, the common shares associated with the Long Term Investor Right are treated as contingently issuable shares and are not being included in basic earnings per share until the actual number of shares can be calculated and the shares have been issued.

 

7. Equity Securities

 

Common Stock Issuable

 

Beginning with services rendered in 2014, and with payments in June 2015 and 2016, non-employee members of the Board of Directors are paid for their services in common stock on June 1 of each year based on the average closing prices for the immediately preceding twenty trading days. As of September 30, 2016, the Company accrued $87,000 for these services, which equates to 26,274 shares. These shares have not yet been issued and are excluded from the calculation of weighted average common shares outstanding for EPS purposes.

  

Potentially Dilutive Common Stock Equivalents

 

At September 30, 2016 and 2015 (unaudited), the Company excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately acquire shares of common stock, from its calculations of earnings per share and weighted average shares outstanding, as their effect would have been anti-dilutive (in thousands).

 

   September 30,   September 30, 
   2016   2015 
         
Long Term Investor Rights   342    412 
Underwriter’s warrants   802    802 
Warrants associated with convertible debt   1,038    1,038 
Common stock options   3,669    3,505 
Restricted stock units   142    190 
Employee stock purchase plan   109    75 
           
Total   6,102    6,022 

 

Rights Offering

 

In June 2016, the Company completed a Rights Offering to existing stockholders by selling 5,978,465 shares of common stock. The Company evaluated the financial impact of FASB ASC 260, "Earnings per Share," which states, among other things, that if a rights issue is offered to all existing stockholders at an exercise price that is less than the fair value of the stock, then the weighted average shares outstanding and basic and diluted earnings per share shall be adjusted retroactively to reflect the bonus element of the rights offering for all periods presented. The Company determined that the application of this specific provision of ASC 260 was immaterial to previously issued financial statements and, therefore, did not retroactively adjust previously reported weighted average shares outstanding and basic and diluted earnings per share.

 

8. Warrants

 

A summary of warrant activity for the nine months ended September 30, 2016 (unaudited) is presented below (in thousands, except per share and contractual life data).

 

           Weighted Average 
       Weighted   Remaining 
   Number of   Average   Contractual 
   Shares   Exercise Price   Life (in Years) 
Warrants outstanding at December 31, 2015   1,840   $7.72    2.80 
Granted              
Exercised              
Forfeited or expired              
                
Warrants outstanding at September 30, 2016   1,840   $7.72    2.06 
                
Warrants exercisable at September 30, 2016   1,840   $7.72    2.06 

 

 12 

 

 

The intrinsic value of warrants outstanding at September 30, 2016 was $0. During the nine months ended September 30, 2016, no warrants were exercised.

 

9. Stock-Based Compensation

 

On May 10, 2016, the stockholders approved amendments to the Company’s 2011 Equity Incentive Plan that (i) increase the maximum number of shares of common stock that may be issued under the Plan from 6.0 million shares to 7.5 million shares, (ii) allow issuance of Restricted Stock Units, and (iii) permit repricing and exchanges of options at the discretion of the Board of Directors.

 

Under the 2003 Plan, as restated in June 2011, the Company was authorized to issue options covering up to 3,500,000 common stock shares. Effective June 1, 2011, the Company adopted the 2011 Equity Incentive Plan (the “2011 Plan”). The maximum number of shares with respect to which options may be granted under the 2011 Plan is 7,500,000 shares, which is offset and reduced by options previously granted under the 2003 Plan. The option price is determined by the Board of Directors but cannot be less than the fair value of the shares at the grant date. Generally, the options vest ratably over either four or five years and expire ten years from the grant date. Both plans provide for accelerated vesting if there is a change of control, as defined in the plans.

 

A summary of stock option activity for the nine months ended September 30, 2016 (unaudited) is presented below (in thousands, except per share and contractual life data).

   

           Weighted Average 
       Weighted   Remaining 
   Number of   Average   Contractual 
   Shares   Exercise Price   Life (in Years) 
Options outstanding at December 31, 2015   3,472   $8.01    6.39 
Granted   690   $4.33      
Exercised   (96)  $5.00      
Forfeited or expired   (397)  $9.03      
                
Options outstanding at September 30, 2016   3,669   $7.28    6.45 
                
Options exercisable at September 30, 2016   1,934   $6.54    4.40 

  

The estimated aggregate intrinsic value of stock options exercisable at September 30, 2016 was $0. As of September 30, 2016, there was $6.9 million of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted average period of 2.84 years.

 

On January 1, 2015, the Company’s current Chairman, who at the time was the Chief Executive Officer, exercised stock options on a cashless basis to purchase 59,063 shares of common stock at an exercise price of $4.75 per share. Based on the closing market price of the Company’s common stock of $10.26 on December 31, 2014, the Chief Executive Officer tendered 27,344 shares of common stock that he owned to satisfy the aggregate exercise price and surrendered 12,055 shares of common stock to satisfy the related $123,684 income and payroll tax withholding amounts related to the transaction.

 

During the nine months ended September 30, 2016, the Company granted stock options to purchase 659,973 shares of common stock to certain employees and contractors. The options are exercisable for a period of ten years from the date of grant at prices ranging from $3.44 to $5.16 per share, which was the fair value of the Company’s common stock on the respective grant dates. The options vest over a period of four years. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $1,350,000 ($1.64 to $2.47 per share). Assumptions used in the model were an expected term of 6.25 years, volatility of 48.2%, a risk-free interest rate of 1.40% to 1.87%, and an expected dividend rate of 0%.  During the nine months ended September 30, 2016, the Company issued 95,493 shares of common stock through exercises of stock options that resulted in net proceeds of $479,000.

 

During the nine months ended September 30, 2016, the Company granted stock options to purchase 30,000 shares of common stock to an outside attorney in connection with his services relating to the Company’s rights offering to stockholders. The options have fully vested and are exercisable for a period of four years from the date of grant at a price of $5.23 per share, which was 125% of the fair value of the Company’s common stock on the grant date of January 14, 2016. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $53,000 ($1.77 per share). Assumptions used in the model were an expected term of 6.25 years, volatility of 48.2%, a risk-free interest rate of 1.87%, and an expected dividend rate of 0%.  The cost of these shares was treated as an issuance cost of the offering and was deducted from the gross proceeds from the offering.

 

 13 

 

 

During the first quarter of 2016, the Company recorded a charge of $55,000 to extend the exercise period of 98,681 vested options for one employee who resigned and became a consultant for the Company. All unvested options for this employee were terminated when this employee ceased full-time employment with the Company.

 

The following table summarizes Restricted Stock Unit (RSU) activity for the nine months ended September 30, 2016 (in thousands, except per share data):

 

       Weighted 
       Average Grant 
   Number   Date Fair Value 
   of Awards   Per Share 
         
Outstanding as of December 31, 2015   190   $12.43 
Awarded   -    - 
Vested   (48)   - 
Forfeited/canceled   -    - 
Outstanding as of September 30, 2016   142   $12.43 

 

As of September 30, 2016, there was $1,699,000 of total unrecognized compensation cost related to the outstanding RSUs that will be recognized over a weighted average period of 2.88 years.

 

On August 18, 2016, of the 190,000 RSUs held by the Company’s Chief Executive Officer, 47,500 RSUs vested at a market price of $3.76 per share.

 

The Company adopted an employee stock purchase plan (“ESPP”) starting in June 2015 for all eligible employees. Under the ESPP, shares of the Company's common stock may be purchased at six-month intervals at 85% of the lower of the closing fair market value of the common stock (i) on the first trading day of the offering period or (ii) on the last trading day of the purchase period. An employee may purchase in any one calendar year shares of common stock having an aggregate fair market value of up to $25,000 determined as of the first trading day of the offering period. Additionally, a participating employee may not purchase more than 100,000 shares of common stock in any one offering period. At September 30, 2016, 154,225 shares had been issued under the plan. Proceeds from the purchase of stock under the plan totaled $337,000 for the nine months ended September 30, 2016.

 

The total stock-based compensation recognized for stock-based awards granted under the 2003 Plan and the 2011 Plan in the condensed consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015 (unaudited) is as follows (in thousands):

 

 14 

 

 

   Three Months   Three Months   Nine Months   Nine Months 
   Ended   Ended   Ended   Ended 
   September 30, 2016   September 30, 2015   September 30, 2016   September 30, 2015 
Cost of sales  $80   $103   $245   $265 
Research and development   77    99    238    217 
Clinical and regulatory   43    84    136    206 
Selling and marketing   74    127    59    312 
General and administrative   624    443    1,903    918 
Total  $898   $856   $2,581   $1,918 

 

10.  Litigation, Claims and Assessments

 

Fifteen oppositions have been filed by a third-party in the European Patent Office, each challenging the validity of a European patent owned or exclusively licensed by the Company. The outcome of the challenges is not certain, however, if successful, they may affect the Company's ability to block competitors from utilizing some of its patented technology in Europe. Management of the Company does not believe any successful challenges will have a material effect on the Company’s ability to manufacture and sell its products, or otherwise have a material effect on its operations.

 

The Company is party to litigation arising in the ordinary course of business. It is management's opinion that the outcome of such matters will not have a material effect on the Company's financial statements.

 

 15 

 

 

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q as well as our audited 2015 financial statements and related notes included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on March 11, 2016 and as amended in a filing with the Commission on August 8, 2016. In addition to historical information, the discussion and analysis here and throughout this Form 10-Q contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited, to those set forth under “Risk Factors” in Part II, Item 1A of this report.

 

Second Sight was founded in 1998 with a mission to develop, manufacture, and market prosthetic devices that restore some useful vision to blind individuals. Our principal offices are located in Sylmar, California, approximately 25 miles northwest of downtown Los Angeles. We also have an office in Lausanne, Switzerland, that manages our commercial and clinical operations in Europe and the Middle East.

 

Our current product, the Argus® II System, treats outer retinal degenerations, such as retinitis pigmentosa, which we refer to as RP. RP is a hereditary disease, affecting an estimated 1.5 million people worldwide including about 100,000 people in the United States, that causes a progressive degeneration of the light-sensitive cells of the retina, leading to significant visual impairment and ultimately to blindness. The Argus II System is the only retinal prosthesis approved in the United States by the Food and Drug Administration (FDA), and was the first approved retinal prosthesis in the world. By restoring some useful vision in patients who otherwise have total sight loss, the Argus II System can provide benefits which include:

 

·improving patients’ orientation and mobility, such as locating doors and windows, avoiding obstacles, and following the lines of a crosswalk,
·allowing patients to feel more connected with people in their surroundings, such as seeing when someone is approaching or moving away,
·providing patients with enjoyment from being “visual” again, such as locating the moon, tracking groups of players as they move around a field, and watching the moving streams of lights from fireworks, and
·improving patients’ well-being and ability to perform activities of daily living.

 

The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. Results vary among patients and while the majority of patients receive a significant benefit from the Argus II, some patients report receiving little or no benefit.

 

Our major corporate, clinical and regulatory milestones include:

 

·In 1998, Second Sight was founded.
·In 2002, we commenced clinical trials in the US for our prototype product, the Argus I retinal prosthesis.
·In 2007, we commenced clinical trials in the US for the Argus II System, which later became our first commercial product.
·In 2011, we received marketing approval in Europe (CE Mark) for the Argus II System.
·In 2013, we received marketing approval in the United States (FDA) for the Argus II System.
·In 2014, we launched the Argus II in the US, completed our initial public offering (“IPO”), and began trading on NASDAQ under the symbol “EYES.”
·In 2015, we commenced a clinical trial in the UK for an expanded indication for the Argus II System in individuals with dry AMD.

 

 16 

 

 

We began selling the Argus II System in Europe at the end of 2011, Saudi Arabia in 2012, the United States and Canada in 2014, and Turkey in 2015. We have full regulatory approval to sell in these regions. We sell primarily through our direct sales force, but use distributors in Saudi Arabia, Spain and Turkey. We recently signed distribution agreements in Argentina, Iran and Taiwan. We are at various stages of discussions with a number of other distributors for other countries outside of the U.S.

  

Going Concern

 

From inception, our operations have been funded primarily through the sales of our common stock, as well as from the issuance of convertible debt, research and clinical grants, and product revenue generated by the sale of our Argus II System. During the years ended December 31, 2015 and 2014 and the nine months ended September 30, 2016, we funded our business primarily through:

 

·Revenue of $3.3 million in the first nine months of 2016, and $8.9 million and $3.4 million in 2015 and 2014, respectively, generated by sales of our Argus II System,
·A $4.1 million grant under Joint Research and Development Agreement with The Johns Hopkins University Applied Physics Laboratory in 2014,
·Issuance of common stock in private placements aggregating $9.1 million in 2014,
·Issuance of common stock in our initial public offering in November 2014, which generated net proceeds of $34.2 million of cash after offering expenses, and
·Issuance of common stock in our Rights Offering in June 2016, which generated net proceeds of $19.5 million of cash after offering expenses.

 

Our financial statements have been presented on the basis that our business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We are subject to the risks and uncertainties associated with a business with one product line and limited commercial product revenues, including limitations on our operating capital resources and uncertain demand for our products. We have incurred operating losses and negative operating cash flows since inception, and we expect to continue to incur operating losses and negative operating cash flows for at least the next few years. The Company’s independent registered public accounting firm, in its report on the Company’s 2015 consolidated financial statements, raised substantial doubt about the Company’s ability to continue as a going concern.

 

In June 2016, the Company successfully completed a Rights Offering to existing stockholders, raising proceeds of $19.5 million net of cash offering costs, and selling 5,978,465 shares of common stock at $3.315 per share, representing 85% of the Company’s stock price at the close of the rights offering. The Company believes that it has sufficient funds to last through the end of the second quarter of 2017. In order to continue business operations past that point, the Company currently anticipates that it will need to raise additional debt and/or equity capital during the next several months. However, there can be no assurances that the Company will be able to secure any such additional financing on acceptable terms and conditions, or at all. If cash resources become insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale back or discontinue its technology and product development programs and/or clinical trials, or obtain funds, if available (although there can be no certainty), through strategic alliances that may require the Company to relinquish rights to its products, or to discontinue its operations entirely.

 

Insurance Reimbursement

 

Obtaining reimbursement from governmental and private insurance companies is critical to our future commercial success. Due to the cost of the Argus II System, our sales would be limited without the availability of third party reimbursement.

 

In the U.S., coding, coverage, and payment are necessary for the surgical procedure and Argus II system to be reimbursed by payers. Coding has been established for the device and the surgical procedure. Coverage and payment vary by payer. Argus II patients are eligible for Medicare, and coverage is primarily provided through traditional Medicare Fee-for-Service (FFS) or Medicare Advantage. A small percentage of U.S. patients are covered by commercial insurers.

 

 17 

 

 

·Medicare FFS patients – Coverage is determined by Medicare Administrative Contractors (MACs) that administer various geographic regions of the US. As of September 30, 2016, five of 12 MACs (who collectively cover 17 states, Puerto Rico and U.S. Virgin Islands) have made positive coverage decisions for the Argus II. For calendar 2016, the Centers for Medicare & Medicaid Services (CMS) established a hospital outpatient payment rate of $95,000 for both the procedure and the Argus II Retinal Prosthesis System. On November 1, 2016, CMS finalized the calendar 2017 Medicare hospital outpatient payment rate of $150,000 for the Argus II and the associated surgical implantation procedure. Prior to 2016, the Argus II was classified as having pass-through payment status and the device was paid separately from the procedure.
·Medicare Advantage patients – Medicare Advantage plans are required to cover the same benefits as those covered by the MAC in that jurisdiction. For example, if a MAC in a jurisdiction has favorable coverage for the Argus II, then all Medicare Advantage plans in that MAC jurisdiction are required to offer the same coverage for the Argus II. Individual hospitals and Ambulatory Surgery Centers (ASCs) may negotiate Medicare Advantage contracts specific to that individual facility, which may include additional separate payment for the Argus II implant system. In addition, procedural payment is variable and can be based on a percentage of billed charges, payment groupings or other individually negotiated payment methodologies. Medicare Advantage plans also allow providers to confirm coverage and payment for the Argus II procedure in advance of implantation.
·Commercially insured patients – Commercial insurance plans make coverage and payment rate decisions independent of Medicare decisions and contracts are individually negotiated with facility and physician providers.

  

For the third quarter of 2016, four individuals in the US received and were implanted with the Argus II technology, all of whom were Medicare FFS patients.

 

The Agency for Healthcare Research and Quality, or AHRQ, which is an agency of the Department of Health and Human Services, is conducting a Technology Assessment that will provide an overview of retinal prosthesis systems (RPSs). On May 18, 2016, AHRQ published a draft of its assessment entitled, Retinal Prostheses in the Medicare Population. This assessment evaluated all retinal prosthesis systems and examined the availability of evidence for each. The draft concluded that the strength of the evidence was insufficient to estimate the proportion of patients who will benefit from an RPS. It is important to note that the literature review combined all retinal prosthesis systems, whether in concept phase or in development, and came to a single conclusion about the strength of the evidence as noted in this draft assessment. Comments have been submitted by various stakeholders, including Second Sight, and it is anticipated that the AHRQ technology assessment final report will be published in the next few months. A description of the draft Health Technology Assessment can be found at http://www.ahrq.gov/sites/default/files/wysiwyg/research/findings/ta/retinalprostheses/eye1215-retinal-prosthesis-draft-report.pdf. No assurance can be given as to what impact, if any, this report may have on us.

 

Based on a review of three-year clinical data, in June 2016 the Ontario Health Technology Committee (OHTAC) recommended that Health Quality Ontario (HQO) should not publicly fund the Argus II. HQO is the agency mandated to advise government and health care providers on evidence to support healthcare solutions in Ontario, Canada. OHTAC recommended that HQO review the evidence for retinal prosthesis systems in one year to re-evaluate the clinical effectiveness. To date, all Argus II implants in Canada have been privately funded.

 

Within Europe, we have obtained reimbursement approval in Germany, France and parts of Italy. We also are seeking reimbursement approval in other countries including the United Kingdom, Belgium, Switzerland and Turkey.

 

In France, Second Sight was selected to receive the first "Forfait Innovation" (Innovation Bundle) from the Ministry of Health, which is a special funding program for breakthrough procedures to be introduced into clinical practice. As part of this program, Second Sight is conducting a post-market study in France which will enroll a total of 18 subjects and follow them for two years.  The French program will fund implantation of up to 18 additional patients that will not be part of the post-market study. After review of the study’s results, we expect Argus II therapy to be covered and funded through the standard payment system in France, however, we can provide no assurance that the French government will continue to fund the Argus II after the first 36 implants.

 

 18 

 

 

To date, we have not faced traditional sales challenges in any of our markets, largely due to the currently unmet clinical need and the lack of any other commercially available device or competitive treatment for RP-caused profound blindness. However, we believe that recently we may have lost commercial implant opportunities in France and Germany due to patients electing to wait or to participate in clinical trials for new products from other manufacturers that are seeking regulatory approval or reimbursement. We have faced what we believe are unfair and illegal marketing practices by our competitors and certain European courts have granted us six preliminary injunctions against two European companies. As these competitive implant technologies expand their clinical trials, or gain regulatory approval, gain national reimbursement and gain market acceptance, they may have or cause an adverse impact on our business in several European countries. Currently, we are not aware of any existing clinical trials by possible competitors in the U.S. market.

  

Our marketing activities continue to focus on raising awareness of the Argus II System with potential patients, implanting physicians, and referring physicians. We believe we are differentiating our product by highlighting the Argus II’s unmatched durability in long term trials, the large number of centers performing implants, the relative availability of reimbursement, and the fact that over 200 Argus II units have been implanted, making it by far the most performed solution among those available. Our marketing activities include exhibiting, sponsoring symposia, and securing podium presence at professional and trade shows, securing journalist coverage in popular and trade media, attending patient meetings focused on educating patients about existing and future treatments, and sponsoring information sessions for the Argus II System. In the US, our efforts in 2016 include media ads dedicated to RP patients and their families. These ads are being placed in geographic areas where we have proven implanting centers and established reimbursement. As a result of the above efforts, as of September 30, 2016, the Company had a patient interest list in the U.S. with over 150 conditionally qualified individuals.

 

Product and Clinical Development Plans

 

In the first half of 2016, we introduced new clinical software that is used for programming the Argus II that we believe helps clinicians with the initial programming and follow-up training of patients. In 2017, subject to FDA approval, we plan to introduce new eyewear (including camera) and a more powerful VPU that will allow us to implement various software enhancements and an improved user interface. We believe that new, more sophisticated software enhancements may improve the quality and usefulness of the vision provided by Argus II. Commercial rollouts of the software enhancements are dependent on outcomes of testing and additional regulatory approvals.

 

Currently, our Argus II System is approved for persons suffering from RP. We believe we may be able to expand the market for the Argus II System beyond RP to patients with severe to profound vision loss due to dry age-related macular degeneration, or AMD. We have enrolled and implanted five patients in a pilot study to evaluate the safety and benefit of the Argus II System for use in persons suffering from AMD. We plan to expand the number of patients implanted and will submit a revised protocol to the U.K. authorities. Based on the results of this expanded study, we may decide to begin a larger scale efficacy trial. The size and timing of the pivotal study are dependent on multiple factors including the actual subset of AMD patients we target and whether we decide to modify the Argus II system prior to commencing a pivotal study. The subset of patients will influence the regulatory and reimbursement pathways, the size of the study and the length of time required to enroll the study. The Company is also evaluating the potential benefits of system changes optimized for AMD. No assurance can be given that we will be successful in any of these endeavors. If the Argus II System is successfully developed and approved for sale to treat AMD, as to which there can be no assurances, we believe that the potential addressable market opportunity for that device will significantly exceed our existing RP markets for the Argus II System.

  

We are also conducting preclinical development, including animal studies, of a product for cortical stimulation that we refer to as the Orion I visual cortical prosthesis (or “Orion I”), which we expect will be able to provide some vision restoration to individuals with almost all unpreventable forms of blindness. Our objective in designing and developing the Orion I is to bypass the retina and optic nerve and to directly stimulate the visual cortex region of the brain. In October 2016, we announced the first successful implantation and activation of a wireless visual cortical stimulator in a human subject. While this device was not the Company’s Orion I, the study provides the initial human proof of concept for the ongoing development of the Orion I. Human clinical testing of the Orion I is likely to take the form of a feasibility study followed by a premarket approval pivotal trial. The details of these trials will be determined collaboratively with the FDA at that time. We cannot accurately estimate the timing or exact cost of these trials at this time although we do plan to apply to the FDA to begin a feasibility study by early 2017. If the Orion I is successfully developed and approved for sale, as to which there can be no assurances, we believe that the potential addressable market opportunity for that device will greatly exceed our existing RP market for the Argus II System. 

 

 19 

 

 

Critical Accounting Policies

 

The preparation of our condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Item 7 of our Annual Report on Form 10-K, as amended, for the year ended December 31, 2015. There have been no material changes to our critical accounting policies during the nine months ended September 30, 2016.

 

Results of Operations

 

Net sales. Our net sales are derived substantially from the sale of our Argus II System. We began selling our products in Europe in 2011, Saudi Arabia in 2012, the United States and Canada in 2014, and Turkey in 2015. Our objective is to increase our product revenue over the next several years as we pursue commercialization of our product, as our product becomes more well-known and accepted in the market, and as insurance coverage becomes more widespread.

 

Cost of sales. Cost of sales includes the salaries, benefits, material, overhead, third party costs, warranty, charges for excess inventory, and other costs required to make our Argus II System at our Sylmar, California facility. Historically, our cost of sales has been greater than our revenues, which has resulted in gross losses. However, beginning in the second half of fiscal 2014 and continuing through the first quarter of 2016, due to higher revenues and increased manufacturing output and efficiencies, we began generating positive gross margins for the first time in our operating history. In each of the second and third quarters of 2016, due to lower revenues, lower production activity and a reserve for excess inventory, we once again recorded a gross loss. Our ability to generate a gross profit in the future will be dependent on our ability to (1) generate higher revenues and (2) to produce our product in sufficient amounts that will allow us to absorb all production costs in a given period by spreading our costs over a larger production base, which will lower our cost per unit.

 

Operating Expenses. We generally recognize our operating expenses as we incur them in four general operational categories: research and development, clinical and regulatory, sales and marketing, and general and administrative. Our operating expenses also include a non-cash component related to the amortization of deferred stock-based compensation allocated to research and development, clinical and regulatory, sales and marketing and general and administrative personnel. From time to time we have received grants from institutions or agencies, such as the National Institutes of Health, to help fund some of the cost of our development efforts. We have recorded these grants as offsets to the costs as they are incurred to complete the related work.

 

·Research and development expenses consist primarily of employee compensation and consulting costs related to the design, development, and enhancements of our current and potential future products, offset by grant revenue received in support of specific research projects. We expense our research and development costs as they are incurred. We expect research and development expenses to increase in the future as we pursue further enhancements of our existing product and develop technology for our potential future products, such as the Orion I visual cortical prosthesis. We also expect to receive additional grants in the future that will be offset primarily against research and development costs.

 

·Clinical and regulatory expenses consist primarily of salaries, travel and related expenses for personnel engaged in clinical and regulatory functions, as well as internal and external costs associated with conducting clinical trials and maintaining relationships with regulatory agencies. We expect clinical and regulatory expenses to increase as we assess the safety and efficacy of enhancements to our current Argus II System, seek to expand the indications for the Argus II System, such as AMD, and prepare to initiate clinical studies of potential future products, such as the Orion I visual cortical prosthesis.

 

 20 

 

 

·Sales and marketing expenses consist primarily of salaries, commissions, travel and related expenses for personnel engaged in sales, marketing and business development functions, as well as costs associated with promotional and other marketing activities. We expect sales and marketing expenses to increase as we hire additional sales personnel, initiate additional marketing programs, develop relationships with new distributors, and expand the number of doctors and medical centers that buy and implant our Argus II System and any future products.

 

·General and administrative expenses consist primarily of salaries and related expenses for executive, legal, finance, human resources, information technology and administrative personnel, as well as recruiting and professional fees, patent filing costs, insurance costs and other general corporate expenses, including rent. We expect general and administrative expenses to increase as we add personnel and incur additional costs related to the growth of our business and operate as a public company.

 

Comparison of the Three Months Ended September 30, 2016 and 2015

 

Net Sales. Net sales decreased by $1,047,000, or 47%, from $2,227,000 in the third quarter of 2015 to $1,180,000 in same period in 2016, primarily due to lower revenue per implant in the third quarter of 2016 compared to the same period in 2015. Revenue recognized per implant was $84,000 in the third quarter of 2016 compared to $148,000 in the same period of the prior year. The lower revenue per implant reflects the reduced CMS reimbursement rate for 2016, the timing of revenue recognition due to certain deal terms and certain incentives provided to customers. For the balance of 2016, due to our temporary discounting strategy in the U.S. we expect the overall revenue per implant will be approximately $80,000 to $90,000. For 2017, given the CMS hospital outpatient payment rate of $150,000 for U.S. Medicare patients, we would expect our average revenue per implant to increase to $100,000 to $120,000, depending on the geographic mix of implants.

 

There were 14 Argus II Systems implanted in the third quarter of 2016, compared to 15 in the same period of the prior year. Of this total, there were 10 implants in Europe and the Middle East (EMEA) in the third quarter of 2016 compared to seven in the third quarter of 2015. The increase in EMEA in the current year quarter compared to the prior year is primarily due to an increase of four units implanted in Germany.

 

In North America, there were four implants in the third quarter of 2016 compared to eight implants in the same period of 2015, with all implants in both periods occurring in the U.S. The decline in U.S. implants was due, in part, to the 2016 Medicare reimbursement level being reduced to $95,000, which in Q1 was approximately $50,000 below our U.S. list price. We made the decision in late February 2016 to implement temporary discounts in the U.S., lasting through December 2016, to alleviate concerns of our customers that they would lose money on Argus II patient cases due to the difference between the device cost and the reimbursement amount. With this U.S. pricing issue addressed, and with the hiring of a new commercial vice president for the U.S. and Canada in March 2016, we expect that implant volumes in North America will rebound from current levels, and potentially grow, over the next few quarters.

 

Cost of sales. Cost of sales increased by approximately $1,858,000, or 145%, from $757,000 in the third quarter of 2015 to $2,615,000 in the third quarter of 2016, and consists of approximately $900,000 for cost of goods shipped in the quarter, approximately $700,000 for unabsorbed manufacturing overhead and approximately $1.0 million of additional reserves for excess inventory. Our gross margin was a negative 122% in the third quarter of 2016 compared to a positive 66% in the third quarter of 2015. We made the decision during the second quarter of 2016 to reduce our production levels and lay off certain direct manufacturing personnel and reassign certain other indirect personnel to where the Company could better utilize their skills. As a result of the reduced production output, we are spreading our production costs over a lower number of units, which resulted in unabsorbed production variances that we recognize in the period incurred. In addition, we are utilizing certain manufacturing resources to support our research and development efforts to build prototypes for our Orion I cortical product. We will continue to monitor our inventory levels, sales volume, and sales projections. In future quarters, if implant volumes and projections are lower than we now expect them to be, we may book additional reserves for slow-moving inventory. Conversely, if implant volumes and projections remain constant or improve from current levels, we may increase production of Argus II units and components. Until then, we intend to utilize a significant portion of our manufacturing resources to support our research and development efforts.

 

 21 

 

 

Research and development expense. Research and development expense, net of grant revenue, increased by $995,000, or 168%, to $1,588,000 in the third quarter of 2016 compared to $593,000 in the third quarter of 2015. The increase from the prior year was due to higher costs in the current year for compensation costs, supplies and outside services, as well as higher labor and material costs for internally produced prototypes for new and next generation products. In the third quarter of 2016, we utilized $713,000 of grant funds to offset costs compared to $778,000 in the prior year period. Excluding the effect of grants, research and development expense increased by $930,000 in the current year quarter, primarily due to an increase in expenditures related to next generation products. We expect that the amount of grant funding utilized to offset research and development costs will decrease in 2017, resulting in a higher level of recognized expense.

 

Clinical and regulatory expense. Clinical and regulatory expense decreased $375,000, or 38%, from $984,000 in the third quarter of 2015 to $609,000 in the third quarter of 2016. This decrease is primarily attributable to lower new enrollment in post-market studies being conducted in the U.S. and Europe due to the lower level of implants in the current year compared to 2015. We expect clinical and regulatory costs to increase in the future as we conduct clinical trials to assess new products, further enhancements to our existing product, and continue to assess the safety and efficacy of our current product for treating blindness due to age related macular degeneration.

 

Selling and marketing expense. Selling and marketing expense increased $130,000, or 6%, from $2,132,000 in the third quarter of 2015 to $2,262,000 in the third quarter of 2016. This increase in costs was primarily the net of $232,000 less in people related costs, including lower salaries, stock based compensation, travel and commissions, offset by $325,000 in higher costs for consultants related to items such as customer outreach programs and insurance reimbursement for our products in the U.S. and foreign markets. While we expect these costs to increase in the future as we increase our selling and marketing resources to accelerate the commercialization of our product, we expect selling and marketing expense to decrease over time when expressed as a percentage of product revenue.

 

General and administrative expense. General and administrative expense increased $182,000, or 8%, from $2,423,000 in the third quarter of 2015 to $2,605,000 in the same period of 2016. This increase is primarily attributable to $315,000 in higher compensation costs, including higher stock-based compensation charges, and $57,000 related to higher business insurance expense in the current year offset, in part, by $161,000 in lower costs for outside services. In the third quarter of 2016 as compared to the third quarter of the prior year, stock-based compensation (which includes the value of fees earned by directors and paid in stock) increased by $161,000 primarily to new-hire grants made in August 2015 to the Company’s Chief Executive Officer.

 

Comparison of the Nine Months Ended September 30, 2016 and 2015

 

Net Sales. Our net sales decreased from $6,588,000 in the first nine months of 2015 to $3,270,000 in same period in 2016, a decrease of $3,318,000, or 50%. This decrease in net sales was due to a lower number of implants in 2016, and at a lower average amount of recognized revenue per implant than in the same period of the prior year.

 

35 Argus II Systems were implanted in the first nine months of 2016 compared to 54 in the first nine months of 2015. Of these, there were 25 implants in EMEA in the first nine months of 2016 compared to 32 in the first nine months of 2015. The decrease in EMEA between the 2015 and 2016 periods is primarily attributable to a decrease of 10 implants in France due, in part, to two potential competitors recruiting RP patients for a clinical trial in France.

 

In North America, there were 10 implants in the first nine months of 2016 compared to 22 implants in the same period of the prior year. The decline in U.S. implants was due, in part, to the 2016 Medicare reimbursement level being reduced to $95,000, which in early Q1 was approximately $50,000 below our U.S. list price. We made the decision in late February 2016 to implement temporary discounts in the U.S., lasting through December 2016, to alleviate concerns of our customers that they would lose money on Argus II patient cases due to the difference between the device cost and the reimbursement amount. With this U.S. pricing issue addressed for fiscal year 2016, and with the hiring of a new commercial vice president for the U.S. and Canada in March 2016, we expect that implant volumes in North America will rebound from current levels, and potentially grow, over the next few quarters.

 

 22 

 

 

In the first nine months of 2016, revenue recognized per implant was approximately $93,000 compared to approximately $122,000 in the same period of 2015. Average revenue per implant was lower in the first nine months of 2016 compared to the first nine months of 2015 primarily due to the lower Medicare reimbursement rate in the United States in 2016. For the balance of 2016, due to our temporary discounting strategy in the U.S., we expect our overall revenue per implant will be approximately $80,000 to $90,000. For 2017, with the CMS reimbursement rate of $150,000 discussed above for U.S. Medicare patients, we would expect to have our average revenue per implant to increase to approximately $100,000 to $120,000, depending on the geographic mix of implants.

 

Cost of sales. Cost of sales increased from $3,622,000 in the first nine months of 2015 to $6,768,000 in the first nine months of 2016, an increase of $3,146,000 or 87%. This increase of the cost of goods sold in the first nine months of 2016 represents a lower cost of goods associated with the lower volume of implants in the first nine months of 2016 offset by charges in the first nine months of 2016 for excess inventory of $2.6 million and unabsorbed overhead costs of $2.1 million. Our gross margin was a negative 107% in the first nine months of 2016 compared to a positive 45% in the first nine months of 2015. We made the decision during the second quarter of 2016 to reduce our production levels and lay off certain direct manufacturing personnel and reassign certain other indirect personnel to where the Company could better utilize their skills. As a result of the reduced production output, we are spreading our production costs over a lower number of units, which resulted in unabsorbed production variances that we recognize in the period incurred. In addition, we are utilizing certain manufacturing resources to support our research and development efforts to build prototypes for our Orion cortical product. We will continue to monitor our inventory levels, sales volume, and sales projections. In future quarters, if implant volumes and projections are lower than we now expect them to be, we may book additional reserves for slow-moving inventory. Conversely, if implant volumes and projections remain constant or improve from current levels, we may increase production of Argus II units and components. Until then, we will utilize a significant portion of our manufacturing resources to support our research and development efforts.

 

Research and development expense. Research and development expense, net of grant revenue, increased by $776,000, or 31%, from $2,490,000 in the first nine months of 2015 to $3,266,000 in the first nine months of 2016. In the first nine months of 2016, we utilized $1,985,000 of grant funds to offset costs versus $1,308,000 of grant funds utilized in the same period of 2015. Excluding this grant offset, there was an increase in research and development costs of $1,453,000 or 38%, primarily as a result of increased expenditures for compensation costs, outside consulting services and higher labor and material costs for internally produced prototypes for next generation products. We expect that the amount of grant funding utilized to offset research and development costs will decrease in 2017, resulting in a higher level of recognized expense.

 

Clinical and regulatory expense. Clinical and regulatory expense decreased by $588,000, or 23%, from $2,543,000 in the first nine months of 2015 to $1,955,000 in the same period of 2016. This decrease is primarily attributable to a lower level of clinical and regulatory activity reflecting decreased new enrollment in post-market studies being conducted in the US and Europe. We expect clinical and regulatory costs to increase in the future as we conduct clinical trials to assess new products, further enhancements to our existing product, and continue to assess the safety and efficacy of our current product for treating blindness due to age related macular degeneration.

 

Selling and marketing expense. Selling and marketing expense increased by $48,000, or 1%, from $6,425,000 in the first nine months of 2015 to $6,473,000 in the same period of 2016. This increase in costs was primarily the net of $657,000 less in people related costs, including lower salaries, stock based compensation, travel and commissions, offset by $731,000 in higher costs for consultants related to items such as customer outreach programs and insurance reimbursement for our products in the U.S. and foreign markets. While we expect these costs to increase in the future as we increase our selling and marketing resources to accelerate the commercialization of our product, we expect selling and marketing expense to decrease over time when expressed as a percentage of product revenue.

 

General and administrative expense. General and administrative expense increased by $1,556,000, or 26%, from $6,079,000 in the first nine months of 2015 to $7,635,000 in the same period of 2016. This increase is primarily attributable to $1.4 million of higher people related costs in the current year, including $365,000 for higher salaries and $958,000 for higher-stock based compensation charges (which includes the value of fees earned by directors and paid in stock). These higher salary and stock-based compensation expenses relate primarily to the Company’s chief executive officer who was hired August 2015. While we expect general and administrative costs to increase in the future, we expect these expenses to grow at a slower rate than in the past 12 months.

 

 23 

 

 

Liquidity and Capital Resources

 

Our consolidated financial statements have been presented on the basis of our being a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring operating losses and negative operating cash flows since inception, and have financed our working capital requirements through the recurring sale of our equity securities in both public and private offerings. As a result, our independent registered public accounting firm, in its report on our 2015 consolidated financial statements, raised substantial doubt about our ability to continue as a going concern (see “Going Concern” above). In June 2016, the Company successfully completed a Rights Offering to existing shareholders, raising proceeds of $19.5 million net of cash offering costs, and selling 5,978,465 shares of common stock at $3.315 per share. Based upon this funding, management believes that it has sufficient funds to last through the end of the second quarter of 2017. In order to continue business operations past that point, we currently anticipate that we will need to raise additional debt and/or equity capital during the next several months.

 

Cash and money market funds increased by $1,863,000, or 12%, from $15,960,000 at December 31, 2015 to $17,823,000 at September 30, 2016. Working capital was $19,017,000 at September 30, 2016, as compared to $18,782,000 at December 31, 2015, an increase of $235,000, or 1%. We use our cash, money market funds and working capital to fund our operating activities.

  

Cash Flows from Operating Activities

 

During the first nine months of 2016, we used $18,054,000 of cash in operating activities, consisting primarily of a net loss of $22,809,000, offset by non-cash charges of $5,900,000 for depreciation and amortization of property and equipment, stock-based compensation, excess inventory reserve, bad debt expense and common stock issuable and increased by a net change in operating assets and liabilities of $1,145,000. This compares to the first nine months of 2015, we used $14,652,000 of cash in operating activities, consisting primarily of a net loss of $14,545,000, offset by non-cash charges of $2,382,000 for depreciation and amortization of property and equipment, stock-based compensation and common stock issuable, and increased by a net change in operating assets and liabilities of $2,489,000.

 

Cash Flows from Investing Activities

 

Investing activities in the first nine months of 2016 used $2,226,000 of cash, reflecting $1,820,000 used by the purchase of money market investments and $406,000 used for the purchase of equipment. This compares to the first nine months of 2015 when investing activities provided $12,021,000, reflecting $12,599,000 in proceeds from the sales of money market investments, offset by $578,000 for the purchase of equipment.

 

Cash Flows from Financing Activities

 

Financing activities provided $20,299,000 of cash in the first nine months of 2016, $19,483,000 of net proceeds from the Rights Offering and $479,000 from the exercise of stock options and $337,000 from the proceeds from sale of stock for the ESPP plan. Financing activities provided $2,352,000 of cash in first nine months of 2015, $2,476,000 from the exercise of stock options and warrants offset by $124,000 of cash used to satisfy the related income and payroll tax withholding amounts related to stock option exercises for our current chairman, who at the time was our chief executive officer.

 

 24 

 

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements.

 

Item 3.Quantitative and Qualitative Disclosures about Market Risk

 

Interest Rate Sensitivity

 

The primary objective of our investment activities is to maintain the safety of principal and preserve liquidity without incurring significant risk. We invest cash in excess of our current needs in money market funds. As of September 30, 2016, our investments consisted solely of money market funds.

 

Exchange Rate Sensitivity

 

During the nine months ended September 30, 2016, approximately 49% of our revenue was denominated in U.S. dollars, 48% in Euros, and 3% in Canadian dollars. In the same time period the majority of our operating expenses were denominated in U.S. dollars. We have not entered into foreign currency forward contracts to hedge our operating expense exposure to foreign currencies, but we may do so in the future. 

 

Item 4.Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

  

Our management, including our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2016. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. As of September 30, 2016, based on the evaluation of these disclosure controls and procedures, and in light of the material weaknesses found in our internal controls over financial reporting, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective. 

 

Remediation Plan 

 

As of September 30, 2016, there were control deficiencies which constituted material weaknesses in our internal control over financial reporting. Management has taken, and is taking steps to strengthen our internal control over financial reporting. Specifically:

 

·Control over Financial Reporting. We have implemented additional processes and procedures surrounding the closing process, including the preparation and review of journal entries and account reconciliations to ensure accuracy of financial reporting including timely account reconciliation review. We have adopted further procedures and review processes surrounding revenue, deferred revenue, inventory and stock-based compensation that will reduce end of accounting period adjustments. We are also in the process of implementing a software application that will help us to automate controls surrounding the closing process, including the review of journal entries and account reconciliations.

 

 25 

 

 

·Control over Tracking of Back-up Prosthesis Units. We conducted a multi-departmental review of how we track our back-up prosthesis units and implemented a software solution that allows us to track back-up units that are sent to customers and facilitates proper tracking and accounting for these units within our enterprise software system. Additionally, we continue to perform a manual reconciliation of the back-up units.

  

While we have taken certain actions to address the material weaknesses identified, additional measures may be necessary as we work to improve the overall effectiveness of our internal controls over financial reporting. Through the actions in the remediation plan reported in our Annual Report on Form 10-K for the year ended December 31, 2015, as amended, in our Quarterly Report on Form 10-Q for the period ended March 31, 2016, as amended, in our quarterly report on Form 10-Q for the period ended June 30, 2016, and new actions which have since been initiated, we believe that we are addressing the deficiencies that affected our internal control over financial reporting for the year and quarterly periods then ended however we have not completed all of the corrective processes and procedures as contemplated herein for the identified material weaknesses. Until the remediation plan is fully implemented and operating for a sufficient period of time, we will not be able to conclude that the material weaknesses have been remediated. We will continue to monitor and assess our remediation activities to address the material weaknesses discussed above through remediation as soon as practicable and to provide reasonable assurance that they will prevent or detect material error in the financial statements.   

 

Changes in Internal Control over Financial Reporting

  

Other than changes that have been enacted pursuant to our remediation plan, there were no changes in our internal control over financial reporting during the quarter ended September 30, 2016 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

  

Inherent Limitations on Effectiveness of Controls

  

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.  

   

PART II-OTHER INFORMATION

 

Item 1.Legal Proceedings

 

Fifteen oppositions have been filed by a third-party in the European Patent Office, each challenging the validity of a European patent owned or exclusively licensed by the Company. The outcome of the challenges is not certain, however, if successful, they may affect the Company's ability to block competitors from utilizing some of its patented technology in Europe. Management of the Company does not believe any successful challenges will have a material effect on the Company’s ability to manufacture and sell its products, or otherwise have a material effect on its operations.

 

The Company is party to litigation arising in the ordinary course of business. It is management's opinion that the outcome of such matters will not have a material effect on the Company's financial statements.

 

 26 

 

 

Item 1A.Risk Factors

 

The risk factors presented below update, and should be considered in addition to, the risk factors previously disclosed by us in our Annual Report on Form 10-K, which we filed with the Securities and Exchange Commission on March 11, 2016.

 

We will need to further develop and maintain our internal control over financial reporting. If our internal control over financial reporting remains not effective, investor confidence in our company may be adversely affected.

 

Pursuant to Section 404 of the Sarbanes-Oxley Act, we are now required to furnish in our annual Report on Form 10-K a report by management on, among other things, the effectiveness of our internal control over financial reporting as of the end of each fiscal year. This assessment includes disclosure of any material weaknesses identified by our management in our internal control over financial reporting.

 

In response to identified material weaknesses in our internal control over financial reporting, we are continuing to develop and improve our system and process documentation necessary to perform the evaluation needed to comply with Section 404. For example, in connection with the audit of our consolidated financial statements for fiscal 2015, our independent registered public accounting firm identified material weaknesses in our internal control over financial reporting. A “material weakness” is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Our independent registered public accounting firm identified the following material weaknesses during its audit:

 

·Control over Financial Reporting. We did not consistently perform timely reconciliation of certain accounts, including revenue, deferred revenue, inventory, and stock-based compensation expense. This resulted in the incorrect recording of certain revenue and expenses that required various adjusting entries which we timely and fully recorded as part of the audit process.
·Tracking of Back-up Prosthesis Units. For every surgery, we ship a back-up prosthesis unit along with the primary unit in case the primary unit cannot be used for some reason. Following the surgery the unused unit is returned to us. We did not consistently follow internal procedures regarding the tracking and recordation of returned prosthesis units and the exchange of primary units for back-up units with our customers. When uncorrected this resulted in an understatement of cost of sales and an overstatement of inventory that required various adjusting entries that we timely and fully recorded as part of the audit process.

 

We are continuing our efforts to remedy these material weaknesses.

 

If we continue to be unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion on the effectiveness of our internal controls when it is required to do so by the applicable rules, we could lose investor confidence in the accuracy and completeness of our financial reports, which could cause the price of our common stock to decline, and we may be subject to investigation or sanctions by the Securities and Exchange Commission, or the SEC.

 

As a result, we may need to undertake various actions, such as implementing new internal controls and procedures and hiring additional accounting or internal audit staff. Our remediation efforts may not enable us to avoid a material weakness in the future.

 

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

 

We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

 

 27 

 

 

These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.

 

We are a company with limited accounting personnel and other resources with which to address our internal controls and procedures. Our independent registered public accounting firm has not conducted an audit of our internal control over financial reporting. However, in connection with the audit of our consolidated financial statements for fiscal 2015, our independent registered public accounting firm identified material weaknesses in our internal control over financial reporting, as defined in the standards established by the Public Company Accounting Oversight Board of the U.S. A “material weakness” is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses that our independent registered public accounting firm identified related to our failure to (i) consistently perform timely reconciliations, and (ii) consistently follow proper procedures regarding the tracking and recordation of back-up prosthesis units that were sent along with the primary unit in case the primary unit could be used for some reason.

 

During the current fiscal year, we have taken and are continuing to take steps to remedy the above material weaknesses. Our remediation plan is described in greater detail in Item 4 of Part I of this report. We cannot assure you that our remediation efforts will be successful.

 

This Quarterly Report on Form 10-Q contains forward-looking statements which are subject to a variety of risks and uncertainties.

 

Other actual results could differ materially from those anticipated in those forward-looking statements as a result of various factors relating to our business and common stock contained in Item 1A of our Annual Report on Form 10-K and Form 10K/A for the year ended December 31, 2015.

 

 

 28 

 

  

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

 

Not applicable.

 

Item 3.Defaults upon Senior Securities

 

Not applicable.

 

Item 4.Mine Safety Disclosures

 

Not applicable.

 

Item 5.Other Information

 

Not applicable.

 

Item 6.Exhibits

 

EXHIBIT INDEX

 

Exhibit
No.
  Exhibit Description
3.1   Restated Articles of Incorporation of the Registrant.(1)
3.2   Amended and Restated Bylaws of the Registrant, as currently in effect.(1)
31.1   Certification of Principal Executive Officer of Second Sight Medical Products, Inc. pursuant to Section 302 of Sarbanes-Oxley Act of 2002.*
31.2   Certification of Principal Financial and Accounting Officer of Second Sight Medical Products, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1   Certifications of Principal Executive Officer and Principal Financial and Accounting Officer of Second Sight Medical Products, Inc.  pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
101.INS   XBRL Instant Document.*
101.SCH   XBRL Taxonomy Extension Schema Document.*
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB   XBRL Taxonomy Extension Label Linkbase Document.*
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document.*

 

* Included herein.

(1) Incorporated by reference to the registrant’s registration statement on Form S-1, file no. 333-198073, originally filed with the Securities and Exchange Commission on August 12, 2014, as amended.

 

 29 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Name   Title   Date
         
/s/  Jonathan Will McGuire   Chief Executive Officer and Director   November 4, 2016
Jonathan Will McGuire   (Principal Executive Officer)    
         
/s/  Thomas B. Miller   Chief Financial Officer   November 4, 2016
Thomas B. Miller   (Principal Financial and Accounting Officer)    

 

 30 

 

EX-31.1 2 s104460_ex31-1.htm EXHIBIT 31-1

 

Exhibit 31.1

 

Certification of Principal Executive Officer Pursuant To

Exchange Act Rules 13a-14(a) and 15d-14(a),

As Adopted Pursuant To

Section 302 of Sarbanes-Oxley Act of 2002

 

I, Jonathan Will McGuire, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Second Sight Medical Products, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 4, 2016 /s/ Jonathan Will McGuire
  Jonathan Will McGuire
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 

EX-31.2 3 s104460_ex31-2.htm EXHIBIT 31-2

 

Exhibit 31.2

 

Certification of Principal Financial Officer Pursuant To

Exchange Act Rules 13a-14(a) and 15d-14(a),

As Adopted Pursuant To

Section 302 of Sarbanes-Oxley Act of 2002

 

I, Thomas B. Miller, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Second Sight Medical Products, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 4, 2016 /s/ Thomas B. Miller
  Thomas B. Miller
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

 

 

EX-32.1 4 s104460_ex32-1.htm EXHIBIT 32-1

 

Exhibit 32.1

 

Certifications of Principal Executive Officer and Principal Financial Officer
Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), Jonathan Will McGuire, Chief Executive Officer (Principal Executive Officer) and Thomas B. Miller, Chief Financial Officer (Principal Financial and Accounting Officer) of Second Sight Medical Products, Inc. (the “Company”), each hereby certifies that, to the best of his knowledge:

 

1.Our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, to which this Certification is attached as Exhibit 32.1 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

A signed original of this written statement required by Section 906 has been provided to Second Sight Medical Products, Inc. and will be retained by Second Sight Medical Products, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

Date: November 4, 2016 /s/ Jonathan Will McGuire
  Jonathan Will McGuire
  Chief Executive Officer
  (Principal Executive Officer)
   
  /s/ Thomas B. Miller
  Thomas B. Miller
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

 

 

EX-101.INS 5 eyes-20160930.xml XBRL INSTANCE FILE 0001266806 2016-01-01 2016-09-30 0001266806 2016-11-02 0001266806 2016-09-30 0001266806 2015-12-31 0001266806 2016-07-01 2016-09-30 0001266806 2015-07-01 2015-09-30 0001266806 2015-01-01 2015-09-30 0001266806 2014-12-31 0001266806 2015-09-30 0001266806 eyes:SecondSightSwitzerlandSarlMember us-gaap:ExecutiveOfficerMember 2016-09-30 0001266806 eyes:SecondSightSwitzerlandSarlMember 2016-09-30 0001266806 eyes:RightOfferingMember 2016-06-01 2016-06-30 0001266806 eyes:RightOfferingMember 2016-06-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerOneMember 2016-07-01 2016-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerTwoMember 2016-07-01 2016-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerThreeMember 2016-07-01 2016-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerFourMember 2016-07-01 2016-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerFiveMember 2016-07-01 2016-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerSixMember 2016-07-01 2016-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerOneMember 2015-07-01 2015-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerTwoMember 2015-07-01 2015-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerThreeMember 2015-07-01 2015-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerFourMember 2015-07-01 2015-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerFiveMember 2015-07-01 2015-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerSixMember 2015-07-01 2015-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerOneMember 2016-01-01 2016-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerTwoMember 2016-01-01 2016-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerThreeMember 2016-01-01 2016-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerFourMember 2016-01-01 2016-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerFiveMember 2016-01-01 2016-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerSixMember 2016-01-01 2016-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerOneMember 2015-01-01 2015-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerTwoMember 2015-01-01 2015-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerThreeMember 2015-01-01 2015-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerFourMember 2015-01-01 2015-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerFiveMember 2015-01-01 2015-09-30 0001266806 us-gaap:SalesRevenueNetMember eyes:CustomerSixMember 2015-01-01 2015-09-30 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerOneMember 2016-01-01 2016-09-30 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerTwoMember 2016-01-01 2016-09-30 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerThreeMember 2016-01-01 2016-09-30 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerFourMember 2016-01-01 2016-09-30 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerFiveMember 2016-01-01 2016-09-30 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerSixMember 2016-01-01 2016-09-30 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerSevenMember 2016-01-01 2016-09-30 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerEightMember 2016-01-01 2016-09-30 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerOneMember 2015-01-01 2015-12-31 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerTwoMember 2015-01-01 2015-12-31 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerThreeMember 2015-01-01 2015-12-31 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerFourMember 2015-01-01 2015-12-31 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerFiveMember 2015-01-01 2015-12-31 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerSixMember 2015-01-01 2015-12-31 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerSevenMember 2015-01-01 2015-12-31 0001266806 us-gaap:AccountsReceivableMember eyes:CustomerEightMember 2015-01-01 2015-12-31 0001266806 country:US 2016-07-01 2016-09-30 0001266806 country:US 2015-07-01 2015-09-30 0001266806 country:US 2016-01-01 2016-09-30 0001266806 country:US 2015-01-01 2015-09-30 0001266806 country:IT 2016-07-01 2016-09-30 0001266806 country:IT 2015-07-01 2015-09-30 0001266806 country:IT 2016-01-01 2016-09-30 0001266806 country:IT 2015-01-01 2015-09-30 0001266806 country:TR 2016-07-01 2016-09-30 0001266806 country:TR 2015-07-01 2015-09-30 0001266806 country:TR 2016-01-01 2016-09-30 0001266806 country:TR 2015-01-01 2015-09-30 0001266806 country:FR 2016-07-01 2016-09-30 0001266806 country:FR 2015-07-01 2015-09-30 0001266806 country:FR 2016-01-01 2016-09-30 0001266806 country:FR 2015-01-01 2015-09-30 0001266806 country:DE 2016-07-01 2016-09-30 0001266806 country:DE 2015-07-01 2015-09-30 0001266806 country:DE 2016-01-01 2016-09-30 0001266806 country:DE 2015-01-01 2015-09-30 0001266806 country:CA 2016-07-01 2016-09-30 0001266806 country:CA 2015-07-01 2015-09-30 0001266806 country:CA 2016-01-01 2016-09-30 0001266806 country:CA 2015-01-01 2015-09-30 0001266806 eyes:SecondSightSwitzerlandSarlMember 2015-12-31 0001266806 us-gaap:MoneyMarketFundsMember 2016-09-30 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2016-09-30 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2016-09-30 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2016-09-30 0001266806 us-gaap:MoneyMarketFundsMember 2015-12-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0001266806 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2015-12-31 0001266806 eyes:LaboratoryEquipmentMember 2015-12-31 0001266806 us-gaap:ComputerEquipmentMember 2015-12-31 0001266806 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001266806 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001266806 eyes:LaboratoryEquipmentMember 2016-09-30 0001266806 us-gaap:ComputerEquipmentMember 2016-09-30 0001266806 us-gaap:LeaseholdImprovementsMember 2016-09-30 0001266806 us-gaap:FurnitureAndFixturesMember 2016-09-30 0001266806 us-gaap:IPOMember 2016-01-01 2016-09-30 0001266806 us-gaap:IPOMember 2016-09-30 0001266806 us-gaap:IPOMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0001266806 us-gaap:IPOMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0001266806 eyes:LongTermInvestorRightsMember 2016-01-01 2016-09-30 0001266806 eyes:LongTermInvestorRightsMember 2015-01-01 2015-09-30 0001266806 eyes:UnderwriterWarrantsMember 2016-01-01 2016-09-30 0001266806 eyes:UnderwriterWarrantsMember 2015-01-01 2015-09-30 0001266806 eyes:WarrantsAssociatedWithConvertibleDebtMember 2016-01-01 2016-09-30 0001266806 eyes:WarrantsAssociatedWithConvertibleDebtMember 2015-01-01 2015-09-30 0001266806 eyes:CommonStockOptionsMember 2016-01-01 2016-09-30 0001266806 eyes:CommonStockOptionsMember 2015-01-01 2015-09-30 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-09-30 0001266806 us-gaap:StockCompensationPlanMember 2016-01-01 2016-09-30 0001266806 us-gaap:StockCompensationPlanMember 2015-01-01 2015-09-30 0001266806 us-gaap:DirectorMember 2016-01-01 2016-09-30 0001266806 us-gaap:WarrantMember 2016-09-30 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2015-12-31 0001266806 us-gaap:RestrictedStockUnitsRSUMember 2016-09-30 0001266806 us-gaap:CostOfSalesMember 2016-07-01 2016-09-30 0001266806 us-gaap:CostOfSalesMember 2015-07-01 2015-09-30 0001266806 us-gaap:CostOfSalesMember 2016-01-01 2016-09-30 0001266806 us-gaap:CostOfSalesMember 2015-01-01 2015-09-30 0001266806 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0001266806 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001266806 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001266806 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001266806 eyes:ClinicalAndRegulatoryMember 2016-07-01 2016-09-30 0001266806 eyes:ClinicalAndRegulatoryMember 2015-07-01 2015-09-30 0001266806 eyes:ClinicalAndRegulatoryMember 2016-01-01 2016-09-30 0001266806 eyes:ClinicalAndRegulatoryMember 2015-01-01 2015-09-30 0001266806 us-gaap:SellingAndMarketingExpenseMember 2016-07-01 2016-09-30 0001266806 us-gaap:SellingAndMarketingExpenseMember 2015-07-01 2015-09-30 0001266806 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-09-30 0001266806 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-09-30 0001266806 us-gaap:GeneralAndAdministrativeExpenseMember 2016-07-01 2016-09-30 0001266806 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0001266806 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-09-30 0001266806 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0001266806 eyes:EquityIncentivePlan2011Member 2016-09-30 0001266806 eyes:EquityIncentivePlan2011Member 2016-01-01 2016-09-30 0001266806 us-gaap:ChiefExecutiveOfficerMember 2015-01-01 2015-01-02 0001266806 us-gaap:ChiefExecutiveOfficerMember 2014-12-31 0001266806 us-gaap:ChiefExecutiveOfficerMember 2014-12-30 2014-12-31 0001266806 eyes:CertainEmployeesAndContractorsMember 2016-01-01 2016-09-30 0001266806 eyes:CertainEmployeesAndContractorsMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0001266806 eyes:CertainEmployeesAndContractorsMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0001266806 eyes:CertainEmployeesAndContractorsMember us-gaap:MinimumMember 2016-09-30 0001266806 us-gaap:MaximumMember eyes:CertainEmployeesAndContractorsMember 2016-09-30 0001266806 eyes:OutsideAttorneyMember 2016-01-01 2016-09-30 0001266806 eyes:OutsideAttorneyMember 2016-09-30 0001266806 eyes:ConsultantMember 2016-01-01 2016-03-31 0001266806 eyes:SecondSight2011EquityIncentivePlanMember 2016-05-10 0001266806 eyes:SecondSight2011EquityIncentivePlanMember 2016-05-09 2016-05-10 0001266806 eyes:EmployeeStockPurchasePlanMember 2015-06-01 2015-06-30 0001266806 eyes:EmployeeStockPurchasePlanMember 2016-01-01 2016-09-30 0001266806 us-gaap:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2016-08-17 2016-08-18 0001266806 us-gaap:ChiefExecutiveOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2016-08-18 0001266806 eyes:EquityIncentivePlan2011Member us-gaap:MinimumMember 2016-01-01 2016-09-30 0001266806 eyes:EquityIncentivePlan2011Member us-gaap:MaximumMember 2016-01-01 2016-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure SECOND SIGHT MEDICAL PRODUCTS INC 0001266806 10-Q 2016-09-30 false --12-31 No No Yes Accelerated Filer Q3 2016 42246954 EYES 277000 239000 619000 268000 17546000 15721000 447000 1501000 5810000 8209000 603000 1094000 24683000 26764000 1527000 1432000 -55000 -49000 26265000 28245000 2228000 3041000 694000 710000 1711000 2068000 2055000 2069000 555000 616000 195000 322000 456000 2197000 5666000 7982000 186618000 166049000 87000 205000 29911000 27277000 -2000 -5000 -524000 -581000 -195491000 -172682000 20599000 20263000 26265000 28245000 10000 10000 0 0 200000 200000 42247 35942 42247 35942 3270000 1180000 2227000 6588000 6768000 2615000 757000 3622000 -3498000 -1435000 1470000 2966000 3266000 1588000 593000 2490000 1955000 609000 984000 2543000 6473000 2262000 2132000 6425000 7635000 2605000 2423000 6079000 19329000 7064000 6132000 17537000 -22827000 -8499000 -4662000 -14571000 19000 11000 1000 -1000 -1000 -4000 25000 -22809000 -8489000 -4666000 -14545000 -0.57 -0.20 -0.13 -0.41 39929 42220 35836 35555 57000 34000 -70000 -72000 -22752000 -8455000 -4736000 -14617000 311000 231000 2581000 1918000 55000 191000 2611000 206000 233000 -874000 600000 166000 2416000 -492000 -195000 -16000 31000 -377000 469000 -15000 888000 -61000 68000 -135000 184000 -1741000 -1308000 -18054000 -14652000 406000 578000 -1820000 12599000 -2226000 12021000 19483000 816000 2476000 124000 20299000 2352000 19000 -72000 38000 -351000 53000 <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>2.&#160;&#160; Basis of Presentation, Significant Accounting Policies&#160;and Recent Accounting Pronouncements</b></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Basis of Presentation</i></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for Form 10-Q. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2015 has been derived from the Company&#8217;s audited consolidated financial statements.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">In the opinion of management, these financial statements reflect all normal recurring and other adjustments necessary for a fair presentation. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2015. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year or any other future periods.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Significant Accounting Policies</i></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The Company&#8217;s significant accounting policies are set forth in Note 2 of the financial statements in its Annual Report on Form 10-K for the year ended December 31, 2015.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recent Accounting Pronouncements</i></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">In August 2016, the FASB issued ASU 2016-15, <i>Statement of Cash Flows (Topic 230)</i>, which updates the guidance as to how certain cash receipts and cash payments should be presented and classified. The update is intended to reduce the existing diversity in practice. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted, including adoption in an interim period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which requires measurement and recognition of expected versus incurred credit losses for financial assets held. ASU 2016-13 is effective for the Company in the first quarter of fiscal 2020 with early adoption permitted beginning in the first quarter of fiscal 2019. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), a new standard that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. The standard also allows the Company to repurchase more of an employee&#8217;s shares for tax withholding purposes without triggering liability accounting, clarifies that all cash payments made on an employee&#8217;s behalf for withheld shares should be presented as a financing activity on the cash flow statement, and provides an accounting policy election to account for forfeitures as they occur. The new standard is effective for the annual periods beginning after December 15, 2016, and interim periods within those annual periods with early adoption permitted. The Company is currently evaluating the impact of the standard on the Company&#8217;s financial statements.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Management does not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>4. Money Market Funds</b></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Money market funds are the only financial instrument measured and recorded at fair value on the Company&#8217;s balance sheet, and they are considered Level 1 valuation securities. The following table presents money market funds at their level within the fair value hierarchy at September 30, 2016 and December 31, 2015 (in thousands):</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 85%; margin-left: 0.25in; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016 (unaudited):</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Money market funds</font></td> <td style="width: 1%; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">17,546</font></td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">17,546</font></td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2015:</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Money market funds</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">15,721</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">15,721</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>7. Equity Securities</b></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Common Stock Issuable</i></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Beginning with services rendered in 2014, and with payments in June 2015 and 2016, non-employee members of the Board of Directors are paid for their services in common stock on June 1 of each year based on the average closing prices for the immediately preceding twenty trading days. As of September 30, 2016, the Company accrued $87,000 for these services, which equates to 26,274 shares. These shares have not yet been issued and are excluded from the calculation of weighted average common shares outstanding for EPS purposes.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>&#160;&#160;</i></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Potentially Dilutive Common Stock Equivalents</i></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">At September 30, 2016 and 2015 (unaudited), the Company excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately acquire shares of common stock, from its calculations of earnings per share and weighted average shares outstanding, as their effect would have been anti-dilutive (in thousands).</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 74%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Long Term Investor Rights</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">342</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">412</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Underwriter&#8217;s warrants</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">802</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">802</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Warrants associated with convertible debt</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,038</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,038</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Common stock options</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,669</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,505</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Restricted stock units</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">142</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">190</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Employee stock purchase plan</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">109</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">75</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">6,102</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">6,022</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Rights Offering</i></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">In June 2016, the Company completed a Rights Offering to existing stockholders by selling 5,978,465 shares of common stock. The Company evaluated the financial impact of FASB ASC 260, "Earnings per Share," which states, among other things, that if a rights issue is offered to all existing stockholders at an exercise price that is less than the fair value of the stock, then the weighted average shares outstanding and basic and diluted earnings per share shall be adjusted retroactively to reflect the bonus element of the rights offering for all periods presented. The Company determined that the application of this specific provision of ASC 260 was immaterial to previously issued financial statements and, therefore, did not retroactively adjust previously reported weighted average shares outstanding and basic and diluted earnings per share.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>8. Warrants</b></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">A summary of warrant activity for the nine months ended September 30, 2016 (unaudited) is presented below (in thousands, except per share and contractual life data).</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 88%; margin-left: 0.25in; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Remaining</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Contractual</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Life (in Years)</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 58%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding at December 31, 2015</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,840</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.72</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.80</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited or expired</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding at September 30, 2016</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">1,840</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">7.72</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">2.06</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Warrants exercisable at September 30, 2016</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">1,840</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">7.72</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">2.06</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The intrinsic value of warrants outstanding at September 30, 2016 was $0. During the nine months ended September 30, 2016, no warrants were exercised.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Basis of Presentation</i></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for Form 10-Q. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2015 has been derived from the Company&#8217;s audited consolidated financial statements.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">In the opinion of management, these financial statements reflect all normal recurring and other adjustments necessary for a fair presentation. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2015. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year or any other future periods.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Significant Accounting Policies</i></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The Company&#8217;s significant accounting policies are set forth in Note 2 of the financial statements in its Annual Report on Form 10-K for the year ended December 31, 2015.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Recent Accounting Pronouncements</i></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">In August 2016, the FASB issued ASU 2016-15, <i>Statement of Cash Flows (Topic 230)</i>, which updates the guidance as to how certain cash receipts and cash payments should be presented and classified. The update is intended to reduce the existing diversity in practice. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted, including adoption in an interim period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">In June 2016 the FASB issued ASU 2016-13, <i>Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>, which requires measurement and recognition of expected versus incurred credit losses for financial assets held. ASU 2016-13 is effective for the Company in the first quarter of fiscal 2020 with early adoption permitted beginning in the first quarter of fiscal 2019. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), a new standard that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. The standard also allows the Company to repurchase more of an employee&#8217;s shares for tax withholding purposes without triggering liability accounting, clarifies that all cash payments made on an employee&#8217;s behalf for withheld shares should be presented as a financing activity on the cash flow statement, and provides an accounting policy election to account for forfeitures as they occur. The new standard is effective for the annual periods beginning after December 15, 2016, and interim periods within those annual periods with early adoption permitted. The Company is currently evaluating the impact of the standard on the Company&#8217;s financial statements.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Management does not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The following table presents money market funds at their level within the fair value hierarchy at September 30, 2016 and December 31, 2015 (in thousands):</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 85%; margin-left: 0.25in; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016 (unaudited):</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Money market funds</font></td> <td style="width: 1%; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">17,546</font></td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">17,546</font></td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="width: 1%; text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2015:</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Money market funds</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">15,721</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">15,721</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment consisted of the following at (in thousands):</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table align="center" cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(unaudited)</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 74%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Laboratory equipment</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,594</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,369</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Computer hardware and software</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,117</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,960</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">533</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">508</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Furniture, fixtures and equipment</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">135</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">135</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,379</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,972</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated depreciation and amortization</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">(4,852</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">(4,540</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment, net</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">1,527</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">1,432</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">At September 30, 2016 and 2015 (unaudited), the Company excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately acquire shares of common stock, from its calculations of earnings per share and weighted average shares outstanding, as their effect would have been anti-dilutive (in thousands).</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table align="center" cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 74%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Long Term Investor Rights</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">342</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">412</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Underwriter&#8217;s warrants</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">802</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">802</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Warrants associated with convertible debt</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,038</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,038</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Common stock options</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,669</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,505</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Restricted stock units</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">142</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">190</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Employee stock purchase plan</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">109</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">75</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">6,102</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">6,022</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">A summary of warrant activity for the nine months ended September 30, 2016 (unaudited) is presented below (in thousands, except per share and contractual life data).</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 88%; margin-left: 0.25in; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Remaining</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Contractual</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Life (in Years)</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 58%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding at December 31, 2015</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,840</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.72</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 11%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2.80</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited or expired</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding at September 30, 2016</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">1,840</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">7.72</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">2.06</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Warrants exercisable at September 30, 2016</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">1,840</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">7.72</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">2.06</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">A summary of stock option activity for the nine months ended September 30, 2016 (unaudited) is presented below (in thousands, except per share and contractual life data).</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 90%; margin-left: 0.25in; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Remaining</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Contractual</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Life (in Years)</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 61%"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding at December 31, 2015</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,472</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.01</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.39</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">690</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.33</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(96</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.00</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited or expired</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">(397</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">9.03</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding at September 30, 2016</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">3,669</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">7.28</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">6.45</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Options exercisable at September 30, 2016</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">1,934</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">6.54</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">4.40</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The following table summarizes Restricted Stock Unit (RSU) activity for the nine months ended September 30, 2016 (in thousands, except per share data):</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table align="center" cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Average Grant</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number</b></font></td> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date Fair Value</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>of Awards</b></font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Per Share</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 74%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding as of December 31, 2015</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">190</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12.43</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Awarded</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Vested</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(48</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited/canceled</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding as of September 30, 2016</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">142</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">12.43</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The total stock-based compensation recognized for stock-based awards granted under the 2003 Plan and the 2011 Plan in the condensed consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015 (unaudited) is as follows (in thousands):</font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 12pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b></b></font></p> <table align="center" cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nine Months</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nine Months</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2015</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2015</b></font></td> <td style="padding-bottom: 1pt; font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="width: 40%"><font style="font: 10pt Times New Roman, Times, Serif">Cost of sales</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">80</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">103</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">245</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">265</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Research and development</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">77</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">99</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">238</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">217</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Clinical and regulatory</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">43</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">84</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">136</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">206</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Selling and marketing</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">74</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">127</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">59</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">312</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255)"> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">General and administrative</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">624</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">443</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">1,903</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">918</font></td> <td style="text-align: left; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">898</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">856</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">2,581</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; border-bottom: black 2.5pt double"><font style="font: 10pt Times New Roman, Times, Serif">1,918</font></td> <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> 0.995 0.005 19500000 5978465 1181927 3.315 13.36 0.85 0.21 0.12 0.11 0.07 0.00 0.00 0.00 0.06 0.12 0.13 0.13 0.00 0.08 0.03 0.16 0.05 0.03 0.10 0.01 0.02 0.15 0.08 0.10 0.01 0.37 0.29 0.21 0.15 0.00 0.0 0.00 0.00 0.00 0.17 0.00 0.03 0.19 0.10 0.10 0.10 0.47 0.56 0.47 0.46 0.11 0.12 0.21 0.20 0.00 0.04 0.05 0.03 0.07 0.11 0.08 0.18 0.35 0.04 0.15 0.05 0.00 0.13 0.03 0.06 17546000 17546000 15721000 15721000 470000 575000 4920000 5028000 3499000 3156000 8889000 8759000 3079000 550000 6379000 5972000 3369000 1960000 508000 135000 3594000 2117000 533000 135000 4852000 4540000 342089 0 6102 6022 342 412 802 802 1038 1038 3669 3505 142 190 109 75 87000 26274 1840000 1840000 1840000 7.72 7.72 7.72 P2Y9M18D P2Y0M21D P2Y0M21D 0 3669000 3472000 690000 27344 659973 30000 -96000 59063 95493 397000 1934000 7.28 8.01 4.33 5.00 4.75 3.44 5.16 5.23 9.03 6.54 P6Y4M20D P6Y5M12D P4Y4M24D 190000 142000 48000 12.43 12.43 2581000 898000 856000 1918000 80000 103000 245000 265000 77000 99000 238000 217000 43000 84000 136000 206000 74000 127000 59000 312000 624000 443000 1903000 918000 3500000 6000000 7500000 0 6900000 P2Y10M17D P2Y10M2D 479000 10.26 1.64 2.47 1.77 3.76 12055 123684 P10Y P10Y P4Y P4Y P4Y P5Y 1350000 53000 P6Y3M P6Y3M 0.4820 0.4820 0.0143 0.0187 0.0187 0.00 0.00 98681 47500 <p><font style="font: 10pt Times New Roman, Times, Serif">All unvested options for this employee were terminated when this employee ceased full-time employment with the Company.</font></p> 7500000 <p><font style="font: 10pt Times New Roman, Times, Serif">Under the ESPP, shares of the Company's common stock may be purchased at six-month intervals at 85% of the lower of the closing fair market value of the common stock (i) on the first trading day of the offering period or (ii) on the last trading day of the purchase period. An employee may purchase in any one calendar year shares of common stock having an aggregate fair market value of up to $25,000 determined as of the first trading day of the offering period. Additionally, a participating employee may not purchase more than 100,000 shares of common stock in any one offering period.</font></p> 154225 337000 1699000 190000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>1.&#160; Organization and Business Operations</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Second Sight Medical Products, Inc. (&#8220;Second Sight&#8221; or &#8220;the Company&#8221;), was founded in 1998 as a limited liability company and was subsequently incorporated in the State of California in 2003. Second Sight develops, manufactures and markets implantable prosthetic devices that can restore some functional vision to patients blinded by outer retinal degenerations, such as Retinitis Pigmentosa.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">In 2007, Second Sight formed Second Sight (Switzerland) Sarl, initially to manage clinical trials for its products in Europe, and later to manage sales and marketing in Europe and the Middle East. As the laws of Switzerland require at least two corporate stockholders, Second Sight (Switzerland) Sarl is 99.5% owned directly by the Company and 0.5% owned by an executive of Second Sight, who is acting as a nominee of the Company. Accordingly, Second Sight (Switzerland) Sarl is considered 100% owned for financial statement purposes and is consolidated with Second Sight for all periods presented.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Since its inception, the Company has generated limited revenues from the sale of products and has financed its operations primarily through the issuance of common stock, convertible debt (which has been converted into common stock), and grants primarily from government agencies.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The Company&#8217;s financial statements have been presented on the basis that its business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is subject to the risks and uncertainties associated with a business with one product line and limited commercial product revenues, including limitations on the Company&#8217;s operating capital resources and uncertain demand for its products. The Company has incurred recurring operating losses and negative operating cash flows since inception, and it expects to continue to incur operating losses and negative operating cash flows for at least the next few years. The Company&#8217;s independent registered public accounting firm, in its report on the Company&#8217;s 2015 consolidated financial statements, raised substantial doubt about the Company&#8217;s ability to continue as a going concern.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">In June 2016, the Company successfully completed a Rights Offering to existing stockholders, raising proceeds of $19.5 million net of cash offering costs, and selling 5,978,465 shares of common stock at $3.315 per share, representing 85% of the Company&#8217;s stock price at the close of the rights offering. The Company believes that it has sufficient funds to last through the end of the second quarter of 2017. In order to continue business operations past that point, the Company currently anticipates that it will need to raise additional debt and/or equity capital during the next several months. However, there can be no assurances that the Company will be able to secure any such additional financing on acceptable terms and conditions, or at all. If cash resources become insufficient to satisfy the Company&#8217;s ongoing cash requirements, the Company would be required to scale back or discontinue its technology and product development programs and/or clinical trials, or obtain funds, if available (although there can be no certainty), through strategic alliances that may require the Company to relinquish rights to its products, or to discontinue its operations entirely.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>3. Concentration of Risk</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Credit Risk</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash, money market funds, and trade accounts receivable. The Company maintains cash and money market funds with financial institutions that management deems reputable, and at times, cash balances may be in excess of Federal Deposit Insurance Corporation and Securities Investor Protection Corporation insurance limits. The Company extends differing levels of credit to customers, and typically does not require collateral.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The Company also maintains a cash balance at a bank in Switzerland, which is insured up to an amount specified by the deposit insurance agency of Switzerland.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Customer Concentration</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">During the three and nine months ended September 30, 2016 and 2015 (unaudited), the following customers comprised more than 10% of revenues<b>:</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nine Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nine Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%"><font style="font: 10pt Times New Roman, Times, Serif">Customer 1</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 2</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 3</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">16</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">15</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 4</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">13</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 5</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">13</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 6</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2016 and December 31, 2015, the following customers comprised more than 10% of accounts receivable:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" align="center" style="width: 80%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December31,</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(unaudited)</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%"><font style="font: 10pt Times New Roman, Times, Serif">Customer 1</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 2</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">29</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">17</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 3</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 4</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">15</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 5</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">19</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 6</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 7</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 8</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Geographic Concentration</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">During the three and nine months ended September 30, 2016 and 2015 (unaudited), regional revenue, based on customer location, consisted of the following:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" align="center" style="width: 93%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nine Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nine Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">United States</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">47</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">56</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">47</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">46</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Germany</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">35</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">15</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Italy</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">20</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">France</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">18</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Canada</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">13</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Turkey</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Sources of Supply</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12.25pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Several of the components, materials and services used in the Company&#8217;s current Argus II product are available from only one supplier, and substitutes for these items cannot be obtained easily or would require substantial design or manufacturing modifications. Any significant problem experienced by one of the Company&#8217;s sole source suppliers could result in a delay or interruption in the supply of components to the Company until that supplier cures the problem or an alternative source of the component is located and qualified. Even where the Company could qualify alternative suppliers, the substitution of suppliers may be at a higher cost and create time delays that impede the commercial production of the Argus II and impact the Company&#8217;s abilities to deliver its products as may be timely required to meet demand.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Foreign Operations</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The accompanying condensed consolidated financial statements as of September 30, 2016 (unaudited) and December 31, 2015 include assets amounting to $2,228,000 and $3,041,000, respectively, relating to operations of the Company&#8217;s subsidiary based in Switzerland. It is possible that unanticipated events in foreign countries could disrupt the Company&#8217;s operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Customer Concentration</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">During the three and nine months ended September 30, 2016 and 2015 (unaudited), the following customers comprised more than 10% of revenues<b>:</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nine Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nine Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%"><font style="font: 10pt Times New Roman, Times, Serif">Customer 1</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 2</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 3</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">16</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">15</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 4</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">13</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 5</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">13</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 6</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2016 and December 31, 2015, the following customers comprised more than 10% of accounts receivable:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" align="center" style="width: 80%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December31,</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(unaudited)</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%"><font style="font: 10pt Times New Roman, Times, Serif">Customer 1</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 2</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">29</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">17</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 3</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 4</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">15</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 5</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">19</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 6</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 7</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Customer 8</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">10</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Geographic Concentration</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">During the three and nine months ended September 30, 2016 and 2015 (unaudited), regional revenue, based on customer location, consisted of the following:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" align="center" style="width: 93%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nine Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nine Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">United States</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">47</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">56</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">47</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">46</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Germany</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">35</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">15</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Italy</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">20</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">France</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">11</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">18</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Canada</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">13</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Turkey</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Inventories consisted of the following at (in thousands):</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" align="center" style="width: 80%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(unaudited)</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Raw materials</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">470</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">575</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Work in process</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,920</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,028</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Finished goods</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,499</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,156</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,889</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,759</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Allowance for excess and obsolescence</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3,079</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(550</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Inventories, net</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,810</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,209</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>5.&#160; Selected Balance Sheet Detail</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Inventories, net</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Inventories consisted of the following at (in thousands):</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" align="center" style="width: 80%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(unaudited)</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Raw materials</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">470</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">575</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Work in process</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4,920</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,028</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Finished goods</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,499</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,156</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,889</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,759</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Allowance for excess and obsolescence</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3,079</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(550</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Inventories, net</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,810</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,209</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><i>Property and equipment, net of accumulated depreciation and amortization</i></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment consisted of the following at (in thousands):</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" align="center" style="width: 80%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(unaudited)</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2" nowrap="nowrap" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Laboratory equipment</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,594</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,369</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Computer hardware and software</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,117</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,960</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">533</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">508</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Furniture, fixtures and equipment</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">135</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">135</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6,379</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,972</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated depreciation and amortization</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(4,852</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(4,540</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment, net</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,527</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,432</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>6. Long Term Investor Right</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b>&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Investors who purchased shares in the Company&#8217;s IPO, and who complied with certain terms and conditions, such as holding their IPO shares in their name during the twenty-four month period following the closing of the IPO, are entitled under certain conditions to receive up to one additional share for each share they purchased in the IPO. For a more complete discussion of the Long Term Investor Right, see Note 2 in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2015.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2016, the Company identified investors who had perfected and maintained Long Term Investor Rights in 1,181,927 shares of common stock that were acquired as part of the Company&#8217;s IPO. The highest average closing price for the Company&#8217;s common stock on NASDAQ during any consecutive 90 day period ended on or before September 30, 2016 was $13.96. Based on this average closing stock price, an investor who purchased shares as part of the IPO, and who has perfected its Long Term Investor Right, would be entitled to 0.2894 shares for each share purchased in the IPO, rounded up to the next whole share, which represents an aggregate maximum of 342,089 shares that are potentially issuable by the Company pursuant to the Long Term Investor Right at that date. The actual number of common shares issuable pursuant to the Long Term Investor Right is dependent on the future stock price of the Company over the two year period subsequent to the November 24, 2014 closing date of the IPO, and could be as high as 342,089 shares and as low as zero shares.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The Long Term Investor Right is an equity instrument that will be accounted for as a component of the actual price per common share paid by the investor in the IPO. For basic earnings per share, the common shares associated with the Long Term Investor Right are treated as contingently issuable shares and are not being included in basic earnings per share until the actual number of shares can be calculated and the shares have been issued.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>9. Stock-Based Compensation</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">On May 10, 2016, the stockholders approved amendments to the Company&#8217;s 2011 Equity Incentive Plan that (i) increase the maximum number of shares of common stock that may be issued under the Plan from 6.0 million shares to 7.5 million shares, (ii) allow issuance of Restricted Stock Units, and (iii) permit repricing and exchanges of options at the discretion of the Board of Directors.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Under the 2003 Plan, as restated in June 2011, the Company was authorized to issue options covering up to 3,500,000 common stock shares. Effective June 1, 2011, the Company adopted the 2011 Equity Incentive Plan (the &#8220;2011 Plan&#8221;). The maximum number of shares with respect to which options may be granted under the 2011 Plan is 7,500,000 shares, which is offset and reduced by options previously granted under the 2003 Plan. The option price is determined by the Board of Directors but cannot be less than the fair value of the shares at the grant date. Generally, the options vest ratably over either four or five years and expire ten years from the grant date. Both plans provide for accelerated vesting if there is a change of control, as defined in the plans.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">A summary of stock option activity for the nine months ended September 30, 2016 (unaudited) is presented below (in thousands, except per share and contractual life data).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;</font></p> <table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Remaining</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Contractual</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Life (in Years)</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding at December 31, 2015</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,472</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8.01</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.39</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">690</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.33</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(96</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.00</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited or expired</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(397</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="padding-bottom: 1pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9.03</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding at September 30, 2016</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,669</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.28</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.45</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Options exercisable at September 30, 2016</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,934</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">6.54</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.40</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The estimated aggregate intrinsic value of stock options exercisable at September 30, 2016 was $0. As of September 30, 2016, there was $6.9 million of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted average period of 2.84 years.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">On January 1, 2015, the Company&#8217;s current Chairman, who at the time was the Chief Executive Officer, exercised stock options on a cashless basis to purchase 59,063 shares of common stock at an exercise price of $4.75 per share. Based on the closing market price of the Company&#8217;s common stock of $10.26 on December 31, 2014, the Chief Executive Officer tendered 27,344 shares of common stock that he owned to satisfy the aggregate exercise price and surrendered 12,055 shares of common stock to satisfy the related $123,684 income and payroll tax withholding amounts related to the transaction.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2016, the Company granted stock options to purchase 659,973 shares of common stock to certain employees and contractors. The options are exercisable for a period of ten years from the date of grant at prices ranging from $3.44 to $5.16 per share, which was the fair value of the Company&#8217;s common stock on the respective grant dates. The options vest over a period of four years. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $1,350,000 ($1.64 to $2.47 per share). Assumptions used in the model were an expected term of 6.25 years, volatility of 48.2%, a risk-free interest rate of 1.40% to 1.87%, and an expected dividend rate of 0%.&#160; During the nine months ended September 30, 2016, the Company issued 95,493 shares of common stock through exercises of stock options that resulted in net proceeds of $479,000.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2016, the Company granted stock options to purchase 30,000 shares of common stock to an outside attorney in connection with his services relating to the Company&#8217;s rights offering to stockholders. The options have fully vested and are exercisable for a period of four years from the date of grant at a price of $5.23 per share, which was 125% of the fair value of the Company&#8217;s common stock on the grant date of January 14, 2016. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $53,000 ($1.77 per share). Assumptions used in the model were an expected term of 6.25 years, volatility of 48.2%, a risk-free interest rate of 1.87%, and an expected dividend rate of 0%.&#160;&#160;The cost of these shares was treated as an issuance cost of the offering and was deducted from the gross proceeds from the offering.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">During the first quarter of 2016, the Company recorded a charge of $55,000 to extend the exercise period of 98,681 vested options for one employee who resigned and became a consultant for the Company. All unvested options for this employee were terminated when this employee ceased full-time employment with the Company.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The following table summarizes Restricted Stock Unit (RSU) activity for the nine months ended September 30, 2016 (in thousands, except per share data):</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" align="center" style="width: 80%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Average Grant</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number</b></font></td> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Date Fair Value</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>of Awards</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Per Share</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="2"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding as of December 31, 2015</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">190</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 10%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12.43</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Awarded</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><font style="font: 10pt Times New Roman, Times, Serif">Vested</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(48</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Forfeited/canceled</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding as of September 30, 2016</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">142</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">12.43</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2016, there was $1,699,000 of total unrecognized compensation cost related to the outstanding RSUs that will be recognized over a weighted average period of 2.88 years.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">On August 18, 2016, of the 190,000 RSUs held by the Company&#8217;s Chief Executive Officer, 47,500 RSUs vested at a market price of $3.76 per share.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The Company adopted an employee stock purchase plan (&#8220;ESPP&#8221;) starting in June 2015 for all eligible employees. Under the ESPP, shares of the Company's common stock may be purchased at six-month intervals at 85% of the lower of the closing fair market value of the common stock (i) on the first trading day of the offering period or (ii) on the last trading day of the purchase period. An employee may purchase in any one calendar year shares of common stock having an aggregate fair market value of up to $25,000 determined as of the first trading day of the offering period. Additionally, a participating employee may not purchase more than 100,000 shares of common stock in any one offering period. At September 30, 2016, 154,225 shares had been issued under the plan. Proceeds from the purchase of stock under the plan totaled $337,000 for the nine months ended September 30, 2016.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The total stock-based compensation recognized for stock-based awards granted under the 2003 Plan and the 2011 Plan in the condensed consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015 (unaudited) is as follows (in thousands):<b>&#160;</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p> <table cellspacing="0" cellpadding="0" align="center" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Three Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nine Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nine Months</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Ended</b></font></td> <td nowrap="nowrap" style="font-weight: bold"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2016</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%"><font style="font: 10pt Times New Roman, Times, Serif">Cost of sales</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">80</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">103</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">245</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">265</font></td> <td style="width: 1%; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Research and development</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">77</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">99</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">238</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">217</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Clinical and regulatory</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">43</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">84</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">136</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">206</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Selling and marketing</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">74</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">127</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">59</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">312</font></td> <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">General and administrative</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">624</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">443</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,903</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">918</font></td> <td style="padding-bottom: 1pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">898</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">856</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,581</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,918</font></td> <td style="padding-bottom: 2.5pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in"><font style="font: 10pt Times New Roman, Times, Serif"><b>10. &#160;Litigation, Claims and Assessments</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">Fifteen oppositions have been filed by a third-party in the European Patent Office, each challenging the validity of a European patent owned or exclusively licensed by the Company. The outcome of the challenges is not certain, however, if successful, they may affect the Company's ability to block competitors from utilizing some of its patented technology in Europe. Management of the Company does not believe any successful challenges will have a material effect on the Company&#8217;s ability to manufacture and sell its products, or otherwise have a material effect on its operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><font style="font: 10pt Times New Roman, Times, Serif">The Company is party to litigation arising in the ordinary course of business. It is management's opinion that the outcome of such matters will not have a material effect on the Company's financial statements.</font></p> EX-101.SCH 6 eyes-20160930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Business Operations link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Concentration of Risk link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Money Market Funds link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Selected Balance Sheet Detail link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Long Term Investor Right link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Equity Securities link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Litigation, Claims and Assessments link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Concentration of Risk (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Money Market Funds (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Selected Balance Sheet Detail (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Equity Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Organization and Business Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Concentration of Risk (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Concentration of Risk (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Concentration of Risk (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Concentration of Risk (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Money Market Funds (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Selected Balance Sheet Detail (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Selected Balance Sheet Detail (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Long Term Investor Right (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Equity Securities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Stock-Based Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Stock-Based Compensation (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 eyes-20160930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 eyes-20160930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 eyes-20160930_lab.xml XBRL LABEL FILE Second Sight (Switzerland) Sarl [Member] Legal Entity [Axis] Executive Officer [Member] Related Party [Axis] Right Offering [Member] Sale of Stock [Axis] Sales Revenue, Net [Member] Concentration Risk Benchmark [Axis] Customer 1 [Member] Customer [Axis] Customer 2 [Member] Customer 3 [Member] Customer 4 [Member] Customer 5 [Member] Customer 6 [Member] Accounts Receivable [Member] Customer 7 [Member] Customer 8 [Member] UNITED STATES Geographical [Axis] ITALY TURKEY FRANCE GERMANY CANADA Money Market Funds [Member] Asset Class [Axis] Level 1 [Member] Fair Value, Hierarchy [Axis] Level 2 [Member] Level 3 [Member] Laboratory Equipment [Member] Property, Plant and Equipment, Type [Axis] Computer Hardware and Software [Member] Leasehold Improvements [Member] Furniture, Fixtures and Equipment [Member] IPO [Member] Maximum [Member] Range [Axis] Minimum [Member] Long Term Investor Rights [Member] Antidilutive Securities [Axis] Underwriter's Warrants [Member] Warrants Associated With Convertible Debt [Member] Common Stock Options [Member] Restricted Stock Units [Member] Employee Stock Purchase Plan [Member] Non-Employee [Member] Warrants [Member] Equity Components [Axis] Award Type [Axis] Cost of Sales [Member] Income Statement Location [Axis] Research and Development [Member] Clinical And Regulatory [Member] Selling and Marketing [Member] General and Administrative [Member] 2011 Equity Incentive Plan [Member] Plan Name [Axis] Mr Jonathan Will McGuire [Member] Certain Employees and Contractors [Member] Outside Attorney [Member] Consultant [Member] Second Sight 2011 Equity Incentive Plan [Member] Employee Stock Purchase Plan [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Trading Symbol Document Period End Date Amendment Flag Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash Money market funds Accounts receivable, net Inventories, net Prepaid expenses and other current assets Total current assets Property and equipment, net Deposits and other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses Accrued compensation expenses Accrued clinical trial expenses Deferred revenue Deferred grant revenue Total current liabilities Commitments and contingencies Stockholders' equity: Preferred stock, no par value, 10,000 shares authorized; none outstanding Common stock, no par value, 200,000 shares authorized; shares issued and outstanding: 42,247 and 35,942 at September 30, 2016 and December 31, 2015, respectively Common stock to be issued Additional paid-in capital Notes receivable to finance stock option exercises Accumulated other comprehensive loss Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, no par value (in dollars per share) Preferred stock, authorized Preferred stock, outstanding Common stock, no par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] Net sales Cost of sales Gross profit (loss) Operating expenses: Research and development, net of grants Clinical and regulatory Selling and marketing General and administrative Total operating expenses Loss from operations Interest income Other income (expense), net Net loss Net loss per common share - basic and diluted (in dollars per share) Weighted average common shares outstanding - basic and diluted (in shares) Condensed Consolidated Statements Of Comprehensive Loss Net loss Other comprehensive income (loss): Foreign currency translation adjustments Comprehensive loss Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization of property and equipment Stock-based compensation Bad debt expense Excess inventory reserve Common stock issuable for services Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses and other assets Accounts payable Accrued expenses Accrued compensation expenses Accrued clinical trial expenses Deferred revenue Deferred grant revenue Net cash used in operating activities Cash flows from investing activities: Purchases of property and equipment (Investment) proceeds from money market funds Net cash provided by (used) in investing activities Cash flows from financing activities: Net proceeds from rights offering Proceeds from the exercise of options, warrants and employee stock purchase plan options Payment of employment taxes related to stock option exercises Net cash provided by financing activities Effect of exchange rate changes on cash Cash: Net increase (decrease) Balance at beginning of period Balance at end of period Supplemental cash flow information: Non-cash financing and investing activities: Fair value of stock options issued for services rendered in connection with rights offering Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Business Operations Accounting Policies [Abstract] Basis of Presentation,Significant Accounting Policies and Recent Accounting Pronouncements Risks and Uncertainties [Abstract] Concentration of Risk Cash and Cash Equivalents [Abstract] Money Market Funds Selected Balance Sheet Detail Long Term Investor Right Long Term Investor Right Stockholders' Equity Note [Abstract] Equity Securities Warrants Warrants Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-Based Compensation Commitments and Contingencies Disclosure [Abstract] Litigation, Claims and Assessments Basis of Presentation Significant Accounting Policies Recent Accounting Pronouncements Schedule of revenues, accounts receivable & geographic concentration Schedule of money market funds Schedule of inventories Schedule of property and equipment Schedule of anti-dilutive securities Warrants Tables Schedule of warrant activity Schedule of stock option activity Schedule of restricted stock unit (RSU) activity Schedule of stock-based compensation Statement [Table] Statement [Line Items] Ownership percentage by parent Ownership percentage by noncontrolling interest Proceeds from issuance or sale of shares Number of shares issued upon right offering Share price (in dollars per share) Percentage of company's stock price at the close of the rights offering Customer Concentration Assets Money market funds Raw materials Work in process Finished goods Inventories, gross Allowance for excess and obsolescence Inventories, net Property and equipment, gross Accumulated depreciation and amortization Description of transaction Number of shares issued in transaction Shares price (in dollars per share) Subsequent Number of shares issued to Long Term Investor Right Total anti-dilutive securities Accrued services Number of shares issued for services Warrants Details Class Of Warrant Or Right Number Of Shares [RollForward] Warrants outstanding at beginning Warrants outstanding at end Warrants exercisable at end Class Of Warrant Or Right Weighted Average Exercise Price [RollForward] Warrants outstanding at beginning Warrants outstanding at end Warrants exercisable at end Class Of Warrant Or Right Weighted Average Remaining Contractual Life [RollForward] Warrants outstanding at beginning Warrants outstanding at end Warrants exercisable at end Intrinsic value of warrants outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options outstanding at beginning Granted Exercised Forfeited or expired Options outstanding at ending Options exercisable at ending Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Options outstanding at beginning Granted Exercised Forfeited or expired Options outstanding at ending Options exercisable at ending Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Life [Roll Forward] Options outstanding at beginning Options outstanding at ending Options exercisable at ending Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Outstanding at beginning Awarded Vested Forfeited/canceled Outstanding at ending Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Roll Forward] Outstanding at beginning Awarded Vested Forfeited/canceled Outstanding at ending Total Number of shares authorized Number of shares options granted Aggregate exercisable intrinsic value Total unrecognized compensation cost of options Period of recognized compensation cost Number of shares exercised Value of shares exercised Exercise price (in dollars per share) Share price (in dollars per share) Number of shares surrendered Value of shares surrendered Number of options granted Exercisable terms Vesting period Fair value of options Expected terms (in years) Volatility rate Risk-free interest rate Expected dividend rate Number of vested shares Share based charges Description of vesting terms Maximum number of shares authorized Description of plan Number of shares issued Proceeds from purchase of stock Total non vested unrecognized compensation cost Number of vested shares sold Average share price (in dollars per share) Amounts of income and payroll tax Represents information pertaining to deposits and other assets. Represents information pertaining to accrued clinical trial expenses. Represents information pertaining to deffered grant revenue. Represents information pertaining to common stock value. Represents information pertaining to notes receivable to finance stock option exercises. Represents information pertaining to clinical and regulatory. Represents information pertaining to common stock issued for services. Represents information pertaining to increase decresase accrued clinical trial expenses. Represents information pertaining to increase decresase in deffered revenue. Represents information pertaining to proceeds from money market funds. Represents information pertaining to proceeds fromexercise of options and warrants. Represents information pertaining to payment of employment taxes related to stock option exercises. The entire disclosure of long term investor rights. Represent information about the warrant activity. It refers to the name of an entity. A security giving shareholders entitlement to acquire new shares issued by the entity at an established price in proportion to the number of shares already owned. Generally, rights expire within in a short time after issuance. Percentage of per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. Information about customers such as their name and contact information. Information about customers such as their name and contact information. Information about customers such as their name and contact information. Information about customers such as their name and contact information. Information about customers such as their name and contact information. Information about customers such as their name and contact information. Information about customers such as their name and contact information. Information about customers such as their name and contact information. Information about laboratory equipment. The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. It refers to long term investor rights. It refers compensation sometimes granted to an underwriter in the form of common stock warrants. A note that entitles the holder to buy stock of the company at a specified price, which is much higher than the stock price at the time of issue. Information about common stock options. A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. The number of warrants shares into which fully or partially vested warrants outstanding as of the balance sheet date. A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. The weighted-average price as of the balance sheet date at which grantees can acquire the warrant shares reserved for issuance on vested portions of warrants outstanding and currently exercisable. A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Weighted average remaining contractual term for warrants outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for warrants outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for warrants outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Amount by which the current fair value of the underlying stock exceeds the exercise price of warrants outstanding. Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Primary financial statement caption in which the reported facts about clinical and regulatory expense have been included. Information about equity incentive plan. Information by type of related party. Information about outside attorney. Information about related party. Information about equity incentive plan. Information about employee stock purchase plan. Number of shares surrendered during the period. Value of stock surrendered during period. Number of vested shares sold during the period. Price of a average share of a number of saleable stocks of a company. EmployeeStockPurchasePlanMember Assets, Current DepositsAndOtherAssets Liabilities, Current Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Gross Profit Operating Expenses Comprehensive Income (Loss), Net of Tax, Attributable to Parent Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Employee Related Liabilities IncreaseDecreaseAccruedClinicalTrialExpenses Increase (Decrease) in Deferred Revenue IncreaseDecreaseInDeferredRevenue1 Net Cash Provided by (Used in) Operating Activities, Continuing Operations Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities PaymentOfEmploymentTaxesRelatedToStockOptionExercises Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) LongTermInvestorRightTextBock WarrantsDisclosureTextBlock Cash and Cash Equivalents, Fair Value Disclosure Inventory, Gross Inventory Adjustments Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Class of Warrant or Right, Outstanding ClassOfWarrantOrRightWarrantsSharesExercisable Class of Warrant or Right, Exercise Price of Warrants or Rights ClassOfWarrantOrRightWarrantsWeightedAverageExercisePriceExercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Share Price EX-101.PRE 10 eyes-20160930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2016
Nov. 02, 2016
Document And Entity Information    
Entity Registrant Name SECOND SIGHT MEDICAL PRODUCTS INC  
Entity Central Index Key 0001266806  
Document Type 10-Q  
Trading Symbol EYES  
Document Period End Date Sep. 30, 2016  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity a Well-known Seasoned Issuer No  
Entity a Voluntary Filer No  
Entity's Reporting Status Current Yes  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   42,246,954
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2016  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Current assets:    
Cash $ 277 $ 239
Money market funds 17,546 15,721
Accounts receivable, net 447 1,501
Inventories, net 5,810 8,209
Prepaid expenses and other current assets 603 1,094
Total current assets 24,683 26,764
Property and equipment, net 1,527 1,432
Deposits and other assets 55 49
Total assets 26,265 28,245
Current liabilities:    
Accounts payable 694 710
Accrued expenses 1,711 2,068
Accrued compensation expenses 2,055 2,069
Accrued clinical trial expenses 555 616
Deferred revenue 195 322
Deferred grant revenue 456 2,197
Total current liabilities 5,666 7,982
Commitments and contingencies
Stockholders' equity:    
Preferred stock, no par value, 10,000 shares authorized; none outstanding
Common stock, no par value, 200,000 shares authorized; shares issued and outstanding: 42,247 and 35,942 at September 30, 2016 and December 31, 2015, respectively 186,618 166,049
Common stock to be issued 87 205
Additional paid-in capital 29,911 27,277
Notes receivable to finance stock option exercises (2) (5)
Accumulated other comprehensive loss (524) (581)
Accumulated deficit (195,491) (172,682)
Total stockholders' equity 20,599 20,263
Total liabilities and stockholders' equity $ 26,265 $ 28,245
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Preferred stock, no par value (in dollars per share)
Preferred stock, authorized 10,000 10,000
Preferred stock, outstanding 0 0
Common stock, no par value (in dollars per share)
Common stock, authorized 200,000 200,000
Common stock, issued 42,247 35,942
Common stock, outstanding 42,247 35,942
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Statement [Abstract]        
Net sales $ 1,180 $ 2,227 $ 3,270 $ 6,588
Cost of sales 2,615 757 6,768 3,622
Gross profit (loss) (1,435) 1,470 (3,498) 2,966
Operating expenses:        
Research and development, net of grants 1,588 593 3,266 2,490
Clinical and regulatory 609 984 1,955 2,543
Selling and marketing 2,262 2,132 6,473 6,425
General and administrative 2,605 2,423 7,635 6,079
Total operating expenses 7,064 6,132 19,329 17,537
Loss from operations (8,499) (4,662) (22,827) (14,571)
Interest income 11 19 1
Other income (expense), net (1) (4) (1) 25
Net loss $ (8,489) $ (4,666) $ (22,809) $ (14,545)
Net loss per common share - basic and diluted (in dollars per share) $ (0.20) $ (0.13) $ (0.57) $ (0.41)
Weighted average common shares outstanding - basic and diluted (in shares) 42,220 35,836 39,929 35,555
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Condensed Consolidated Statements Of Comprehensive Loss        
Net loss $ (8,489) $ (4,666) $ (22,809) $ (14,545)
Other comprehensive income (loss):        
Foreign currency translation adjustments 34 (70) 57 (72)
Comprehensive loss $ (8,455) $ (4,736) $ (22,752) $ (14,617)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Cash flows from operating activities:    
Net loss $ (22,809) $ (14,545)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization of property and equipment 311 231
Stock-based compensation 2,581 1,918
Bad debt expense 191
Excess inventory reserve 2,611
Common stock issuable for services 206 233
Changes in operating assets and liabilities:    
Accounts receivable 874 (600)
Inventories (166) (2,416)
Prepaid expenses and other assets 492 195
Accounts payable (16) 31
Accrued expenses (377) 469
Accrued compensation expenses (15) 888
Accrued clinical trial expenses (61) 68
Deferred revenue (135) 184
Deferred grant revenue (1,741) (1,308)
Net cash used in operating activities (18,054) (14,652)
Cash flows from investing activities:    
Purchases of property and equipment (406) (578)
(Investment) proceeds from money market funds (1,820) 12,599
Net cash provided by (used) in investing activities (2,226) 12,021
Cash flows from financing activities:    
Net proceeds from rights offering 19,483
Proceeds from the exercise of options, warrants and employee stock purchase plan options 816 2,476
Payment of employment taxes related to stock option exercises (124)
Net cash provided by financing activities 20,299 2,352
Effect of exchange rate changes on cash 19 (72)
Cash:    
Net increase (decrease) 38 (351)
Balance at beginning of period 239 619
Balance at end of period 277 268
Non-cash financing and investing activities:    
Fair value of stock options issued for services rendered in connection with rights offering $ 53
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Organization and Business Operations
9 Months Ended
Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Business Operations

1.  Organization and Business Operations

 

Second Sight Medical Products, Inc. (“Second Sight” or “the Company”), was founded in 1998 as a limited liability company and was subsequently incorporated in the State of California in 2003. Second Sight develops, manufactures and markets implantable prosthetic devices that can restore some functional vision to patients blinded by outer retinal degenerations, such as Retinitis Pigmentosa. 

 

In 2007, Second Sight formed Second Sight (Switzerland) Sarl, initially to manage clinical trials for its products in Europe, and later to manage sales and marketing in Europe and the Middle East. As the laws of Switzerland require at least two corporate stockholders, Second Sight (Switzerland) Sarl is 99.5% owned directly by the Company and 0.5% owned by an executive of Second Sight, who is acting as a nominee of the Company. Accordingly, Second Sight (Switzerland) Sarl is considered 100% owned for financial statement purposes and is consolidated with Second Sight for all periods presented.

 

Since its inception, the Company has generated limited revenues from the sale of products and has financed its operations primarily through the issuance of common stock, convertible debt (which has been converted into common stock), and grants primarily from government agencies.

 

The Company’s financial statements have been presented on the basis that its business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is subject to the risks and uncertainties associated with a business with one product line and limited commercial product revenues, including limitations on the Company’s operating capital resources and uncertain demand for its products. The Company has incurred recurring operating losses and negative operating cash flows since inception, and it expects to continue to incur operating losses and negative operating cash flows for at least the next few years. The Company’s independent registered public accounting firm, in its report on the Company’s 2015 consolidated financial statements, raised substantial doubt about the Company’s ability to continue as a going concern.

 

In June 2016, the Company successfully completed a Rights Offering to existing stockholders, raising proceeds of $19.5 million net of cash offering costs, and selling 5,978,465 shares of common stock at $3.315 per share, representing 85% of the Company’s stock price at the close of the rights offering. The Company believes that it has sufficient funds to last through the end of the second quarter of 2017. In order to continue business operations past that point, the Company currently anticipates that it will need to raise additional debt and/or equity capital during the next several months. However, there can be no assurances that the Company will be able to secure any such additional financing on acceptable terms and conditions, or at all. If cash resources become insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale back or discontinue its technology and product development programs and/or clinical trials, or obtain funds, if available (although there can be no certainty), through strategic alliances that may require the Company to relinquish rights to its products, or to discontinue its operations entirely.

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements
9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Basis of Presentation,Significant Accounting Policies and Recent Accounting Pronouncements

2.   Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for Form 10-Q. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2015 has been derived from the Company’s audited consolidated financial statements.

 

In the opinion of management, these financial statements reflect all normal recurring and other adjustments necessary for a fair presentation. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year or any other future periods.

 

Significant Accounting Policies

 

The Company’s significant accounting policies are set forth in Note 2 of the financial statements in its Annual Report on Form 10-K for the year ended December 31, 2015.

 

Recent Accounting Pronouncements

 

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230), which updates the guidance as to how certain cash receipts and cash payments should be presented and classified. The update is intended to reduce the existing diversity in practice. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted, including adoption in an interim period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires measurement and recognition of expected versus incurred credit losses for financial assets held. ASU 2016-13 is effective for the Company in the first quarter of fiscal 2020 with early adoption permitted beginning in the first quarter of fiscal 2019. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.

 

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), a new standard that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. The standard also allows the Company to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting, clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on the cash flow statement, and provides an accounting policy election to account for forfeitures as they occur. The new standard is effective for the annual periods beginning after December 15, 2016, and interim periods within those annual periods with early adoption permitted. The Company is currently evaluating the impact of the standard on the Company’s financial statements.

 

Management does not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Concentration of Risk
9 Months Ended
Sep. 30, 2016
Risks and Uncertainties [Abstract]  
Concentration of Risk

3. Concentration of Risk

 

Credit Risk

 

Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash, money market funds, and trade accounts receivable. The Company maintains cash and money market funds with financial institutions that management deems reputable, and at times, cash balances may be in excess of Federal Deposit Insurance Corporation and Securities Investor Protection Corporation insurance limits. The Company extends differing levels of credit to customers, and typically does not require collateral.

 

The Company also maintains a cash balance at a bank in Switzerland, which is insured up to an amount specified by the deposit insurance agency of Switzerland. 

 

Customer Concentration

 

During the three and nine months ended September 30, 2016 and 2015 (unaudited), the following customers comprised more than 10% of revenues:

 

    Three Months     Three Months     Nine Months     Nine Months  
    Ended     Ended     Ended     Ended  
    September 30, 2016     September 30, 2015     September 30, 2016     September 30, 2015  
                         
Customer 1     21 %     0 %     8 %     1 %
Customer 2     12 %     6 %     3 %     2 %
Customer 3     11 %     12 %     16 %     15 %
Customer 4     7 %     13 %     5 %     8 %
Customer 5     0 %     13 %     3 %     10 %
Customer 6     0 %     0 %     10 %     1 %

 

As of September 30, 2016 and December 31, 2015, the following customers comprised more than 10% of accounts receivable:

 

    September 30,     December31,  
    2016     2015  
    (unaudited)        
Customer 1     37 %     0 %
Customer 2     29 %     17 %
Customer 3     21 %     0 %
Customer 4     15 %     3 %
Customer 5     0 %     19 %
Customer 6     0 %     10 %
Customer 7     0 %     10 %
Customer 8     0 %     10 %

 

Geographic Concentration

 

During the three and nine months ended September 30, 2016 and 2015 (unaudited), regional revenue, based on customer location, consisted of the following:

 

    Three Months     Three Months     Nine Months     Nine Months  
    Ended     Ended     Ended     Ended  
    September 30, 2016     September 30, 2015     September 30, 2016     September 30, 2015  
                         
United States     47 %     56 %     47 %     46 %
Germany     35 %     4 %     15 %     5 %
Italy     11 %     12 %     21 %     20 %
France     7 %     11 %     8 %     18 %
Canada     0 %     13 %     3 %     6 %
Turkey     0 %     4 %     5 %     3 %

  

Sources of Supply

 

Several of the components, materials and services used in the Company’s current Argus II product are available from only one supplier, and substitutes for these items cannot be obtained easily or would require substantial design or manufacturing modifications. Any significant problem experienced by one of the Company’s sole source suppliers could result in a delay or interruption in the supply of components to the Company until that supplier cures the problem or an alternative source of the component is located and qualified. Even where the Company could qualify alternative suppliers, the substitution of suppliers may be at a higher cost and create time delays that impede the commercial production of the Argus II and impact the Company’s abilities to deliver its products as may be timely required to meet demand.

 

Foreign Operations

 

The accompanying condensed consolidated financial statements as of September 30, 2016 (unaudited) and December 31, 2015 include assets amounting to $2,228,000 and $3,041,000, respectively, relating to operations of the Company’s subsidiary based in Switzerland. It is possible that unanticipated events in foreign countries could disrupt the Company’s operations.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Money Market Funds
9 Months Ended
Sep. 30, 2016
Cash and Cash Equivalents [Abstract]  
Money Market Funds

4. Money Market Funds

 

The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.

 

Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.

 

Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.

 

Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.

 

Money market funds are the only financial instrument measured and recorded at fair value on the Company’s balance sheet, and they are considered Level 1 valuation securities. The following table presents money market funds at their level within the fair value hierarchy at September 30, 2016 and December 31, 2015 (in thousands):

  

    Total     Level 1     Level 2     Level 3  
                         
September 30, 2016 (unaudited):                                
Money market funds   $ 17,546     $ 17,546     $     $  
                                 
December 31, 2015:                                
Money market funds   $ 15,721     $ 15,721     $     $  
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Selected Balance Sheet Detail
9 Months Ended
Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Selected Balance Sheet Detail

5.  Selected Balance Sheet Detail

 

Inventories, net

 

Inventories consisted of the following at (in thousands):

 

    September 30,     December 31,  
    2016     2015  
    (unaudited)        
Raw materials   $ 470     $ 575  
Work in process     4,920       5,028  
Finished goods     3,499       3,156  
                 
      8,889       8,759  
                 
Allowance for excess and obsolescence     (3,079 )     (550 )
Inventories, net   $ 5,810     $ 8,209  

 

Property and equipment, net of accumulated depreciation and amortization

 

Property and equipment consisted of the following at (in thousands):

 

    September 30,     December 31,  
    2016     2015  
    (unaudited)        
Laboratory equipment   $ 3,594     $ 3,369  
Computer hardware and software     2,117       1,960  
Leasehold improvements     533       508  
Furniture, fixtures and equipment     135       135  
                 
      6,379       5,972  
Accumulated depreciation and amortization     (4,852 )     (4,540 )
                 
Property and equipment, net   $ 1,527     $ 1,432  
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Long Term Investor Right
9 Months Ended
Sep. 30, 2016
Long Term Investor Right  
Long Term Investor Right

6. Long Term Investor Right

  

Investors who purchased shares in the Company’s IPO, and who complied with certain terms and conditions, such as holding their IPO shares in their name during the twenty-four month period following the closing of the IPO, are entitled under certain conditions to receive up to one additional share for each share they purchased in the IPO. For a more complete discussion of the Long Term Investor Right, see Note 2 in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

 

As of September 30, 2016, the Company identified investors who had perfected and maintained Long Term Investor Rights in 1,181,927 shares of common stock that were acquired as part of the Company’s IPO. The highest average closing price for the Company’s common stock on NASDAQ during any consecutive 90 day period ended on or before September 30, 2016 was $13.96. Based on this average closing stock price, an investor who purchased shares as part of the IPO, and who has perfected its Long Term Investor Right, would be entitled to 0.2894 shares for each share purchased in the IPO, rounded up to the next whole share, which represents an aggregate maximum of 342,089 shares that are potentially issuable by the Company pursuant to the Long Term Investor Right at that date. The actual number of common shares issuable pursuant to the Long Term Investor Right is dependent on the future stock price of the Company over the two year period subsequent to the November 24, 2014 closing date of the IPO, and could be as high as 342,089 shares and as low as zero shares. 

 

The Long Term Investor Right is an equity instrument that will be accounted for as a component of the actual price per common share paid by the investor in the IPO. For basic earnings per share, the common shares associated with the Long Term Investor Right are treated as contingently issuable shares and are not being included in basic earnings per share until the actual number of shares can be calculated and the shares have been issued.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity Securities
9 Months Ended
Sep. 30, 2016
Stockholders' Equity Note [Abstract]  
Equity Securities

7. Equity Securities

 

Common Stock Issuable

 

Beginning with services rendered in 2014, and with payments in June 2015 and 2016, non-employee members of the Board of Directors are paid for their services in common stock on June 1 of each year based on the average closing prices for the immediately preceding twenty trading days. As of September 30, 2016, the Company accrued $87,000 for these services, which equates to 26,274 shares. These shares have not yet been issued and are excluded from the calculation of weighted average common shares outstanding for EPS purposes.

  

Potentially Dilutive Common Stock Equivalents

 

At September 30, 2016 and 2015 (unaudited), the Company excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately acquire shares of common stock, from its calculations of earnings per share and weighted average shares outstanding, as their effect would have been anti-dilutive (in thousands).

 

    September 30,     September 30,  
    2016     2015  
             
Long Term Investor Rights     342       412  
Underwriter’s warrants     802       802  
Warrants associated with convertible debt     1,038       1,038  
Common stock options     3,669       3,505  
Restricted stock units     142       190  
Employee stock purchase plan     109       75  
                 
Total     6,102       6,022  

 

Rights Offering

 

In June 2016, the Company completed a Rights Offering to existing stockholders by selling 5,978,465 shares of common stock. The Company evaluated the financial impact of FASB ASC 260, "Earnings per Share," which states, among other things, that if a rights issue is offered to all existing stockholders at an exercise price that is less than the fair value of the stock, then the weighted average shares outstanding and basic and diluted earnings per share shall be adjusted retroactively to reflect the bonus element of the rights offering for all periods presented. The Company determined that the application of this specific provision of ASC 260 was immaterial to previously issued financial statements and, therefore, did not retroactively adjust previously reported weighted average shares outstanding and basic and diluted earnings per share.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrants
9 Months Ended
Sep. 30, 2016
Warrants  
Warrants

8. Warrants

 

A summary of warrant activity for the nine months ended September 30, 2016 (unaudited) is presented below (in thousands, except per share and contractual life data).

 

                Weighted Average  
          Weighted     Remaining  
    Number of     Average     Contractual  
    Shares     Exercise Price     Life (in Years)  
Warrants outstanding at December 31, 2015     1,840     $ 7.72       2.80  
Granted                      
Exercised                      
Forfeited or expired                      
                         
Warrants outstanding at September 30, 2016     1,840     $ 7.72       2.06  
                         
Warrants exercisable at September 30, 2016     1,840     $ 7.72       2.06  

  

The intrinsic value of warrants outstanding at September 30, 2016 was $0. During the nine months ended September 30, 2016, no warrants were exercised.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation
9 Months Ended
Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation

9. Stock-Based Compensation

 

On May 10, 2016, the stockholders approved amendments to the Company’s 2011 Equity Incentive Plan that (i) increase the maximum number of shares of common stock that may be issued under the Plan from 6.0 million shares to 7.5 million shares, (ii) allow issuance of Restricted Stock Units, and (iii) permit repricing and exchanges of options at the discretion of the Board of Directors.

 

Under the 2003 Plan, as restated in June 2011, the Company was authorized to issue options covering up to 3,500,000 common stock shares. Effective June 1, 2011, the Company adopted the 2011 Equity Incentive Plan (the “2011 Plan”). The maximum number of shares with respect to which options may be granted under the 2011 Plan is 7,500,000 shares, which is offset and reduced by options previously granted under the 2003 Plan. The option price is determined by the Board of Directors but cannot be less than the fair value of the shares at the grant date. Generally, the options vest ratably over either four or five years and expire ten years from the grant date. Both plans provide for accelerated vesting if there is a change of control, as defined in the plans.

 

A summary of stock option activity for the nine months ended September 30, 2016 (unaudited) is presented below (in thousands, except per share and contractual life data).

   

                Weighted Average  
          Weighted     Remaining  
    Number of     Average     Contractual  
    Shares     Exercise Price     Life (in Years)  
Options outstanding at December 31, 2015     3,472     $ 8.01       6.39  
Granted     690     $ 4.33          
Exercised     (96 )   $ 5.00          
Forfeited or expired     (397 )   $ 9.03          
                         
Options outstanding at September 30, 2016     3,669     $ 7.28       6.45  
                         
Options exercisable at September 30, 2016     1,934     $ 6.54       4.40  

  

The estimated aggregate intrinsic value of stock options exercisable at September 30, 2016 was $0. As of September 30, 2016, there was $6.9 million of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted average period of 2.84 years.

 

On January 1, 2015, the Company’s current Chairman, who at the time was the Chief Executive Officer, exercised stock options on a cashless basis to purchase 59,063 shares of common stock at an exercise price of $4.75 per share. Based on the closing market price of the Company’s common stock of $10.26 on December 31, 2014, the Chief Executive Officer tendered 27,344 shares of common stock that he owned to satisfy the aggregate exercise price and surrendered 12,055 shares of common stock to satisfy the related $123,684 income and payroll tax withholding amounts related to the transaction.

 

During the nine months ended September 30, 2016, the Company granted stock options to purchase 659,973 shares of common stock to certain employees and contractors. The options are exercisable for a period of ten years from the date of grant at prices ranging from $3.44 to $5.16 per share, which was the fair value of the Company’s common stock on the respective grant dates. The options vest over a period of four years. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $1,350,000 ($1.64 to $2.47 per share). Assumptions used in the model were an expected term of 6.25 years, volatility of 48.2%, a risk-free interest rate of 1.40% to 1.87%, and an expected dividend rate of 0%.  During the nine months ended September 30, 2016, the Company issued 95,493 shares of common stock through exercises of stock options that resulted in net proceeds of $479,000.

 

During the nine months ended September 30, 2016, the Company granted stock options to purchase 30,000 shares of common stock to an outside attorney in connection with his services relating to the Company’s rights offering to stockholders. The options have fully vested and are exercisable for a period of four years from the date of grant at a price of $5.23 per share, which was 125% of the fair value of the Company’s common stock on the grant date of January 14, 2016. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $53,000 ($1.77 per share). Assumptions used in the model were an expected term of 6.25 years, volatility of 48.2%, a risk-free interest rate of 1.87%, and an expected dividend rate of 0%.  The cost of these shares was treated as an issuance cost of the offering and was deducted from the gross proceeds from the offering.

 

During the first quarter of 2016, the Company recorded a charge of $55,000 to extend the exercise period of 98,681 vested options for one employee who resigned and became a consultant for the Company. All unvested options for this employee were terminated when this employee ceased full-time employment with the Company.

 

The following table summarizes Restricted Stock Unit (RSU) activity for the nine months ended September 30, 2016 (in thousands, except per share data):

 

          Weighted  
          Average Grant  
    Number     Date Fair Value  
    of Awards     Per Share  
             
Outstanding as of December 31, 2015     190     $ 12.43  
Awarded     -       -  
Vested     (48 )     -  
Forfeited/canceled     -       -  
Outstanding as of September 30, 2016     142     $ 12.43  

 

As of September 30, 2016, there was $1,699,000 of total unrecognized compensation cost related to the outstanding RSUs that will be recognized over a weighted average period of 2.88 years.

 

On August 18, 2016, of the 190,000 RSUs held by the Company’s Chief Executive Officer, 47,500 RSUs vested at a market price of $3.76 per share.

 

The Company adopted an employee stock purchase plan (“ESPP”) starting in June 2015 for all eligible employees. Under the ESPP, shares of the Company's common stock may be purchased at six-month intervals at 85% of the lower of the closing fair market value of the common stock (i) on the first trading day of the offering period or (ii) on the last trading day of the purchase period. An employee may purchase in any one calendar year shares of common stock having an aggregate fair market value of up to $25,000 determined as of the first trading day of the offering period. Additionally, a participating employee may not purchase more than 100,000 shares of common stock in any one offering period. At September 30, 2016, 154,225 shares had been issued under the plan. Proceeds from the purchase of stock under the plan totaled $337,000 for the nine months ended September 30, 2016.

 

The total stock-based compensation recognized for stock-based awards granted under the 2003 Plan and the 2011 Plan in the condensed consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015 (unaudited) is as follows (in thousands): 

 

    Three Months     Three Months     Nine Months     Nine Months  
    Ended     Ended     Ended     Ended  
    September 30, 2016     September 30, 2015     September 30, 2016     September 30, 2015  
Cost of sales   $ 80     $ 103     $ 245     $ 265  
Research and development     77       99       238       217  
Clinical and regulatory     43       84       136       206  
Selling and marketing     74       127       59       312  
General and administrative     624       443       1,903       918  
Total   $ 898     $ 856     $ 2,581     $ 1,918  
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Litigation, Claims and Assessments
9 Months Ended
Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Litigation, Claims and Assessments

10.  Litigation, Claims and Assessments

 

Fifteen oppositions have been filed by a third-party in the European Patent Office, each challenging the validity of a European patent owned or exclusively licensed by the Company. The outcome of the challenges is not certain, however, if successful, they may affect the Company's ability to block competitors from utilizing some of its patented technology in Europe. Management of the Company does not believe any successful challenges will have a material effect on the Company’s ability to manufacture and sell its products, or otherwise have a material effect on its operations.

 

The Company is party to litigation arising in the ordinary course of business. It is management's opinion that the outcome of such matters will not have a material effect on the Company's financial statements.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements (Policies)
9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for Form 10-Q. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet at December 31, 2015 has been derived from the Company’s audited consolidated financial statements.

  

In the opinion of management, these financial statements reflect all normal recurring and other adjustments necessary for a fair presentation. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year or any other future periods.

Significant Accounting Policies

Significant Accounting Policies

 

The Company’s significant accounting policies are set forth in Note 2 of the financial statements in its Annual Report on Form 10-K for the year ended December 31, 2015.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230), which updates the guidance as to how certain cash receipts and cash payments should be presented and classified. The update is intended to reduce the existing diversity in practice. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted, including adoption in an interim period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

 

In June 2016 the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires measurement and recognition of expected versus incurred credit losses for financial assets held. ASU 2016-13 is effective for the Company in the first quarter of fiscal 2020 with early adoption permitted beginning in the first quarter of fiscal 2019. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.

 

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), a new standard that changes the accounting for certain aspects of share-based payments to employees. The new guidance requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. The standard also allows the Company to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting, clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity on the cash flow statement, and provides an accounting policy election to account for forfeitures as they occur. The new standard is effective for the annual periods beginning after December 15, 2016, and interim periods within those annual periods with early adoption permitted. The Company is currently evaluating the impact of the standard on the Company’s financial statements.

 

Management does not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Concentration of Risk (Tables)
9 Months Ended
Sep. 30, 2016
Risks and Uncertainties [Abstract]  
Schedule of revenues, accounts receivable & geographic concentration

Customer Concentration

 

During the three and nine months ended September 30, 2016 and 2015 (unaudited), the following customers comprised more than 10% of revenues:

 

    Three Months     Three Months     Nine Months     Nine Months  
    Ended     Ended     Ended     Ended  
    September 30, 2016     September 30, 2015     September 30, 2016     September 30, 2015  
                         
Customer 1     21 %     0 %     8 %     1 %
Customer 2     12 %     6 %     3 %     2 %
Customer 3     11 %     12 %     16 %     15 %
Customer 4     7 %     13 %     5 %     8 %
Customer 5     0 %     13 %     3 %     10 %
Customer 6     0 %     0 %     10 %     1 %

 

As of September 30, 2016 and December 31, 2015, the following customers comprised more than 10% of accounts receivable:

 

    September 30,     December31,  
    2016     2015  
    (unaudited)        
Customer 1     37 %     0 %
Customer 2     29 %     17 %
Customer 3     21 %     0 %
Customer 4     15 %     3 %
Customer 5     0 %     19 %
Customer 6     0 %     10 %
Customer 7     0 %     10 %
Customer 8     0 %     10 %

 

Geographic Concentration

 

During the three and nine months ended September 30, 2016 and 2015 (unaudited), regional revenue, based on customer location, consisted of the following:

 

    Three Months     Three Months     Nine Months     Nine Months  
    Ended     Ended     Ended     Ended  
    September 30, 2016     September 30, 2015     September 30, 2016     September 30, 2015  
                         
United States     47 %     56 %     47 %     46 %
Germany     35 %     4 %     15 %     5 %
Italy     11 %     12 %     21 %     20 %
France     7 %     11 %     8 %     18 %
Canada     0 %     13 %     3 %     6 %
Turkey     0 %     4 %     5 %     3 %

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Money Market Funds (Tables)
9 Months Ended
Sep. 30, 2016
Cash and Cash Equivalents [Abstract]  
Schedule of money market funds

The following table presents money market funds at their level within the fair value hierarchy at September 30, 2016 and December 31, 2015 (in thousands):

  

    Total     Level 1     Level 2     Level 3  
                         
September 30, 2016 (unaudited):                                
Money market funds   $ 17,546     $ 17,546     $     $  
                                 
December 31, 2015:                                
Money market funds   $ 15,721     $ 15,721     $     $  
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Selected Balance Sheet Detail (Tables)
9 Months Ended
Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of inventories

Inventories consisted of the following at (in thousands):

 

    September 30,     December 31,  
    2016     2015  
    (unaudited)        
Raw materials   $ 470     $ 575  
Work in process     4,920       5,028  
Finished goods     3,499       3,156  
                 
      8,889       8,759  
                 
Allowance for excess and obsolescence     (3,079 )     (550 )
Inventories, net   $ 5,810     $ 8,209  
Schedule of property and equipment

Property and equipment consisted of the following at (in thousands):

 

    September 30,     December 31,  
    2016     2015  
    (unaudited)        
Laboratory equipment   $ 3,594     $ 3,369  
Computer hardware and software     2,117       1,960  
Leasehold improvements     533       508  
Furniture, fixtures and equipment     135       135  
                 
      6,379       5,972  
Accumulated depreciation and amortization     (4,852 )     (4,540 )
                 
Property and equipment, net   $ 1,527     $ 1,432  
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity Securities (Tables)
9 Months Ended
Sep. 30, 2016
Stockholders' Equity Note [Abstract]  
Schedule of anti-dilutive securities

At September 30, 2016 and 2015 (unaudited), the Company excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately acquire shares of common stock, from its calculations of earnings per share and weighted average shares outstanding, as their effect would have been anti-dilutive (in thousands).

 

    September 30,     September 30,  
    2016     2015  
             
Long Term Investor Rights     342       412  
Underwriter’s warrants     802       802  
Warrants associated with convertible debt     1,038       1,038  
Common stock options     3,669       3,505  
Restricted stock units     142       190  
Employee stock purchase plan     109       75  
                 
Total     6,102       6,022  
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrants (Tables)
9 Months Ended
Sep. 30, 2016
Warrants  
Schedule of warrant activity

A summary of warrant activity for the nine months ended September 30, 2016 (unaudited) is presented below (in thousands, except per share and contractual life data).

 

                Weighted Average  
          Weighted     Remaining  
    Number of     Average     Contractual  
    Shares     Exercise Price     Life (in Years)  
Warrants outstanding at December 31, 2015     1,840     $ 7.72       2.80  
Granted                      
Exercised                      
Forfeited or expired                      
                         
Warrants outstanding at September 30, 2016     1,840     $ 7.72       2.06  
                         
Warrants exercisable at September 30, 2016     1,840     $ 7.72       2.06  
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of stock option activity

A summary of stock option activity for the nine months ended September 30, 2016 (unaudited) is presented below (in thousands, except per share and contractual life data).

   

                Weighted Average  
          Weighted     Remaining  
    Number of     Average     Contractual  
    Shares     Exercise Price     Life (in Years)  
Options outstanding at December 31, 2015     3,472     $ 8.01       6.39  
Granted     690     $ 4.33          
Exercised     (96 )   $ 5.00          
Forfeited or expired     (397 )   $ 9.03          
                         
Options outstanding at September 30, 2016     3,669     $ 7.28       6.45  
                         
Options exercisable at September 30, 2016     1,934     $ 6.54       4.40  
Schedule of restricted stock unit (RSU) activity

The following table summarizes Restricted Stock Unit (RSU) activity for the nine months ended September 30, 2016 (in thousands, except per share data):

 

          Weighted  
          Average Grant  
    Number     Date Fair Value  
    of Awards     Per Share  
             
Outstanding as of December 31, 2015     190     $ 12.43  
Awarded     -       -  
Vested     (48 )     -  
Forfeited/canceled     -       -  
Outstanding as of September 30, 2016     142     $ 12.43  
Schedule of stock-based compensation

The total stock-based compensation recognized for stock-based awards granted under the 2003 Plan and the 2011 Plan in the condensed consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015 (unaudited) is as follows (in thousands):

 

    Three Months     Three Months     Nine Months     Nine Months  
    Ended     Ended     Ended     Ended  
    September 30, 2016     September 30, 2015     September 30, 2016     September 30, 2015  
Cost of sales   $ 80     $ 103     $ 245     $ 265  
Research and development     77       99       238       217  
Clinical and regulatory     43       84       136       206  
Selling and marketing     74       127       59       312  
General and administrative     624       443       1,903       918  
Total   $ 898     $ 856     $ 2,581     $ 1,918  
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Organization and Business Operations (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended
Jun. 30, 2016
Sep. 30, 2016
Right Offering [Member]    
Proceeds from issuance or sale of shares $ 19,500  
Number of shares issued upon right offering 5,978,465  
Share price (in dollars per share) $ 3.315  
Percentage of company's stock price at the close of the rights offering 85.00%  
Second Sight (Switzerland) Sarl [Member]    
Ownership percentage by parent   99.50%
Second Sight (Switzerland) Sarl [Member] | Executive Officer [Member]    
Ownership percentage by noncontrolling interest   0.50%
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Concentration of Risk (Details) - Sales Revenue, Net [Member]
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Customer 1 [Member]        
Customer Concentration 21.00% 0.00% 8.00% 1.00%
Customer 2 [Member]        
Customer Concentration 12.00% 6.00% 3.00% 2.00%
Customer 3 [Member]        
Customer Concentration 11.00% 12.00% 16.00% 15.00%
Customer 4 [Member]        
Customer Concentration 7.00% 13.00% 5.00% 8.00%
Customer 5 [Member]        
Customer Concentration 0.00% 13.00% 3.00% 10.00%
Customer 6 [Member]        
Customer Concentration 0.00% 0.00% 10.00% 1.00%
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Concentration of Risk (Details 1) - Accounts Receivable [Member]
9 Months Ended 12 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Customer 1 [Member]    
Customer Concentration 37.00% 0.00%
Customer 2 [Member]    
Customer Concentration 29.00% 17.00%
Customer 3 [Member]    
Customer Concentration 21.00% 0.00%
Customer 4 [Member]    
Customer Concentration 15.00% 3.00%
Customer 5 [Member]    
Customer Concentration 0.00% 19.00%
Customer 6 [Member]    
Customer Concentration 0.00% 10.00%
Customer 7 [Member]    
Customer Concentration 0.00% 10.00%
Customer 8 [Member]    
Customer Concentration 0.00% 10.00%
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Concentration of Risk (Details 2)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
UNITED STATES        
Customer Concentration 47.00% 56.00% 47.00% 46.00%
ITALY        
Customer Concentration 11.00% 12.00% 21.00% 20.00%
TURKEY        
Customer Concentration 0.00% 4.00% 5.00% 3.00%
FRANCE        
Customer Concentration 7.00% 11.00% 8.00% 18.00%
GERMANY        
Customer Concentration 35.00% 4.00% 15.00% 5.00%
CANADA        
Customer Concentration 0.00% 13.00% 3.00% 6.00%
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Concentration of Risk (Details Narrative) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Assets $ 26,265 $ 28,245
Second Sight (Switzerland) Sarl [Member]    
Assets $ 2,228 $ 3,041
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Money Market Funds (Details) - Money Market Funds [Member] - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Money market funds $ 17,546 $ 15,721
Level 1 [Member]    
Money market funds 17,546 15,721
Level 2 [Member]    
Money market funds
Level 3 [Member]    
Money market funds
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Selected Balance Sheet Detail (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Raw materials $ 470 $ 575
Work in process 4,920 5,028
Finished goods 3,499 3,156
Inventories, gross 8,889 8,759
Allowance for excess and obsolescence (3,079) (550)
Inventories, net $ 5,810 $ 8,209
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Selected Balance Sheet Detail (Details 1) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Property and equipment, gross $ 6,379 $ 5,972
Accumulated depreciation and amortization (4,852) (4,540)
Property and equipment, net 1,527 1,432
Laboratory Equipment [Member]    
Property and equipment, gross 3,594 3,369
Computer Hardware and Software [Member]    
Property and equipment, gross 2,117 1,960
Leasehold Improvements [Member]    
Property and equipment, gross 533 508
Furniture, Fixtures and Equipment [Member]    
Property and equipment, gross $ 135 $ 135
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Long Term Investor Right (Details Narrative) - IPO [Member]
9 Months Ended
Sep. 30, 2016
$ / shares
shares
Number of shares issued in transaction 1,181,927
Shares price (in dollars per share) | $ / shares $ 13.36
Maximum [Member]  
Subsequent Number of shares issued to Long Term Investor Right 342,089
Minimum [Member]  
Subsequent Number of shares issued to Long Term Investor Right 0
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity Securities (Details) - shares
9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Total anti-dilutive securities 6,102 6,022
Long Term Investor Rights [Member]    
Total anti-dilutive securities 342 412
Underwriter's Warrants [Member]    
Total anti-dilutive securities 802 802
Warrants Associated With Convertible Debt [Member]    
Total anti-dilutive securities 1,038 1,038
Common Stock Options [Member]    
Total anti-dilutive securities 3,669 3,505
Restricted Stock Units [Member]    
Total anti-dilutive securities 142 190
Employee Stock Purchase Plan [Member]    
Total anti-dilutive securities 109 75
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity Securities (Details Narrative) - USD ($)
$ in Thousands
1 Months Ended 9 Months Ended
Jun. 30, 2016
Sep. 30, 2016
Right Offering [Member]    
Number of shares issued upon right offering 5,978,465  
Non-Employee [Member]    
Accrued services   $ 87
Number of shares issued for services   26,274
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrants (Details)
9 Months Ended
Sep. 30, 2016
$ / shares
shares
Class Of Warrant Or Right Number Of Shares [RollForward]  
Warrants outstanding at beginning | shares 1,840,000
Warrants outstanding at end | shares 1,840,000
Warrants exercisable at end | shares 1,840,000
Class Of Warrant Or Right Weighted Average Exercise Price [RollForward]  
Warrants outstanding at beginning | $ / shares $ 7.72
Warrants outstanding at end | $ / shares 7.72
Warrants exercisable at end | $ / shares $ 7.72
Class Of Warrant Or Right Weighted Average Remaining Contractual Life [RollForward]  
Warrants outstanding at beginning 2 years 9 months 18 days
Warrants outstanding at end 2 years 21 days
Warrants exercisable at end 2 years 21 days
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrants (Details Narrative)
$ in Thousands
Sep. 30, 2016
USD ($)
Warrants [Member]  
Intrinsic value of warrants outstanding $ 0
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation (Details)
9 Months Ended
Sep. 30, 2016
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Options outstanding at beginning | shares 3,472,000
Granted | shares 690,000
Exercised | shares (96,000)
Forfeited or expired | shares (397,000)
Options outstanding at ending | shares 3,669,000
Options exercisable at ending | shares 1,934,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]  
Options outstanding at beginning | $ / shares $ 8.01
Granted | $ / shares 4.33
Exercised | $ / shares 5.00
Forfeited or expired | $ / shares 9.03
Options outstanding at ending | $ / shares 7.28
Options exercisable at ending | $ / shares $ 6.54
Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Life [Roll Forward]  
Options outstanding at beginning 6 years 4 months 20 days
Options outstanding at ending 6 years 5 months 12 days
Options exercisable at ending 4 years 4 months 24 days
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation (Details 1) - Restricted Stock Units [Member]
9 Months Ended
Sep. 30, 2016
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]  
Outstanding at beginning | shares 190,000
Awarded | shares
Vested | shares (48,000)
Forfeited/canceled | shares
Outstanding at ending | shares 142,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Roll Forward]  
Outstanding at beginning | $ / shares $ 12.43
Awarded | $ / shares
Vested | $ / shares
Forfeited/canceled | $ / shares
Outstanding at ending | $ / shares $ 12.43
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation (Details 2) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Total $ 898 $ 856 $ 2,581 $ 1,918
Cost of Sales [Member]        
Total 80 103 245 265
Research and Development [Member]        
Total 77 99 238 217
Clinical And Regulatory [Member]        
Total 43 84 136 206
Selling and Marketing [Member]        
Total 74 127 59 312
General and Administrative [Member]        
Total $ 624 $ 443 $ 1,903 $ 918
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 18, 2016
May 10, 2016
Jan. 02, 2015
Dec. 31, 2014
Jun. 30, 2015
Mar. 31, 2016
Sep. 30, 2016
Sep. 30, 2015
Number of shares exercised             (96,000)  
Exercise price (in dollars per share)             $ 5.00  
Number of options granted             690,000  
Share based charges             $ 2,581,000 $ 1,918,000
Restricted Stock Units [Member]                
Period of recognized compensation cost             2 years 10 months 17 days  
Total non vested unrecognized compensation cost             $ 1,699,000  
Mr Jonathan Will McGuire [Member]                
Number of shares exercised     59,063          
Exercise price (in dollars per share)     $ 4.75          
Share price (in dollars per share)       $ 10.26        
Number of shares surrendered       12,055        
Value of shares surrendered       $ 123,684        
Number of options granted       27,344        
Mr Jonathan Will McGuire [Member] | Restricted Stock Units [Member]                
Share price (in dollars per share) $ 3.76              
Number of vested shares 47,500              
Number of vested shares sold 190,000              
Certain Employees and Contractors [Member]                
Number of shares exercised             95,493  
Value of shares exercised             $ 479,000  
Number of options granted             659,973  
Exercisable terms             10 years  
Vesting period             4 years  
Fair value of options             $ 1,350,000  
Expected terms (in years)             6 years 3 months  
Volatility rate             48.20%  
Expected dividend rate             0.00%  
Outside Attorney [Member]                
Exercise price (in dollars per share)             $ 5.23  
Share price (in dollars per share)             $ 1.77  
Number of options granted             30,000  
Exercisable terms             4 years  
Fair value of options             $ 53,000  
Expected terms (in years)             6 years 3 months  
Volatility rate             48.20%  
Risk-free interest rate             1.87%  
Expected dividend rate             0.00%  
Consultant [Member]                
Number of vested shares           98,681    
Share based charges           $ 55,000    
Description of vesting terms          

All unvested options for this employee were terminated when this employee ceased full-time employment with the Company.

   
Minimum [Member] | Certain Employees and Contractors [Member]                
Exercise price (in dollars per share)             $ 3.44  
Share price (in dollars per share)             $ 1.64  
Risk-free interest rate             1.43%  
Maximum [Member] | Certain Employees and Contractors [Member]                
Exercise price (in dollars per share)             $ 5.16  
Share price (in dollars per share)             $ 2.47  
Risk-free interest rate             1.87%  
2011 Equity Incentive Plan [Member]                
Number of shares authorized             3,500,000  
Number of shares options granted             7,500,000  
Aggregate exercisable intrinsic value             $ 0  
Total unrecognized compensation cost of options             $ 6,900,000  
Period of recognized compensation cost             2 years 10 months 2 days  
Exercisable terms             10 years  
2011 Equity Incentive Plan [Member] | Minimum [Member]                
Vesting period             4 years  
2011 Equity Incentive Plan [Member] | Maximum [Member]                
Vesting period             5 years  
Second Sight 2011 Equity Incentive Plan [Member]                
Number of shares authorized   6,000,000            
Maximum number of shares authorized   7,500,000            
Employee Stock Purchase Plan [Member]                
Description of plan        

Under the ESPP, shares of the Company's common stock may be purchased at six-month intervals at 85% of the lower of the closing fair market value of the common stock (i) on the first trading day of the offering period or (ii) on the last trading day of the purchase period. An employee may purchase in any one calendar year shares of common stock having an aggregate fair market value of up to $25,000 determined as of the first trading day of the offering period. Additionally, a participating employee may not purchase more than 100,000 shares of common stock in any one offering period.

     
Number of shares issued             154,225  
Proceeds from purchase of stock             $ 337,000  
EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 156 183 1 false 51 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://secondsight.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://secondsight.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://secondsight.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (unaudited) Sheet http://secondsight.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) Sheet http://secondsight.com/role/StatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss (unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://secondsight.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Business Operations Sheet http://secondsight.com/role/OrganizationAndBusinessOperations Organization and Business Operations Notes 7 false false R8.htm 00000008 - Disclosure - Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements Sheet http://secondsight.com/role/BasisOfPresentationSignificantAccountingPoliciesAndRecentAccountingPronouncements Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements Notes 8 false false R9.htm 00000009 - Disclosure - Concentration of Risk Sheet http://secondsight.com/role/ConcentrationOfRisk Concentration of Risk Notes 9 false false R10.htm 00000010 - Disclosure - Money Market Funds Sheet http://secondsight.com/role/MoneyMarketFunds Money Market Funds Notes 10 false false R11.htm 00000011 - Disclosure - Selected Balance Sheet Detail Sheet http://secondsight.com/role/SelectedBalanceSheetDetail Selected Balance Sheet Detail Notes 11 false false R12.htm 00000012 - Disclosure - Long Term Investor Right Sheet http://secondsight.com/role/LongTermInvestorRight Long Term Investor Right Notes 12 false false R13.htm 00000013 - Disclosure - Equity Securities Sheet http://secondsight.com/role/EquitySecurities Equity Securities Notes 13 false false R14.htm 00000014 - Disclosure - Warrants Sheet http://secondsight.com/role/Warrants Warrants Notes 14 false false R15.htm 00000015 - Disclosure - Stock-Based Compensation Sheet http://secondsight.com/role/Stock-basedCompensation Stock-Based Compensation Notes 15 false false R16.htm 00000016 - Disclosure - Litigation, Claims and Assessments Sheet http://secondsight.com/role/LitigationClaimsAndAssessments Litigation, Claims and Assessments Notes 16 false false R17.htm 00000017 - Disclosure - Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements (Policies) Sheet http://secondsight.com/role/BasisOfPresentationSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements (Policies) Policies http://secondsight.com/role/BasisOfPresentationSignificantAccountingPoliciesAndRecentAccountingPronouncements 17 false false R18.htm 00000018 - Disclosure - Concentration of Risk (Tables) Sheet http://secondsight.com/role/ConcentrationOfRiskTables Concentration of Risk (Tables) Tables http://secondsight.com/role/ConcentrationOfRisk 18 false false R19.htm 00000019 - Disclosure - Money Market Funds (Tables) Sheet http://secondsight.com/role/MoneyMarketFundsTables Money Market Funds (Tables) Tables http://secondsight.com/role/MoneyMarketFunds 19 false false R20.htm 00000020 - Disclosure - Selected Balance Sheet Detail (Tables) Sheet http://secondsight.com/role/SelectedBalanceSheetDetailTables Selected Balance Sheet Detail (Tables) Tables http://secondsight.com/role/SelectedBalanceSheetDetail 20 false false R21.htm 00000021 - Disclosure - Equity Securities (Tables) Sheet http://secondsight.com/role/EquitySecuritiesTables Equity Securities (Tables) Tables http://secondsight.com/role/EquitySecurities 21 false false R22.htm 00000022 - Disclosure - Warrants (Tables) Sheet http://secondsight.com/role/WarrantsTables Warrants (Tables) Tables http://secondsight.com/role/Warrants 22 false false R23.htm 00000023 - Disclosure - Stock-Based Compensation (Tables) Sheet http://secondsight.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://secondsight.com/role/Stock-basedCompensation 23 false false R24.htm 00000024 - Disclosure - Organization and Business Operations (Details Narrative) Sheet http://secondsight.com/role/OrganizationAndBusinessOperationsDetailsNarrative Organization and Business Operations (Details Narrative) Details http://secondsight.com/role/OrganizationAndBusinessOperations 24 false false R25.htm 00000025 - Disclosure - Concentration of Risk (Details) Sheet http://secondsight.com/role/ConcentrationOfRiskDetails Concentration of Risk (Details) Details http://secondsight.com/role/ConcentrationOfRiskTables 25 false false R26.htm 00000026 - Disclosure - Concentration of Risk (Details 1) Sheet http://secondsight.com/role/ConcentrationOfRiskDetails1 Concentration of Risk (Details 1) Details http://secondsight.com/role/ConcentrationOfRiskTables 26 false false R27.htm 00000027 - Disclosure - Concentration of Risk (Details 2) Sheet http://secondsight.com/role/ConcentrationOfRiskDetails2 Concentration of Risk (Details 2) Details http://secondsight.com/role/ConcentrationOfRiskTables 27 false false R28.htm 00000028 - Disclosure - Concentration of Risk (Details Narrative) Sheet http://secondsight.com/role/ConcentrationOfRiskDetailsNarrative Concentration of Risk (Details Narrative) Details http://secondsight.com/role/ConcentrationOfRiskTables 28 false false R29.htm 00000029 - Disclosure - Money Market Funds (Details) Sheet http://secondsight.com/role/MoneyMarketFundsDetails Money Market Funds (Details) Details http://secondsight.com/role/MoneyMarketFundsTables 29 false false R30.htm 00000030 - Disclosure - Selected Balance Sheet Detail (Details) Sheet http://secondsight.com/role/SelectedBalanceSheetDetailDetails Selected Balance Sheet Detail (Details) Details http://secondsight.com/role/SelectedBalanceSheetDetailTables 30 false false R31.htm 00000031 - Disclosure - Selected Balance Sheet Detail (Details 1) Sheet http://secondsight.com/role/SelectedBalanceSheetDetailDetails1 Selected Balance Sheet Detail (Details 1) Details http://secondsight.com/role/SelectedBalanceSheetDetailTables 31 false false R32.htm 00000032 - Disclosure - Long Term Investor Right (Details Narrative) Sheet http://secondsight.com/role/LongTermInvestorRightDetailsNarrative Long Term Investor Right (Details Narrative) Details http://secondsight.com/role/LongTermInvestorRight 32 false false R33.htm 00000033 - Disclosure - Equity Securities (Details) Sheet http://secondsight.com/role/EquitySecuritiesDetails Equity Securities (Details) Details http://secondsight.com/role/EquitySecuritiesTables 33 false false R34.htm 00000034 - Disclosure - Equity Securities (Details Narrative) Sheet http://secondsight.com/role/EquitySecuritiesDetailsNarrative Equity Securities (Details Narrative) Details http://secondsight.com/role/EquitySecuritiesTables 34 false false R35.htm 00000035 - Disclosure - Warrants (Details) Sheet http://secondsight.com/role/WarrantsDetails Warrants (Details) Details http://secondsight.com/role/WarrantsTables 35 false false R36.htm 00000036 - Disclosure - Warrants (Details Narrative) Sheet http://secondsight.com/role/WarrantsDetailsNarrative Warrants (Details Narrative) Details http://secondsight.com/role/WarrantsTables 36 false false R37.htm 00000037 - Disclosure - Stock-Based Compensation (Details) Sheet http://secondsight.com/role/Stock-basedCompensationDetails Stock-Based Compensation (Details) Details http://secondsight.com/role/Stock-basedCompensationTables 37 false false R38.htm 00000038 - Disclosure - Stock-Based Compensation (Details 1) Sheet http://secondsight.com/role/Stock-basedCompensationDetails1 Stock-Based Compensation (Details 1) Details http://secondsight.com/role/Stock-basedCompensationTables 38 false false R39.htm 00000039 - Disclosure - Stock-Based Compensation (Details 2) Sheet http://secondsight.com/role/Stock-basedCompensationDetails2 Stock-Based Compensation (Details 2) Details http://secondsight.com/role/Stock-basedCompensationTables 39 false false R40.htm 00000040 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://secondsight.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://secondsight.com/role/Stock-basedCompensationTables 40 false false All Reports Book All Reports eyes-20160930.xml eyes-20160930.xsd eyes-20160930_cal.xml eyes-20160930_def.xml eyes-20160930_lab.xml eyes-20160930_pre.xml true true ZIP 57 0001615774-16-008049-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001615774-16-008049-xbrl.zip M4$L#!!0 ( *Z+9$D6U)/H284 /8V"@ 1 97EER7,I8[] MTUGKHGFF$=MP3&J__'3VZ^/YY>.7V]LS[?_\_)__H<'__O[_G)]K7QC1/6)J MSW/ML:W=4 L>=AO:UZ]?SK6)Y\T^?OCP]O9VX;;'XJ<+PYEJY^=0Q-_?GYE% M/^*_&E1LNQ_?7?K36>REM\Z%PUX^M)O-UH?_[]O71V-"IOHYM5U/MPUR%KX% MY?Z^Z;W6:#3ZP'\-'UU[$BL/Z^A\P)^?=7=1,@+<\?P:$OC5]*(7X@_W/H@? MEQZE&Q_MBT=I^*A)5IYSB7'QXKQ^@!_@^5;WO-DZ[[3"QQD9;X7<_P"_A@]2 MU^FV6X-=\HDGPA=\]_Q%UV?1"V/=?>8/!S\@F/XR&/B%.19Q-[[#?]GPDNW8 MMC_=C,OTV =O/B,?X*%S>(HP:D3O[7]I^07#\6V/S3=K-_AQ SXRCPD$CSNV MZ=*7B8?4YH\W1YWF6=A)D%0?74[=!S+6.!\_3G@K84'GX0L7[ZYY%OR,8'\Z M<^ET9@&Y/H1%B0X#]7GDW=.H^=/9#7.F(,E51% BXI:8E)N2BI=]YJHTFIK)(" ?)1TL*L M#>IEU@9RF;5 S[V8GGO5UW/O$#WWBM%SJUYZ3C],YZKGP+AVJVY]/PBP=_M:9]8U,GPG[5S 3 M^M?U.S%\C[Z2N_&8&H2)GTO3]:+_DILOY JQ\?B(6QAGNP,_,GIMNN M;GCP@/MY'O]%P O?V=P2^W%%5FU%8Y7P+E/25O&R+NV_<)S[,<>Y'^/" ^H$ M^@(4;[]4N_G#+O[H/[O4I#J;/^H6]/-'SS%^CY%A@\A%M__J/*!_R#R@GW]X M0U&E=*HLFXI^ :9B=8X=>3&H(_>!O!+;)]])('C(CB_\/X3=V:0>W/CBV :\ MS73T*1ZH^_OG^6=B&Y.ISGY?]BDVZB5;5^>;_F^'A2IV8PQ=4WO9IDS.D$9V MM%[]X>G-47POGN^1VA7?"^;[A!%EXLJDFY1=Z5XPO MF/'T51GY,A@?Z5TQOEC&/])W1?CB"1^I7?$]X5*\"L=4@-9RA&-DWOF0$:U5 M.$8*OLL1CCE%OJMPS&F'8TZ0\RH<<]+AF%-DO K'G'(XY@09K\(Q)QR.D9;O M&P[6J7!,!6@M1SA&OG.,F=-:A6.DX+L(RLK!>CM#,B;+^%*,SLO!>D@#- M:3+_%&,TDA!?DC#-B?+^!",ULO!>CF#-:?+^!.,UDM!>CI#-B;(>HW6*]^7P M?J%[Q?R\F'^-Z<$5P4LA>$SWBN#[5Y_X!4(J&E\9>LL1C3]PJ6GIMBIIR:V" M[J<==*\WN55L_>1CZ[4FN JAGWH(O=[T5I'R$X^4UYK>*B!^V@'Q>I-;Q;U/ M/NY=:X*KN+>*>TM+\$U7Q/"68_-__?I8=;X^>J P?/\7XKPP?3:AAFX)F@1" M?OSUL>P%D>KRK88U?,Q%#$* ML1C5\S$4,0JQ&-7S,10Q"K$8U?,Q;DZ!&#>E6XSJ^1B*&(58C.KY&(H8A5B, MZOD8BAB%6(SJ^1A7UR= C*OKLBU&]7P,18Q"+$;U? Q%C$(L1O5\#$6,0BQ& M]7R,+YQWXMWXMNE6N]E# W&C4_8/W?+)Y_FE MZQ+OBZ6[[O)!N,V"E]CZ*\-"B:T?_1RI\=:>^9[[E;P2JZ48LH'45OR>C=.0EZK^9H4&ZG M+&YG$9..9*VOW,Y*&:[RWYG96B=_EN9XWHK=Q.V>A=OMM9)+V#:/=7 M_=EANN>P^?4?/IVA//4@YCUS0$_>_-X"%5[:9B3>Y_G3?$9BX>^M*C@1)H16 MZHLSA;Y V"D289$U;J,.3HP)7XGNDHECF;?3&7->^;IB3>:CJ=BP0P\GQH@; MG]G4\QD!E=W0=_QTBH38KH::\R':2:.\!HF]AC*B\LIKD-%K*(,)RFN0V6LH M@Q'*:Y#7:\B5#PFNXKR]OZL'%1[]9Y>:5&?S1]TB=^-'SS%6,HQ'LA;=WI+O MS-UB-A0U3M04+&+N^CN=^E/%@N.BX@^Z_;(R%BUI5IFC#*A*;475?*@:UZRB M:N+#3D&(QK%?G@B;WMJO!+Y@#[B]OR;>]R64:U++]^@K>22&SZA'B7O];EB^ M24S4C9B1\[M?[L;7.OC?]HM[3]CC1&>X5+FQ@'AT9X?V%!43'Z]25*PQ%>4[ MT+7?*OYJFX2]@8X)^TUG3*]-A"I_'FY5G;*'*>VA(F'-2%A%2QBJ[])U'8-" MS>9OU)M\<6"481Y]ML@5>:[)6D[^M$RA3&4M4UI+1=03)&H5+2JTS=2Q>XD8Q<)W:5#9Q*0V41&R_H2LI(7D2L1F@<;D[8*[B!0=$]-QA_Z4=4QK'149 MZTG&2EK&*\J(X3FL'OQ[(!9&6.Y!\_,GI@,_##ZS^#R/_[),IV4-*'.69+]@ M$-2J!VFB1)ZXI=B;HV5Q;-Q!OLR3)9F+IHE$>P=WNJ;M_F#0'G2ZS:J3XO)- M9^;ZQG)Y_7)I;G_0L:2]8NE%@<972]NS'N?*U) MV/S6-IPIB3R*KX[!9RBKAQ=7I"Y[X*C.A1.*./(0IU(74BCBR$,<^5S5!%$[ M19SRB2-SA&VKCP.^'\&D:)=0,28]<_BIY>MW#%^2$Z)2 CV4;96JYPE?*YP4Z9%;7X;FVT^D!??XDG#3H!38E_E=N'+ MME+5\:\4D>0E4J5\*44D>8E4*;])$4E>(E7*1XJV(1(+U/D"NA0W!<#GT_.^ M]RFA;/M4'8])T:HJM*J4_Z1H515:54X.<\/GH'>JHY*"$;9WKH-1=O>55\4E2/L6&K&Z>)R$#HR/J M:'*CHTA2%9(L&9V@"=,9G15N%;[WA#!/I_;U=&8Y\LW'2[W[I%S?HRU=!3I&-:FZWX>X\ST7J''I@3)L4I.-W*DYLE$+:H1. M,$(K_DC#GW*-2@>#B=&=%+;K6UYM$G2F'W-6%%!)4]+)+62X,"6]\U9D2AX) M/&,^XEV7N'JX85&Q'FS:L(":5/1R30HV5MXF!3=MA"9%D4-JPKWBO> MYS8YB1-8JOV^]5R?RGX7\+%+#FHK0?X,KM,> OD8K+8'+#'8A]&%T_?7QZLU MLDV)[OJ,_$Q=I]MN#3[",V%AX4_+56!I6\KG5[^Y6ZL(E, ?.K@.P'>_I1Z3 MO@++UW6+[W[WIX1AEJ%UFJ70P2K&3:7&*KTBMC.E]KYJ]^MEM=Y-!8>_+VDA M@4)A[DGV--D,/B9O,)/0C]>\SSR0%WX&SO;0/F@!.1_(>)E1N_W^Y>\?MM6QCN$+P25JZ]8VR?O_ MD'EB$'$+NK6T>'57CN&C_4!G+W$MK>;Y_XKRXZ]O*O:>=_=K80P2EQ\W)UM+ MBU=W";^:^,2-I;\DKF:L6RX1-2P5$"_YB\\8?DU=0[?^27265I;SK7_<"S?!GL_OZ$68>Z! MU:V4LH'>0@\/9.8P3/>!)U3]Y+7]$RW.OM+6:^5HOH"Z7QR6O$M=&@:QT%X2 M4^,EQ*M>*G)3!Q!-+8A[ ]\E%_)_.\OD7RMI>W7(K'25X>=-U44E;6A#9SIU M;#X1%",;KH+#O,N$%EBJ-XH M/#HTYF&5I?_$ R(FDD,.H6^^-/9[?>;LY^[ M[7:W/^IUEYIX1V5Q:#"3QJ\>Y]-GQTHL_?4_KQ]%;4OOAP5'TV_=G6R63)2S MD Q=EIA8YQW0\& QOGO'^*%):T@N"9M3P6=T<$5=)-4T&\=7D$OD8I@W-I7 MP3<'-UCP-$$WOFVZE]X7G;$YM-D_=,LG!S=/:]#K]I=JWU-3!L 2-6NK-VBW MC@$&]LL!:^P^$(/05_W9(M^)%YC,@]75[2ZS>5S2=8GG'LN& M?K.SA"-!71G!2\:-YJA[++YL% 4#VW!95<=5FFQ@Z _ZW>25WC,')NG>',,? M'N@&HR+\3H!C.D>KUQZL-,'V6HY%E(P4W4X[-2(>)KH"/].EGKO,FX-5<][K M<1P[RCZP^D1Z..^.DE:_3)_#.T&_W>]MX&/R:I+1?MCN'E?-2I TMA'G\8UZ M?Q(&3#$?=68%$='=<-KM819"9X.FT^RVDJ )!M%[?8XCZ-'CQ(H=WES\X2 2 M\6*P,DPG!L%\8GZE^C.UJ$?)T6-!:]!:\U@V5W$4EF1]I;GB>B?&$FX("18M M,]1/N]E;[KY[J\H$6U)]C0[#QLULH-TPG?P3H[H5.".'F]5>?!S95<-14!*I MI]_JIX,2JO&*C FHRWP@X,CZ1]N;UFB909N+/QQ$(F5TVNT4(()A6#SR"P:( M@^<.GZKU^O$!?KWD@ZI.UDU:HT&RND/E9&@_>OW^\H1^O\'(T$(,1L-VRMHQ MQD4]]#C#0VHPI2>V05,9A7>7?K2I]=.9![WN3/MP9"U;A-U7"\RP1&/SD%W: MT$Q&I1^(/19K/#*F-.SW6RLAK96R#ZD[V?0&R-\=):H[.+*R_&/K8*F'L2Z_ M5FKZ.A..Q[T$E4;.C6E2W&NE6_KIUN*X!P?7UW/!(+DSTY-]36;4/L\;V;X>O7[X09]!COY+R]:* T%6:*--F$ MN'<"O!*1F/6KX[K?B7->$;+8]8V0 J3LR$8U6[WRE S)C#"8[>>AT9QN_V594%M -C?FFA M+;N6WYU[G:5S L-M7BF=V-TU;13^P)K$6Y>^-W$8_9.8R23;LE:_$DO;7=/Q MN-;U4!2NO9L;$BIL#Z@-VQJ.0)5878>CBCG;>7:6Q-4W ]*A;.*/BP;]?',=T5]=P=^S3VA-F'2P3>E--1Z!9O6MK3_B%QWUR M0K/A8J:]:X^#/-&L7K*R9W6@-QRF1O/%<6':QW]]!/\M$\KT!ZL;SI8K.0Q# M.J*T^ZU>QAA2TV/0&V0/(1TG.OV559(]&'YACNO>,V=,L[$>YYWN:)D+L1K2 M5YZ. ^>M;J>74>6I&[_57;&;1]6=KM7;HY4EFAUU/Q"7Z,R8P"SN"DR%Y?"] M.<%"8D8CR J:G55F@2_EF+)J-_/%EYI)O5&G6'@IR<:70]+BVW[O>R:<:XWB MJ_8;ZSD823IV]9NC7("DIM%HV,T+2$K"]+J=A$@B3V;K3;;9."S=P4KD<&M] M1R-+Z<:T^^U"D*7W?5N=PI"E](.[[=Z!R/9+ MQIB>@-UVIWB,*:G8'(R.P7@WPP-R"[XF/GBV9W#LM)=AK=5S*)!T-!LT5S;0 M9X,C-97ZJ[8L,QSIZ-(:]#J# X$L%G*SF;BUV\/V%BR+J@Y'DW(F-^R.MC#V M:#"IV7+>[?>WT"4+,.DH W/B%[(R+JLG)W:6-5QB-(-& ME(!"^U9(TM66TJP<(C[?*O+=L9UE-F7I"9VO\'9GC9G@2QL_*A3? 8:H:'QI M)WI'X/M.O!R&M)6#G4N5'((@]3 VS!+ 04-7/UL Z8>KE9TD.Q&$FZSN">-+ M8)]UEQH86**6[Y'#EBONMZR^G3K$5P3U59X-T-W]V(&TWBT2ZEV@[D+8Z M!2/=S<@=2+NM@Y'^1O# (#$O7\&VO9#O/AX5O!OS5V.KMD?3=]O"\6C4'BW M'X8F5YEV$'W[ GVTPTJ'>Q[+:2^_6K2PUG[SZ4CJE@[8\ZMM0[\8C(4?,@@:]U3TA6ZL\'EWJ&5)O M==].7N .F#T-.OWBP*6>6?5;J_N-$J.[(O"D03E]X;-% E9?3I&Y?_+OL]D, MLA*,2U)Q5F#3!S ZQX,-9P_$Q.: MLA.E^W5DUZ;ZSH<4?I(XVCE7&[6B%9T MM/-VO#U9'0[ ><^<5XH)IV$DN'+\9V_L6V&:DXQBY\L-NJO"8\$E:-S]0>L@ M+]K7VYL[W/;#7LGU>$P,[\Z.[$TV5.^O!?$35)T9WB-TM7IT&K>YX_@/K?0( M]5,CHT7==C.6CF)W?4=".\",=M)"6[28P0ATRRLB_GMKK^4FTDI0LHV7,?31:J343F.F/ JP.H%F@7$EF MEM&9@95D&TEJS@IM:K5V^ZO[';( NSWO64:4W=?=M@/(&GQJC0]7MNL? IZ[ M(JLO)L[9=K#:^ZV%(Y2F]DQAI_AWMY0*SG;,N)V9Q^Y5ZK-!&?ZN?)P MG\.Y!>;&=EA[NI61,@?='9Q=KS4#D =X#YWF#HIN!QG;@H Y\?D,VB3FY_FO M+C%O[6AOU*7AT5>18L[!O&X^?!?\Z-A96>1AL[=,B.-0Y2_C02'*E=!SMC*" MY\(3\#TYE\8?/F5D:^[I3-JLVUQV_))7GRWPU W1&PR/!,X[&CQE$&*Z"&/U M\H2L.D6[N>C8N^H["EAZV]T.4RHE!K:'\3C3=)<9G]5R3WMMQU=" -E"/T#) MS94;.@Z''F\A'G:R#1@7X%'=NO>?+6KX>G-#POHS!7YLV#)> M>9B/[VXL\O-AVJ??=(8Y9[-AZC">W#AIS9G!/2!Z-#@:KS"[=V,Q7^'WO>GO MF+*!3UN>G+WY%Y/K>G<[9P7D@#X>.Y1Z$(R$1DHDF,S>OH*-&JUMZ4T((%OH M!X3EDSEC"9 'BRCCZW=C@C>P/D![W=E8&.9"AO^@ _&J6R2[A;(EY&GJSQK[ MT=M-C@&_^2EQF=WJ/"B;]?OUJ\22UI\U]O2*[_1:F:&/5K"(F650 M?MJZ,UC:Q?V9[MWXGA$7=*('&QT>Z8M-Q]3 68&(%O-86^>EL#"]]U%K-F??!=ACH17NB4S!UW\F;]N!,=;LAOFAH MC]! XT_:5&ZC;='@N75?9,& M>^Y-#(WS3RY8 Y-??SL6'A;(Y (#1*_7)OHKT9X)L;49+GTR>([:&A;,3)P% M:F_4FVC>A&C,MP 6FA(F,JC@I",D%C[P2 R?"<<1GPH=#8W?6>'BGB%M[##M M!O2JX1W4%]P8,=RG;\T;FD$8IKR&ZL>H>;XW"\L9.XYG.Q[13.H:EH,7@;N: M:!QK#D]CKF5B@,Y1\H:F%?D$< M9TH]?&GF,YPW>QR(YVBN;TPVZ^Q"@_;;UDC/NL6QN1-"/$WW-/ ,^$8SK=-J M:#C2 A!7X#"!$*_8L##X\1;X(M@@R#]LMP:?1 /%B+&;#A=U["U%R:2LUF[I M;FW1-X"HSHS:V+_!E,(. MYN V/-L6#C8">X[HZFW.SHVMCG3*.8!8;!7EG%)[_'DOI3AS?@@X*EI#H MW)3 ._\&_XE;JLA,)NYK@<42Y@N+V]*#M4O;]N%-<4&Z!G6%%O1_N&#XVISH M3",V%K1F+RZTQ3E_$-RW0!9\C^()?3H5&N&3$;!4C(!VO4AUE%M8$UQ,3!^# MS>5L+$NWH7:/,FP\O'A< .(_S(.6&?L>6&XMJ*F>AJ;6W3?R*&/3#B[+IJF' MI+ZE:N?DSN4F4^3&9IQQ+REH=FX_7/!;P": .02;AE?P:&TM\! WVE5T^;PM M5HX#26[IZM@<]29;9%1$>&+-GJR'*)15J:1T@?-WZ;] -=A;^]S=TVXN'S]K M5.3]OWS\E?]RWNHUM,5P$YH*M"(81-5N+.?-U7YX B_2T-J=YH\+8C2TMPF% MB9<_0\?+Y56\^%3,]V#>!!.SB?,6SC4Y) .+9+B!?>:)N1K_9A;L5HCY?8'? MB#-$?,K285([IL04$SI1)\#2(*$B?BK\RX_SZ\S$88$/%BPSGQ:8AB\G[#+HOB( =WT<+P;L#&!%1 MN24J%WT[J%E$;L3IAPFQH$?%Y%^W"5Z\N]F!N\7 UO[AZPR[.\ ([$:[V6[N M[N:\[H6]V%M>:Y2VO^_NZ+S^-PIS?1YU4]V^]MW^&^9RW]?OFZ.&=CN=,>[ A,P: U_A"%3LP%2-*QX$UT,0")B+=R& MV/P&^U<8GM9=[,I\-<[E-3[S&B-W 2"1 %(0Z<6JHK$\LACD'4,LFJ>_P\!L MDS$-(D)H/?!+D]_R&%SM#(7RN!.&KA?!(LH/DR[H#T:)B%_T-Q#+U7##&H_" MB&F99Z&O<@LR!/?*-H2K,^;^%!/[7\+X]09\&N^1M@/F"K3$$)*+@75X#;KY MPA]"1TL/^R-@3X6H1% HDP$H62"XX!-1TU,-3 MX(K&/<]=*RQJ,*J%=-^BQ0@N@>GPI48/*&M1\DJ";@X,8CQ<@=%Q/D3!Y IL M!CXY)]ZB!S3B/2VD$E1(QX*B^.+"R]%!9J0\Z$:4('J:O35TMHU@B^T]Q^RO M2;:1ZBI:E*WMQIRN&)#XEGM-[+G7^*9[67>0J(Z>? >%N";3$^M;D9?&QQ+H M-.CJX9"(2X?:*[^U%%PJ_=FB[H2XP9IB\,.$$H9.[%Q8B1F,2K@;XL_ G:3V MS!?N83#>!#--CQ@3F_[APV.^*V)&P60R7C@,A@X4P\#/M?"VHR#L$WF3PC") MR2+^8,5/P^J,<:_,BY<(CL7"8XL\SV"/A? Q@?!B',1J#; Z+SQ'00,]@44L M#&RC\W:A+0Q!$&?S,%79&.:[(CX$0ZC/A]6O'+_6XM^UA1RA%Q/NXN#/:)TX MWM@,&RVH*WS"0 &F&FLK)QUO8Q%[O-#NGC%-#L]"$'04OG\&F/2'[_#M-8PG MBN$;>'A?G7)#'"T_4P2'9X-%+\!9S\)GY[TC/F^8Z,$<3SP0SGEP!Y#+'=W M_8N'=3#J<*$M D-;>IOOP:<_<< 7)&Z% @5+_0'^96ZVSG>SO"=X0/N7@/C+GCOTS 1V/,>7;$$5$IT+*:\? M0/GV"N6#&=(['U5$R"(B>@.\9GO1&=:8WM"FOH?3O#%Z7&*TP%'A/!ATB?E2 M?'=0UC_#3M*YT'ZUG37[#UU!] #L.'P-#-CFP>] ;]N),W177U@)T_-]K'R' M ;(51XR%\3?%+9(\T.R\8:#/]:>S8,=FZC[0637[U!XC##YK/!>"_F*E$3?0VB\6[S\8T^/C4:Q#H)$(ABH3O$BQ<97[9X'SA+8&OYTZ)OA> MJKM43CH^^>3@ ^+SUN<-S_=3VC Z+$($-%JS6M B7)7B >3EJ<#VV-;R=F1! MMB@&B)7CB@RX7EA!Z.Y$TYN8E1?AM[&#$5P>:.,]/>"H"[3$J?6R9-QA XA\ MNK,(_L5G11S%8MH%KSSB!FZQ)Z@I8HD<\OH>ZA]$)-%WX6?WQX]UI,S&TT1) MY!2-8Q#+9>+-6.OO<8 M\8Q)6-/90AH4A(4H7PGCDX-0\\^.YSG3Q=,8Z.)OF-F%C9*=- IJ7 815ASH M^US !0BH8"[W6Z#@9\'$^W3J,UJHBY @Q:N*V(NW4:[5)%S)7C4OLTVJ6*F"O'I4Y- MVX5_9!+X>#L MF./;)D8_'/918R_//[2;W8;6[@SAGU[OQTV#V%( )J?!>3V<%H'X(4HW$43/ MTG@;%"#D5I'BE^*7XI>DRI,"A-PJ4OS* M.W*RR35]FX#'M\L;#1;ZNL._+L? 4/9/VFITJ7W1FV6@DL7B. **+R.G;*T M?>NON4%-/Z%:A[:NUXW12(Y8,QW_V2+' __+@7B;*X!Y'RT$<6O0Z'7[6:I9 M8DY(#$W15=%5T;5N=(UVB;4SU;7$Q) 8FN+L:7(V(Z\^6<"Y>*:7U[=RF+9E M 26K"6Z%U7+2PBM.*$XH3BA.*$X4ZR#M#7MBW7DMPJ\=7E'K[6H]02[E20%" M;A4I?BE^*7Y)JCPI0,BM(L6O,M;;TVT%K=Z"NVPQ]4H$TDM:G^PU!NW6T?J4 MK<5EPZ,8J!BH&"@I P]?0%0T5#14--SG(G_@J6?PJWVWIV](.[SQ^G+,[TZ8 MBV]Z<[R,3()\Q1G.208B-;$03UM5IBUN ZL+N)R MB?#.Y"!!,.>Q=NNZ/N\ 9-S'G(4\"RO#& MK^"":K X79%IC3\3W24!/X5W(_5$[F1^50+/(1C>@3+E*T51^MK/#K^Z8*Q= M\6R@#A,9XV8Z%8D&@\2)E"V0\&MMD7L@(_+."6IM\6N,=&,B;F 4>3J#Q''Z M*V'Z"^:3=H+<@[RH,"TCG4Z)2<4E(3-,G,]OW/#>0*H@^2+3^5>F/GJ6=6Q@V]_$3Z>R3Z/;@=MD=U*\C&>T4MGZ>P%D9> M$P8^YMS47"^U3M1Y*6[MV)*(4N2>7!R=7[9ID77A*3UCIB*6%]SUIR 7_3-, MO!]9.$>>,WKBW, MFRM& (9#F(LWZXBWQ4BU:O9$P1Q!3)!&<(<0##CBAA/MC5]RQ.TNM[4G/L_9E$ZTD%)N9$W=EJR2<1>_MR3@K6=%9QR(K%V$#:U<[14L. M3_% HD5T"H>G!:FQ.7P M'2>0)4"U\4SW\;@ZW7:MU*0(5#"!NJVJ$2@C<[SWQ%KVPOV*2YAO#.IE\2ND MHOK?=,9T.['Q+8^3$G6/'+K$L)FV2TB@#SE:0)&AVL=XCSM-<;RDOP46$.^0 M= S<$6$NK"/N]3 ?94[RBU=[0:SAJ1HPT4':IN+DOP(;\L M;3T3E^\JUI?*^DZCWQ]53R-RM$$=Z=!K]JJ@D9KXC _$]1@U<&^5L(J^3=4< MNFQ/('5<4@)]R-$"-23#J%D%?93E%*X?,6ME<<#L.CCR$*$0UG'F,V.BNT2; M6;J=LEERP9GW^<=HYX(D4'>=@LP0:ZMYK$^:$R\S.W^KV"L#ED:]0 MMU@Y.:5#.:2U_K$ M_*U(UL-'Q3#MYIX -C\C'LCUISW/-)9:%W_<: MH\&PT>WWMIQUYUE PMHX$/*J6Y@Q1!S#'U-;MPT*NJ/PB.'A^S>7CY^UR\IAZI*'I4]R2[N!A?"@5'T8I=4^C8Y"+";EX MKA$.@2+,,4\( S+JEK5%3BA M^$WP@R*,4_,NQ*4ZX+]=?&PO2YRM(QURC24 MC(3)88*C_O!1/!&>X><(EL_Q+R4CP//^S[I+#?Z)G]4'G!L2 \"_@/R9:.+( M.#S$B,<<4")]Q20$(!HC8PO3 &#]SX[MNQJQ"*:[X2 "H(%ZG+#9,7$*E@PU M4<=T,:>,BRD+NK09S,+_/PP6PLTA:NY,V+0,8@S8\XK M=8.?H'DY!FAB[4UW,8D--"5#(@!NJ/*5.KX+4@098A8\X6TN4O: @KB"04P' M6 '*,GEZF64]"/7$RV1DYK"P*;;D5CBH3;:E4%BD6TN<-2U,MT;FQ/T8[FRK M5W:UH2PY.@Z1_( M5*=V&#FNM'+K--1(IUSYF/O=7TJTYXQKIV3)X4G @=JXR=6")T'+?UG$%JNO MWCJ.7')GY-M/:-G2(SZ*1.(GT1Q5Q%P!"ET'Z^,1]'M<)S^-YJDBY@I0ZBL= M+^B$ZX+_)#IS?ZQI^QPP3F>6(K(WS"!I7I1X9VG/A*==$6,E;7F++P6G/=ZC M\OOM0[4**[.4+,-NVM.W[5FSLP97 RJEAKR1(DCJ^UI7PRK9GHR M&LBWGH$Z6H9?<)@.%F3VJ[4\:DG$\MP.]F5QOW )>I&C)>I*BFJJY:2%5YRH M9.J#,&JE!D,9.*X&P^H)KPR?XH3B1$E3P6W"Y93YZ,9A8T+C6XD=II'W&66) M!] =L7B)R*$2<>4S.*MT<%76U@;JR0M01@7*A49V;2FZU732K9QIY4PK3BA. M*$XH3L@[&):5@W+3-JH(@>YM2*EQI!>JT@3*GR;PD"U8,J4)K"H3"8MS_*<>V<$L7W13#N R:0^-?.ND^NH/&K%"<4)Q0G%B9.> M>0>Y?GD:57_BR M\1*/B?Y*M&=";+P08*;CI2S4UK!@9L+31'NCWD1<5.);A%_ZH3'RXEN<0Q&Q M\(%'8H ]\&CPU/6[,='M%WYER92Z_.H1O+#@!O0*@I[_[X5VR:L!\-:\H1DP M3]6A;FJ/4?/\%A,L9^PXGNUX1#.C?N\&>>OQ@A+;L'PSV!D-;V\4$39.P"(*W# %(R^8L."Z8I?*Q3M&QY\$@T4(\9N M.I1TC8,:VS.\:@J)X,RH'5SU \_J+[QU^64]+MG<1<*[BJ G!)T+OH+^S,(+ M>,3U3N(N"?&*#6,;PVJC]5R$E)P6& M;N5-,/NGY5C%5,';>*$/+52(K"Y6Q2]:*M3'VF0QW$73+SD+0;/S;N["\ U= M%ZP6F!Z\94QKAW?3;31_Z/EX6XP1!Y+<(.WM^\EZ\6K?!VW%GF:.#1\-@?YT MIUP#LSM':G^>."&(W@2DU_A@Z-RZMX\:F8IX"_#Q.* MB?,6SI$X) .+!!^-T)FXC%'CW\ST^:H_M;CJC3]EZ3 9&]/P1DE1)5X)AQX+ M-RG\[DK3Y]=MDL7MG";X*,S%B^<""#-,UDP-(@K2I^+M"#<42<9CPF^"Y)8K MYKR DA%,X"1%MUVBFR7\QJBRD'W@X;P$.$-?N>D M,^->XPSOR,3I62.8*/)2PE]Q-FBO0%B^91,D0!\8E >E!E>GAA$O<6-J? (< M%1Q=OHEA-)V9:,>Y=3_Y"5@-I5N]X7>'>>C$S,--U/JWMNLQGS?_^1?H=]33 MOCJN2R)3T6GW?_RH?2,ZQCXBB[+T)#H*88$<3JS0=2O#R!\^Q3#*-%:FB%(8 M#K@&(8G)^PQZ+XB _=Y' \%[ ]@04;DE*A==.Q0'K O!P!*Q3''#:$S^=9,0 MOPTYF*.-*0-3^X>O,^SM ",P&^UFN[F[E\=,1;PLCF)3>:U1VNZ^IY^_49@^ M\T"18Z]U> Y#=?I:2!=T^F\Z@^ZTQRMHCAK:[13O7PYKZ9(!A9@T!K^" .F9@.DB&QX[[/P!'B<53@-L>D(=J\PJ*KC M/=#\FFEQE>OY,Z\Q M^*4)7\$DPN;3("B41W,PX+H(P8 1<:9D07^P2<$=W?H;B.6"L8'NC[$-,8OR M+/14;D$&T^26J2$V M0(M,83D8C@87H->OO"& MT,W20SN&;D)XRZX.#WLBR"I"+8$$6,D"B;!U3_SJ\:"!=,OE]YLCSKB=X^[5 MS ?J0"-H4X?QR _&>((F6)YLB@NQN;&$&M$ X@W6?,+ILYF#%AB_='RP3HR^ M@(SAR26+ZL_4XC)$M&B@R PE=L7-X1CQ6_86FSR&OC;3GN-UZB(ZB/?(BU_%8"3RI?"5 M IWK?B[\- /,^X+>44-M')5T,1,//=-M7J@6>*#]_0YMT%.6BMTYGJ4>G0)' M-.YW[EH74(-1+:3[%H7XN02FPQ?(/+S8FY)7$G1S8!#CP0J,.?,A"J968#/P MR3GQ%CV@$>]I(96@0CH6%,47%XZ.#C(CY4$WH@31T^RMD:[]X:FT@::U(+4Q M@=FK1>[&..V^M$W\SS6,8-!GL) GW*UR$F&J,(@Y=G 4XL:"WU(>&&<7=VR0 M.6+['<.5OHUK%-S)I4RS@#O6PH 1OL 3[!>94,+0]YEOV2&"IG!IGAZM7B[= M,__CQSKVQX,7''.\0KZGKI"OSY4E*Y@K<*7,D^,=<:=;I5JCBI@KP*"O.!I% MN%NGT2Y5Q%PY+K5/HUVJB+ER7.K4M%VL]"<,\_'Q*G! -M%%NB6<=#F%&I7R ME?)E4(52?J&J.&!X.OX.SSP'YPU'WD,0/T0'/8+H61IO0PZW+K]<"3FARRJK M1.V5)P4(N56D^*7XI?@EJ?*D "&WBA2_\HZ<')2;*5CHZPXW7+^;6[J(;[A\ M' &*+R.G;*W8W<&R)0;9<:UQ(8F0#KU:O+GI8NAB4C<-&KUNVA0G.]4L,2;BMH]1;<98NI5R*07M+Z9*\Q:+>.UJ=L+2X;'L5 Q4#%0$D9>/@"HJ*A MHJ&BX3X7>7RQ+>*HT2JM)F.X97F7@S>\MS#)NF_CB#',XG43BI5!ZKF!, MAD1"\7E*4.IBMM(P'7R4G$GW9$Z/U&KGS<^M*9$XKI_.@C.,^61(PMTQ-4J& M=*CUSV-!)9^SK/FF1XA.8"YR.S0;!T='\D2:0?!&5G@2\& IBQVG0:L&-#@@ M2I:/F^,:J(N1H$ZLG?&+GL99'#IY/5PY;+/E%<824YC0Z1U%B M8'''68[B X@[#\4<#Z?3Z(VZ,NGG^%:3 <-),*?3'\FD'XEV^V8O'%Z-X>-] M'A.=F6]XY8QNFU'MKC/V\$N)ACF)]G@7MD^IW6BU!M73B!QM4#\ZM!JC?K,* M&BG%)\&*UZ5#R8C7_49GD'8I0 *- MR-$&]:-#KS$:M*N@D4)=NX(]VTO#\*>^I859)WO>ZQ*V"%\T[YO",SA@OG6Y%'$NK70W-)L:DS\!EZ'ADG VGTVL=NQE))&!0!CR!@ MMY/]I$NZ] O[$RBLIEQ8)&RXM#UJ4LOWZ"MY)(;/J$>)>_UN6+Y)3,RU(/:] M\@#%W?A:9S;HPKTG['&BLT52ASJG:+CTN/K7;]KEHQF>78M?M=O@J1I0:[H] MUTB@2?ZEXWNN!^]@!@ XPZ>"%Z"]AP1Q!3)"&IKN(D#*-C,?$ M\+0WQ[=,;0*O@3@$PUP>/0\YMI*VXF*=^[FFK_!R)LT\VE;:B M_..\7,1JG-Q5R2T4#Q0/5':+%!,4E9S@./%4=@N9,5>#0!7(;E%M^UF!X/LI MIUPHN\:35OX!G53Z?!>._:(]$3:-:K^U7XGK.4Q[0*MX\*WR)09RRSZ:7TX. M@V[: *W<:E($*IA W5;5")21.2XA!<:O-OC5;PSJ95%^Z\$G-ZK_36=,5P>^ MR]X ,6Q68N^O(H,B@US;8(Z7]+? FJZZSJXSSNV]_N->A-<)N72X**/29Z3 M[GZ1@Y+UZQVM1K-3B80(B@Z*#K7P(;_$-B5HSHSO0E"L+Y7UG48_=1Y!"30B M1QO4D0Z]YK')(JID!,OV&1^(ZS%JX%8K815]FZHY=-F>0.JXI 3ZD*,%:DB& MT2DED90E:=KU=&8YFZWMTM=4\UB=5^=(4^P[% M.E#ITE2Z-!D&=75L5G%"<4(J_S>G X%/CJ=;1[H4)WD8-7>_(ENX_4;KZ#59 M=2Q:,3$+)C;;56;B!H._^WKZK$X[;S]/_8@QBN"P+I[#]N;?'8^$VP+NF-B= M6O:QZ809]$FT+9$U^)'C ME8,F^1Q#WM%7MIXYSN60\?"OH0;.T3J$(JJ3QQ*"*.Q01%T4)@4(U6II%18W M9#(%)T/0/9*I3 MG&177[EU&FJD4ZY\S/WN+Z7#<<:U4[+D\"3@0&W\^H"T MFW!5%IY]J%9A979P>ICZFBFY%55;"J6]NB%GY@PN4M]4J8A33C@3R_"^Y^P6$Z6)#9K];RJ"41RW/;?C]LM]H5U(L<+5%74E13+2&7X%"<4)TJ:"FX3+J?\!#<.&Q,:WTKL,(V\SRA+ M/(#NB,5+1 Z5+B.?P5DE;:FRMC903UZ ,BI0+C2R:TO1K::3;N5,*V=:<4)Q M0G%"<4+>P;"L3%&;ME%%"'1O0TJ-([U0E9;GW#LCB.V+9MH!3";UJ9EWG5Q'Y5$K3BA.*$XH3IST MS)N(76$\V:B:>:N9MYIYUV9&I&;>BF=2:TS-O ]W-G;G!T^9O7M'&G#,EO%9 M=XF)"<6)[>J849P7?R?NO+T,,F,_(9ZR\X$'[87)E^EX7E22\/@=P"I3>%SA M62<%W_0IB6SY)0H?-56B\&)FS1F 4#E?JPA"M5I:A<4-F0SY7@YI3Y4H_#!= M'Q"84H.&,C_*_*A$X:KI5:+P4QUJI%.N?,Q5B<(5!VKC)E<+G@0MKQ*%2SYR MR9WR=3^A94O)JQ*%RXVY A12B<*KA;D"E%*)PHM*%-[/(@-NL$BN\H27A:J9 M3Z[>3J.KTCU7@T*'Y@G/B3G#BV9+)O4HXE3-]O0O.J.*Z2FC<5SE"9>(Y7DP M>W3L]O,2]"%'"Y0S5N; @>Y%IU.Z'DZ:!#)9A&JII=#IZM$"J83@#7<$GH%7"[VS)H1)^+PV^G='@:(7FTN!) MA^2JL"X7?#F<<>PL5K84T'*AD5U;*J-W36?-REM6WK+BA.*$XH3B MA+R#85EYQ3;L=XH J+1BIYE6K-/H]]-N6) I^TY5F7B":<7:0UFUIG@FT]0[ M(XC]BV[:';LRJ4]-O.OD.2J'6G%"<4)Q0G'BE"?>*I^WFGB'<%N-4:=;8?^T MJDP\N8EW_Z*G>%8;GE5@XMV]J/1%!1M\C3WYO ],PYTVL?<#<3U^8O.Q? M;>JYEV\Z,T\OR_?31#A08\>RG#<\MRV22(N\W_1/>'VA+8VK2T-]:3\\//[Z MXZ%IP!/D^>8IO3^N/7)\'K 7$19;6J2]P::U=R>!(T?IC=,T3&LR)47]%U,F%2 M@"@\)7Z0>KB:RI*M.\AG=ZYT;V%T;G3*M'_HEE^#+,,969YM('K4 *T/M8WD@>QJUIRTCCME5@0TF, MMJ<@K]*PM!M@#LJU.^AFD6LWGF/7Q8M959K=HE#EE.JRE3HAH-QJJBV!)$NR MVVI?=-/F7RB;.1G9W_QRI/)YBLH65_*NVO/J:4,._2LJ5-FL%73(Z!_$56F@ MR^;U#]UCCW$>C^$4$V+*Q(%3LFVISXQDF_#P@Z';!K%4FD/93H-DB/78[B1; M]C*YT,BNK:*2T567985ZJ=M(G-51P*4X:%2W,U:G $_R%& W[45E,AV5J2H/ M3^X,X"$A5YF(MF$$..1,5LH35-L/:%U/9Y8S)P2$>*4&V5S;I06%\$]WXP=B M."\V_9.8]R"W \^YGGM21[4\QP.$+NK]_!E5!4(O=*6Q2$'\4%;\.9UOP=%> MQ"U@&HSH1)S::C>;'>W>TFT-!M3@FU9+?,//:A%4+(CC!HGCX2_NLNM8#@S# M,-Z"K'PUTID1IHM3^N&A,&_"".%%)SH>A@_B\J7V@V_KOHF3MQ\UZN)JISBF M)D;[I5-DA1\5"UNWU2YA(U(^DF4I1CKPA9UQ:S75(3?IMY/*MW/W"0U8A.L; MMU^UT[/D\!0-% WDH,%W&& 4"Q0+:LB"#=-#Y=?4E\/7MEF'P]O5@J?:7;6[ M:G?5[JK=E7*-]ZG=NK;UQ1O%&^ -_VJ\28C+V[O0;/LA7L@+M&9,>%[%TWR M2BQGACLB$S9 >1U"(ON00Q<8#*JG#CD:H'Y<&!U[.;/B0OE0LAH:.^4?O5=D MD(4,K4J,$ADY1^E"7-E+^L6B-B+EGA(C+[ZE>PZ;JSY0:A\X^DR;LH?E0\DJ MO'GL)8>*"^5#R2IFV4E[=EX"?_$@[\4ZYB-Y)2E;2-[<=BKOXRK6?OM8+TVV7(9R MH5'LVQD\S2$CF&*?8E_"24ECE'ICH>*?XE]66$>M8]?2*Y\/-W5F\XSR/3YA M)L CNY9\.44+2!:;07[1 E .1]GWK+*;6S8\BG[;Z=<[=KE'T4_1[V"4[49O MV%($5 0L+:-\(P_75N)4WQGGXEY-^OV-V@ZCWOP6SS\3U[M[LPES)W0&+^.A M:/V%?)[?0YV@DG@:[TOW;KQ(W?TOPW=!D?]Z))B1^A'9\/A&O3\)LW3X6V?6 M-W[R^4SS;2H*N/<9.=-,8M"I;KD_G=U^OSG[N7DQ&O466D@![B"YOCLVRL0< MOL(O'LE RG\%(/YU_4X,'Z/<=^,QM!U+JH1F,ZT2-DFRJI)[YAB$F"YF8+]U M71]O7KICCSIGV1\^5+$E47L_EJB]']/# VH 1 .:V2]KLOWZ>!47[;QS]G-K MU&OB_Q;"[<>TEJ6>_\83W'_WL4P:] &C+W]W2T5(1['Z+ M )V+3FMSDRQ!.!+J7O7N0-@"B/WD",F61:_>'IS4DJ;*M=>6$QWW=B<2O?MC>.G]QO&%1>6G"6DGM)59?VD;[+ M)FPO)FPO9\-;/9F.,+S-?N6%365X"QIG\A,WC>%M=2HO;0K#6WUI)32\NZ9N MF1O>8=5D.L;P%L36'(5-97@+&F?R$S>5Q]NKO+1I/-[*4SF%X6T5YQVV"O-X M"YJ.9B?3,8:W.!L.C;P-2Z@RB;8L@?1:I]W6GD.JE42*\TJ:4&^0B9B MI1DBJ]1>J:8CQ86DCY' MS?_UZ^-^G-WB+/?:VE0:G+T2P_22ZG,M\I$*9W'ZW,K/VR=Y-B3MXF+J5GXGT6>(Z3BI]%K=E92L_KZX3K#(4U]^W\C,)3AGL9Q*< M9:ZJIM)G<:'XK?S\H6/.C>Z)3]0[=\;?> [E&]\VW41G!@>];G_IS&!B M2"7($OTESMY)6NQQ4DVH$][M9^!5D<-G_0W[[I'F$4N &R M/OJSF47)KI0 NYG5'2R?=M]741; E7O!M8;]+(!]IO#?K^U^2E^]P@]C=I; M%+54_N$HDBFEV1X>@^(&TQI/B/F+XYB'ZZ+3'8TVHU@J_W 4B731:?7ZQZ#X MA3E'\&$X'&[1 2\W?:V)9!X.>@?5>FG^VW<]O%CVB%9O#K;4'2O]4 3)V-_; MT@5W ( >,2/,F]];NNV!N<"!@=^P>USS]SLKRMA=S_&HDBEH-&B7@2I\UAJH7B7LFI="B[>Z-N*;"/8G>[ MU1J4BOIP=G>@,/EL$/T !EU.'>?1/_OW6 MP@]WD(>]Y;$G*T1%2IIHE.WVNLU<)5W-7K0WGU7J_<-1)JC%=%=_IU-_ND;4 M;=FKNNWF<+2>:&D_U%*%A(E!"B&;Q\@7DM@O[GV0K J(XV_-F[4J^GZ1^JWXD<=,L!4F\(;UA00" M-]N5%7CCPD_@BSCVRQ-A4YP"P1>,9TI;'V:V]]ZJZF3C(E,6.NFV*JN3'3SY MU38)>X.:"/M-9V"FDBMD6"M+<=H*V<&04 N7KNN@XT+,WZ@W^>+8_!J+9XM< MD>?U&<.VE)'-SK"J.MI!&J6C_3R"$J>.S9VDNQF6FWPTZO='557(#M( M?*M.M12RRR%_@&&940.Z#]?*KZ &]^'QU\0=IUY>2U9:&36KJI6=.7Q0%_'\ M\3A;3FYB:V50,M')(&^3\D!X!.1>9]X\-B$6#[MWXZ?#\X)?448,\.B3A-&& MRV'+%*C64FVCNL44_\K'#-3W_+*"^-3_QF'!I0=N9C)M:;]VOSV(;8A-!VYM MIX2ENR!\X-?^YGF[CK1/)HH#;>M]P)3ZVK[8LT*U'[K)&QT-!&Q\. MW4-1X_4[809U\5!C-FH\H.)$&@V>)SPY>O2C&_SJMA*'@K!?Q+R$R87^0I8*3LVMO4)EAN=@ 1_(5*Y#UQL EUP'F2HB@U(2U)&EY.AR9717=U*-*%DO/=2K6T^_J#3 M[=918[OBAH1Y8+##.^1P2V]HN1V6.&36[XU&@\Z)J0Z- S7)I0>:PLWJ2<.+ MQ??+79/5>(0T="[-C&S0^6AYBW!Z(/F(LA+E@<_M;"Q(;]3L=^23-_?^/^IU M1]G*?62ON''8F/!M8"C1]?N,BK.,44?)B.&=T2#3WKP7=]:*BOGE1SN?K5&G MFZDVUL#EZ'SNFF=G,-EO#W/Q2G>AEDA9J<(]PZ7\TK(JRTTU+B=66")3M$-Y MW8M.&C\L.RDR5V!8>O$Z[%VD,F*9"B*?&H]WEG;2-;XP=NJJ/M)/V[O1=N=] MN*FFOJHADC7$EFW=.XU/_'XFU1 '3[]WZKB=Y2"9KXZ/G3$4-FR.EE+=E"I7 MCK.D7.<)_8M>A@'(A*@W*NMY?[7/J3WN38M#N&6\G7QEJO_/[K=V\VI%2<6B M73Y#4WC]*=8J^__L?6NUPW6\$J!FS:WME,Y 6UWD5C=#;AV -C/+]=VQ!0H\ MW^;-;VW78SX?S=*LN&6P39('AC**>:<02A9%9K<+M\GWX-91D3S*D#QTG4B5 M[?Y@@ MZFZ*6^]+]Y"!BZOC\T4(N$:<[S)LWV8?RM]>UU3>4BT%'C!S?'7Z* MCJQZN;RG7.D>B9);96F\=WBFK?9%=]6[+T0^N31[J#6OC&8S6XE.I]X\^FI< MYWGWUW\<0*FJRQPQ;7G&7C4U7%J68^ AA13%9W MIHA7$.2Z#V 5[+2E0!X1Y:$C7FL6N6J>%.^\&A]QW&]NS&_ M5SC1X9]FV;I?RRA^H"2M9J?L1MEJ#5.*TN[VRFZ5K4?JTHK2+U>475T%QBBB M,P,SX%YAIEF'YQ0*"DLBW&!0=C-M[3Q'R[:2L%2FWG2T;.U.Z4/DKL/-1PK7 M*I>5&R^S"!9B+6I30[= M@?R@OF_'+9Q%7 M@5BYIGWCO1='BC3LEMU*6Y?+ M#Q6IU9'.D3M:IG:S7)EVC5^/Q *Q7D FD74=/J<9O,HEX*[!ZSC!6NW2#>#V M) U'2=8K=TS>F6GA*,$ZK7;93;:UE_U";,*XY;@TIY@GG=^Q\TI2B-=OR]O7 M,A"O6_+PO*O#92!>:U3RS')7O\M OFRB&8>O&2TE"+WTO8G#Z)\KJVZ;\TN' MJTQXSQ7(C,E=X*'U^V&V;:#DV?$S66/;(D-92NJ=MR(E/1)XQGS$^"XJ9X/. M$A\9;%957Z\ZM7!+QXW#>&@[?VX-\N+6JB@Y;M=9/D._*[M)6J6M6*$F/]>? MOP2KN@IW! =)?S8W4;1FPNMPGQQ/M^*_8T#LN^/]DX!HAO-B(X_C!^9R59LX M,AY37B$B%:9'L2X)5 ^^PN=29[5.N!2%*31:S6^MP54!VMPH6#74FHBS@3+; MTNARR_E6;A=*.)2[WI.[*]?CI :\<2#8NL?YL"P,N_9$-"_:JZ<@MN]5WK?W MNJ@S-*V+_NKN[2- ;SQ#G MD8HY>J-MN,DXVE&:2S_:Z:1T>AM"MKF&)2JF$.LX:Z: M_N%84(P%AOI!]_)(01'KBO<^(^N7ZUUTA^TL5A222RF_8O<9M9/0Y -U?[]A M!)<[8*+M>CD1=&^@;8NRFZVUTU)Y2EXO56])1[-5UII>-X:A'K*;?%DBV:[N,6E!,T>&^40U\L<2[R?_V9Y MGV9_>_$^X8JVPWQ14-[A GP M^ Q?OK0L4+18\M:<8,/(V&&:-Z&N1@*+J[W!6*'!@#&E-F[,^]M_M3J?WB;$ M7GG,("BX-O8MZ]R#JH)?4 W:&_4F\#C14'6Z/;] W!\0;"C$!RY.QC$EH>W, M]W5=FB9?Y]>MU=#REH;%?9-AP^:S.R[['5_;A^6'X<,'8I5J/] ?-81#,'0+!G2= M:7,"_RSTMP1^HK]B?3J\^O+"R MZ-!O%]F>:YVA_:?<:P'7H L(HH7JC1N'2 MAR)P"-NE!S$BDEOSAJ9K,YUYU* S':W'LH2VXRVDG#IH$B> N-5LU)C4H2+]U!=V1/T($2[%,]8+_-ZN)+?^5 M<6ER;MS8([S/8,N*8VWK4V7ZVV%&OIVX5]GT7<>46W?C.[!V^GHS[\JMR,?O MM&/V)QPP7JC]46M^TK":<]VB+_#GOZ&ST?'\[&B' %]^Q@^MB[_IT]FG_VKU MFY^XA;]C+SHP0-@ W3:USSX,W\1UM87TW, _1Z9^W>[SDL0_VD[V=B?#"6>>PN<>N?2,FGNK5[IEC^H8' M#X/K?J']('0R;+>;P3L:?S[ZNO4)W:[84S%G,O;0CPWM3-]PV,QA.(7#PK#2 M1P]=+?!9OH &8>)G4QU_:C>;G0LMCAW, <\& #*"#PP;O@G,&S)GGAQ\]XUP+?W#_NC6(YF@$OT%IU3B'#Y,#RC.OC#4 <,@,I5W8.3^ MM<^<&6D@LSD$O(ZO\>^Q8WVCI@E=X!JF4S#)<(.YU1N? M'\3 I=AR@_] +J%1?CPV-;4&CS!VB7 "Y9W4(-R9 M;BQ1&B9.6C @\(%1#) ,QBW;A_+'X&SRY[$#(V&C3H\,PI<%U7!PA"^=A!/X5T?0XG&Q3-\HL37,(.TT ;C3=2C\^\ MT#WSB!LPF4#W ,F#20N06'==$O0(T57 A4)?+_@Y]#:!<*$':<-P#* -QV%_4U]J:$SG!RMQ3H0K:?BSZ?A@FO5GF%=L M;?Q@?A778SC+6.EHR@970*Q@8O%_?; :&&]:]B%@#@F=VL4ES#D:DIE%D%"Z M%BS;WH7A>V #>:=\C7'92>B:D#X$NF[-G8E&PK]%@Q.V;ZV,0$B?P.+LW MN1D2:TLQ]PD, I09=6Y7..Q_^#KSQ#(8--#@0KN%L8>98A(6F;)H0(@[:J(" M0#&#?NDM-RVWMSP0@IV?+_$L,(LE;6@?:!QH;ZB(6PM-CY:'A!<'3?,!;"#A MZ[31:&#Z@A.A070)G@^R-+[8!U;QOYTW_(;C@;D>QC^><>3$<3@%0+@X61 N8.HG#"VP>CB,V&E08#<1;A$V%>4?ETB!6(NPX3(A MNP$+HR&-HWB&MICBL!)K2 3 '8+Y]I'2#BRB*)'/;0/SNR27XULF"A8\PC7N MXE(A^#7 1(!G4G?)W.)XX!%C8CN6\R+FK^'H;BX25>)WX#<+B;&E5F;\7'+G MF8_5G)5&(D#%R4^8^-B,<\XQ&,: 9JDR[:DB\9 MAK/[N.S(+>@Q-OR".A(]"P?FF+_ 8<)W,27@[\)J+/B.'1S*2K"98CT0OQJJ M_^+P70?B5]PF> 5U@PV UYZ TY\MM!!U"=YW+@(_/"8SVAN4NZ;!ZYH.Y]$Z MQ!>P(H$=CUJ1JE:LAE@WH<,N3/WBWAYA2J.9X[(9->+=5WA&G 0:3BM%2-'U M8O&3P-]JX+A,YN'>DF 8X%->IIN!G!@[\X%KABJ./A MX+52Q61U,1M!P:CG"[C!(($Q93YRF81,^93'YP-W(]@VPG<.>4)AO*IGW1*C M3+#%B&+T%B[(2;W/*Y@YN2")F[MP,$ X"*F'*Y./J(K(6;RMWR5&T:< M>^; $,L?B3T>MDE0$)\WK\QH@1,$Y35IZ,I:.";'VP3;B^]XX$XRU_9\AB,S M-(SI K<7A..EX9C\;"[;JDY507$6HEK@2?D.K$>HB\1ESN>\(>->Z/B:R%A MG(JZW.U$KU!L]\)M85/LCIH[(P8=4[%@@=; #'@>T5/T&@R*SE>66HI<_E-, MV3M5Q!+;S**)*\R*B(C&VAB6%1-@G.?S%=N9QS<;:9UF@\=> M^(,\?/>#;^N^B>';'\5,<0PC@//&IY+AJ,'C,8S'\.*[+WEP(PSP1A[^1^7& MXWQE$*T,,*0GW"J&91\,-XY)@*J] HL?S3H>5_O@ELI#2W]5M*D& M;9HR*4FQIB*L&00^2#2 M@T7U(W0KK:>N;%KM*""S45,4*(0"RK<]>0KT2E=''>(T747C4FD\*%T;RI"5 M;,C4+/W4*2#S4*884 0#TJY:5M"9*39.D[1+R<&B^A$Z[>8-9=+JQ@#EUYP\ M!10#3IT!+9G'@8PAZTC=TL5AU=E8^@I-:JA*H.L H9I1 :=%4*(9GS,S3SR<_02;M/6J7U4+2I M3 JAC,RI2NM1^Q6H]JAT=:A%R)(7(64^,E2@8YB=45-G^DLV:C*OJRL*G/KV MJNIX9^HPKSJ3KBA0*@5D/O)02>=,'>13([-B0*FCFLPQA^HX9^H,CS)DB@&E M&C*9*5!)YRQI*%(.&M6/T3(36C% V;3*.&=)\^_(P9WZT5AF%BL&*$.V;LC4 MX:VX[2X)5^+[71N:(R\ MT"SZ\ M$MLG#? L\ RM8T=':S7+,3A7&IKAV"YUX2*SXBL%5/%'>ELI@4]4,-AMS MTVDJD5*59:@3#4\EO5(-9:@3#94UK*P,=:+AJ5C#C#S=X]&GW1=5?(U+_-ZP M(ZJT=&2G4*-2OE*^#*I0RB]4%0<,3QEE/>RNYD?+9L/KKS8-=[QAU8^>[A$W M*1.6$:K<=EM1M?/);==5*1$5;=+CZB4]AZQHHVBCK(VBS7&TJ8BURI* 96#75&@8AE8Y K0W##=-HBB<*D4EOEJ%,4 MYP5PHMKOF8O)_:_/$O\#CN MAN?Z&;9;@T^N9OB,00':)7OQ7>WV5ILQQ_0-3],9T?17G5H\E?V8.5/-L:TY M_$,T%_E#"6MP,+P^_QED]WP/JAP[#*MSB0;SDBE4H=NVXVG/1'.>/9W: (CH M+L6RF/;F^):I,?*'3QD1Q>BV!W)H)G%!J_@,Z,,?ZX;'KSO0IHY)QU3<0.!> M< 27]ES#A_GW( S( *"G&GF?@4Z(;4"5SP)ZH+E-JG =$-3E/262$- ' %W? M\E"1.@"S=(Z=XJE=YL_XO1F((] S?WF.52T:2/.<>,6:#T):\(WN175A6X#Z M\*E0 *A$ARHMJ,<&@5\C?*L$T*CHW/QJ!I 6V^0/'W@YIL2\T*Y?B0WS1,+( M$@@AFWANOEQ-*'\CD"AH7I 4ZUZH9PJJ@)8%,71M D-=D(;#<%R/@S 8 4": M!VP6BG.%T'0Z(R8)A9@29F";!^0+:L$?(UYB8? 2T&!K ^K/U*(>11TZ' 54 M",) 0X'^@Z+AJ0@T@H)V"LAG8A--"?$ )S#.O)#$>J@K;1(,<#<.(U ?%^ . M.KVP#I*-3T(W-*I,@F;3O$\3D15<-PS1W='^&P[6@L,:WCZ#.8>XQ1M3 M6[>Y$7'Q0/Z4&UWHZ^CNK%]^$[OSAEN6*V($3[1$[B P[H;E@X7279=XPKCJ M4P?--F 2_&7=J/='C::S28OX"^=1K/;PC_Q#AUW1@RTH]8<_[+T\"4GHN;. M@0BL+36ISN;!Y3LPKCR^4>]/PBQNF!#,+=I\;>:X+L4!FAM5$ KP&73&-8(7 M^( .X.6QZ!UH[VV/H8$4EM^D+@Y?6X$LX&XSAG__X+OG+[H^^[ATB]0#=7^_ MHJYA.2Z,:4_ C<\P,OW^\W_^!\Y4_AZ^\VA,B.E;Q+T;+[U^-\8"/L_QWQNP M^ Z+BL!&1ZX]D/%/9S?@E6!SGC=;\'_/$9]'YYWFV<]5XGG4H\.;%7D+RWPO M5V:2UW-**\+74?2-*N4)G[0-2U-)65H4XT/)5K:6HH0YUHJ*QA966H$PU/Q1IF MY.D>CU[&*V)V\'O#<89:WY93=HU*^4KY,JA"*;]051PP/&5W2=?Q.@WW36II M\YBI*T[VHN67Q:A MR#E+FB^_/$9)1&YU84'Y>J\?!61.AZ884 0#9$XDHQA0! -D'@4R7B J[-2=_7;J$X*.L[WI;AX\T/#(JCK]C>'VNEQURRO7/D/YT% MISQ#7,&>_F&ZY.]G2_WK]#):20)7PCQN&_-@U+XA*@970MZ$(P,,#/53_P$Q ME_K93*FRU:3O$+(E'%(9KJHL0S4)IW)9E6RO4X<%RD>0@.EYT#9VLUAU=%4^ M@I):JQ*J.L J9)1":-!5*81DSL_0S"<_0R?M/FF5UD/1IC(IA#(RIRJM1^U7 MH-JCTM6A%B%+7H24^DOV:C)O*ZN*'#JVZNJXYVIP[SJ3+JB M0*D4D/G(0R6=,W603XW,B@&ECFHRQQRJXYRI,SS*D"D&E&K(9*9 )9VSI*%( M.6A4/T;+3&C% &73*N.<)K87$@:B5NV[*UV)INXZ]F@5SZC]@N'C8=@O0DC MA)^2M:E-M"D4-7$U I6:VX[3XI9\+;;3N:$Q\@(LT"WX\$ILGS3 L\ SM(X= M':W5+,?@7&EHAF.[U(4WPV.[2X=Q"SM3FW7_MU+M^<_G0.VHHP[45N!DGOP' M(Y_0+$0XOW&K4/MVJ!A<11LYVJ%B<"6DS7=P/11KI(:K6%-.,VR8#BL_3?6! M4)QKG*C57O$5@ZMXHGBB>"*QXBL&5_%$>5LJ@TU5,]ALS$VGJ41*59:A3C0\ ME?1*-92A3C14UK"R,M2)AJ=B#3/R=(]'GW9?5/$U+O%[PXZHTM*1G4*-2OE* M^3*H0BF_4%4<,#QEE/6PNYH?+9L-K[_:--SQAE4_>KI'W*1,6$:HR7RKC*) (2O/I6M#,:!< M!J3=25-!GR:_Z,R3SWXG:J5).3** 64R0&V>.74&R+QS0C'@U#W9#7Y,/?+\ M__V#[YZ_Z/KLXZ,Q(:9O$?=NO)0N_V[\0-W?/\_QWQO=\!SV!$ _6X[Q^\__ M^1_8+']?+>)N?&N_0@$.FW_Q&8-/3ZBKZ#U,JH[2/I#Q3V"RN9-1F9VZR:'_!8\?G/8[QJUM1ES#.(FM:CE]0.)S$(> M%K,QDN"HE909%J45/L\5\4:S7?Y^=3G=S U3[SR,_PVUJ3N)9<)\<1PSK>.9 M3YC@4*+N"])(U*?20,UJ#T*C.QH=W[Y2J5'QKTK\:Z7.PRD/__)VA)5O4SJ4 MC'A>9;6C"R$,7:81MYQZ4?3;5-SGEW'(JY!DBVN7-TEF7M^>[3=#V12\?46/'U!H1%IMX1S8,QRL; MG3DHS73\9XO(L',F)_U ]3[3C^OG9KV9S.+3.$YW?JL6^B@/TX(\:ZH:UB.ZS/B%G]R.@/%6L%! MAMY%3,>HP$=B$0,/1@?2:EQ<[8IX.K6X=I\CO2^U1S7.1%NI#G#D+5,VA]OQ M9;K1?0A=!UJD>#L/]+?:>0\$)0BELA2H+ 6U/6@K"5P)3YNK+ 45@"LA;U26 M@I,QGE*=0Z[%H7&5I:"R,E23<"I+04X]ZZR%%2IM2JAJ@.L@LI2 MD.=2QBF=-E=9"A1O#EI455D*5):"_[^]:^UM(T>VWQ?8_T $&6P"R!J];64R M SBOP M*A8I\AR;MBTZE@('AS+@X%@*5K?3L12XC92.I<#ASQI3'4O! 0IA5]N4;LI1 M'EQRF'"8*+'H=1 OW13'4E!^']01#HZEP&4X.TPYRD'<8<)AHL3"[L S>,=2 MX!:9\&;'4F!#9QXA[AQ+P=H-=2P%.X"S.R2.-SN6 @? 4@%8:Y:"^IS.M?EP M_(4*9S#8SLE8G*J(_R1RALP.#1R\\(@U][QDFO@<3UR/Q$P)3_)8A@'-;/@T MA*'Z.WU [3_HH?HZ\B 3[3C$[8[<5ZFW*N&J M)V0%NX_GRW"K-L/BX:ZD]3WC=G32>INHS_LV>0?=P:_,LCI M#C;]QJ9LY.PH\Y9P"O]M.)TE,$2R"5>C.ZX$?F61O3T*QS%^N&9WE!<@%N6+ M/81$I]%NGU;/(W;T0?W@T&X,!Y7@:BBA(-U#$2IX)":A/V)R.E/A+7'Z.[J2 MDODINMWJ^<..'J@A&%K'1%6R\7;.??&3)"J0<:)$OI5S++_A!WI#_U-GZFY7 M=75V5;>[F_*EV4,8X=#GT%=YNA)WA-^"@=T=9G28<)BPH@9VN"[=E!WA>M#H M;GQ.U */V-$']8-#OS$\[53!(P@IYEGQV@ M>0>A%4G[,"++[R8AFR7*F_!(0-!...Z>(?X0P7!K-@_FV@]GG?;I+Q'[X^)S M@ZH.O-&#"WP)]]W)>,(\J$PXW@I(T3MP /(CB0MQ8$"4>!/&(X8;&9&G!%X@ M%3Z.S%AX,7P>\*E@HT29*UE\!SZ8GXS#1+$IM';"H Z2X:A ?(*787SBSX85 M11NK!(.;9>R#H5#@"959FMM'1L0A4\(3\E:P9,;@MS 0#/,77L)][1U-&\JA M,?I7>,^\X$'C.GASDWV *SF8"U>1IT0,;8(DDD01KE8:([/H(AL6(PS<)@3[ M%,*-G<=ZY3P($C#P4LQ"%8/9^.HI .+D?\A# G4?B. MB,VXBE.LK\@H3?8%_CB!M\%[&8=)&K_)@WFFI" ?LUZ3T"&KNDIOA+P+$W\$ M[^[EX.6Y:^&HRFPY@S*1?BQP'@&DWRA;ZQ@2N"\!2%7\)$ MN"L=C"8;^,V-$C<<\M:4?Y/39(HMZ_8ZC=;9,#6"X$*OA_P&IG+?!^Q&44*L M3=?S!4R#B? '"!UCRBH7(/\5/IBL&($!&EO&G'XS +5N*_QN?%L*5OR2(&PR;^\UVHT+BA><#,Z=+\BF8! M6A\MNA%YD$YPT2>&< FB6"7$":>SK_1]0H '8 @P7V"H0S=S*D&@H FR)&-B M0J?7&99%A9@@&V9 HTHIHHBKN'Z((S!!1@E,O#\9*33VBHSH22, MI5]T2)8DBD'C@<_!KQ[W/4.SB*_#N\P%$Q@$X H1D%UBM*JF>OWSC^>*Z:PR MG9'F,\_/8TPC(HCH^^U+0::\#:,XND(S:%BZX',Z(91-4JLX]1SJJ><5YM(3 M/=H66U[FU-,5J:N;]5D/_W]!;=5>J$UI4,2YGX!:E,_H'!MNUH 1E,":#GG+ M*D1X2IN]UPGOCP 9-;"$N_!YH)/>"_D20UWA.3EZB*DYR)1\R'^L:IV"P1#> M.G3-+!&?1"\90\BP0;/%II!=99[-P.339O_>IPTP!^SA."W5*2K(ZX!+B'5( MMY@^"-GL:P#UG!Z]X3:X#_+25,9444E/5ZXC5*F8<$A[9'PXHQFK+G3TA%*) MN#"A?!-R1<2@[Z $][#X/]C\S@7).LWZBO#2*P[079U6JTLX:^ (!PB*:7B! M(>O/)! $_L7I'!)/0B6_Z^*>8)L!P\,*$Z&C"_=NH]]J-5JMUB+LTY(/ MS7@_QLD%!A6]4J\*W'LK'\'SA1[R'@G(%_CW-'H[K5_H4OQ+]EG[EY>Z)D]G M!DO'6RH/X(<9&(:MT!.-M(DF7&\4IQHGC]?L=5@FG68M3T-3/T5B'(TC$5-P MP30U\035.>;QNO91XE:&202%QK+7F#[3+='WF4J*9@:X!D:S:E,]/8Q)=IW$ M6%7H:H7Y*$,#JIF["T M8(KC&K>9=PAP*_Q#ZVA0:(VQWW .8D[,?9M)++B@B*$/R03*?O=?^";$)3AP M %12D,KE2$_0H>P4/EB"WL*74Q%&QBMR#%2AE,AT$@YB%?J$^I$8D[=,;4D/ M=HM2%6C6N8[99 IOG],@J]=?=$!P3"J8)-+%&ZB]A5Z_C+S[$R);TOQP*1RU_68"A<]M,ZC5J/#=L8 M9PAMAIO17Z=N.,'O]!91MNY>C*7[+*I ZVJ'4671T]76H58:Y7JY),9<2\RU MD*?\_^A5A9,9Y^9+D=KUA;_Y!D,WJ+ET9Y-#;0^Q"J6[NON^8N9:")5+@;LL M8'Y5/^7)2&1-N:!ML4?9?75H0P4A^%&. M<_CAE\?_CUL;7AY)_SVACMB1)--@%X(UG\U.EC")HY@'(Z-PO4P4E67R>VOT MY:*I]976V=JJO6GL]#9F4[/;4;6%D&7J3&?-5MLF]SC@5"WW#)I=)^^UV,ZM MV_"[WB*[IEO+@Y9%*-\'LH>54&6J+Q@V'2OW@(%>TRD35:SQ>T1#M=QRP,GJ MULU)5[;J ML9#%[=_(,$/'"=<=(!^QN$1P.#;T1P??[G!;1E+'P5^>DS8=PW]HUHY@-6RV M-IW#VB.LY_!U /O*KAGL<6"5YLRN5G:ULL.$PX3#A,.$O4/AQG/J'4D6+-GK ME!G XR5,*5O6+$>IM' H:W>V3VHPV'2S@DV2"]5 XL$\MNV$>XEA.P+::;-S M9JO7',YLLG!GN[!ZF^[6MUP5D%IMV]9F_3/9,VN6])K9%+N&8? M582^^T$C*TP$G\I6(>G_5.LC91)P,HB5#%!^*9,S*-+$+Y1>RTLNK;W7:K)S MDD!9(8!H5*OHVD%SF FSH'Q"&'.?)8$27G@3D&Z&5Y 3@E]0*4'+*9'R9^&\ M^:*M"S);A<>1O )G=T4:W%3)T B\@1V=YEE/:RL<6MY \RHX=8.-I@9:S>A/ M'B0H;V X!AHKA8J\1"D46'L[X5+1(U&_T>AU0%P(PC'=/9%BS-Y_2_4H/X_' MTA.JD88"*D,684=VH*("\W@T(;$0%#0C#:)4O9'UAXW6H+M*YPC%%H/L^4:L M!"YZWFN>]G,]M 5MRUR$$_S_MS R"^F=*]VP(,4);VA#APSPB?>59WN-Q[R! M0B10_(,QG=-&M]?+6T9V/%1Q0NF3NT!', 9V--;J*WDJNM=\U(F(J-/T>]J= M1JO?7ZD4M?!4LB%-&<_;G6YC +$M [A%/WC&YRJ$/!'S;R1GDRH?\RE*\T7% M=$/X4!RRD8?=[:1/*M"L=Z0L2V:O*VVRJ*B4R@K=&U\* 3V B!Z>KHQHN-0H M6>NA=SKSP[D0T8+\"G,$1EZC\L4_Y)U4:U A $&D4/ M()@'-XAHO)!,>-YM0IB"7<_[31BU"UJ06GDI37^H;\06M(U^G$=T/C*24)@E MZ2'7[KC@1U1]A32)2K(/=Y7AGV#*Q$G5QZJX4;F MIA,CVD863,.1\!O4Y((>%-P-=O2PL,R4@.'^Q#>R:H% (>>$*-( M#X"G0^P*EW4KT*P#9-UN43-N6=*%2,#Y 42 KO)A6JP"@6*\F'4#06.X5K!# M=?!(J%N=+G' I\!8K76IM.1Z.!X+92XM2F*Q'ZSTUV>S]N=_D]I2;9=;L\3.MZ95=U:^WJP5L;6A>'3LC9[-&/W MNUFZ/GT\2Y,-ZV=JMD66?C0YZ\2W+$'G/WTAB>8HSIV9ZB_B2)T++_,@TS(M M7I_CE,3JR7&CA*PHR :&42JI:))N]K?T]OVG7I=0UTNH8ZF@=_\#D1=KU=R' M&107/12F6E)S5#89G,$]J,Y.KTDP&^$F M4\?2Y!FP"$XP6>U:>!PG5YAF<3S'P$ZE!8UU$(X^+O0\?#YTR7&QG MFRE3YAL+UMF?L'0;0J6IU"TQUT(9@2/R?L7,M1 L]97]6O+-JLN2#OA'Z/V* MF6LA6%(-I]128H>M7T<<4\JTPZBRA6"-H%T]G&E[>-F?Y][Q.$]R'W!E^M^X M,EV_KMA3IENUP] >O9O*&;P#@9Z]AHSYH@@M/K_C:K0[.3)[^Z22PD&[Q]6A ML_-%01^(I.^.I.=VE*RWM[X"QPD+L#Z&]CH/6WO\\0D*:Z>]72BL%975:+N+ M$U<[E%5[$CAJ;RP#8[>;:@L@RZ35VIUF;U/>W;*1LZ/LNS]E+)KE.)60DAD5 M3JKG#3O\[Z!0Y;1V$'JI?]-6.X?J4E']HK=^(V-II:4CC9HPE1!>Q5T%L.964O?.Z+ FYA#31[]U*FD2V[JVPN M),?^ML8Z6*^SBUZVRI.VX=!QOSUIN=4FH"W)_U7CXGK0M H?P3HW)$&/T&-I M&JUV8S DPH.G$&/1J=W"<'EY];7 B446/,J+Q99R8IV5PXEEU9FXJC3+D&*= M)S?P&M8^2Q%F3H2WAYH^@8 Q$?Z(7<]7L@"LI,'JG3;ZZ4-26@,D)- T5)J7 M((7[\V[SM, U8PN('(9^?#0W/5+.1^%,4U?D)Z\U-43&RC'SX8\O4O1T6K^\ MO[JXR'YM__(2;N"*Z#5DP/Y, D%[%C3SA>\S >V2>.HTHTEJLJ](^Y71U. # M&P7:CP)H_W6/L&+*YT@*D1I'X(SDMQ,Z':R)&FZY'^''9\2.00_SPSM]IKY( MK$:$%@5VM07FC(67OI O4Z8,?4H_5IQR\(C/'_ QI.E5P6WY?3Y??EO:D/2@ M,MS:9.>%SL &9UT!_L5.P[/Z,,,3P8AK+I%5E"D3?JLI(@I$;(5FYW0>R0R& M&++A>4?3"11X.'C6*>NV'IH U1(.8P" .9)IS! AGIQQPLE"ZX(P7G3#-$2" M@ E8W6X]R@A3<,=# Y:Q6398NP_SW4Y&-#?AR&T@@I3W*$%Y2D>-;10F,[DM-UNZ?4@$U.LKLT6ITTJHLXPL#)->6CA1JN4(TA M HK7<=J#G9$BY0#JM%I==H$HXH;+ T#1UI\8;ALOQ.:DA#=(R8%+L5R3*\$_ MR)%!T1)"-/ B#P?&%3+:X*/78E7 "RF;OT@"GHQP!?XE! OF!,WNH&O?!?(% MS;"PP?99^QAGMK9_!SP+D/P*F>M@8T<_ M5,Q<"V'S">H*AQJKS76H*:<;EBS+VQ*/KPCJTH4XP[!]G%]:A#76"HJT=<(2\-;HV$?=%M&Y'W?NRW%&5W#.FLQ^JDC/'<.-@ M\X0C%ZVJ\=LXW-B FT[OR>1G#C?'C)M!U7"SHQKNA_0,NV_NZPHP/JAX7AL'KNL*,#ZH<%F-U7SQ]V M]$ -P="NQ"BQH^)HDP6NW;?SK2\#M)/J)"5N4"D[5',7 :5&P,9,$!:XPXX. MJ!\6SGK5 /.WJ@?F#HM"H!AAV5226L(5T)W]=4!2-# M3@"_.="7NX#D1L-J-7Z?HV&G$O-$!X9#@*'O5A.KU?@]8J';WI2RL\J5T3:4 MN7OB"_Y=!$)Q/S,"*R@^FLI 1C&2O]R*#?O'+K9JQY3^F*V#SJ8UFCTLU@Y] M54=?;VL678<^A[XG3TD:PXTW%3K\.?SM;$]%>]/OT>U!WX[*X8VU@'9$?O\% M:1>W='[9//REZ$%LNDNS'!F(L^&VD>5D(!S\G@Z__DZT9AS\'/R>]%UCHW_6 M=@!T "Q-A:FQ?6EKK3S.ZY^3Z.2&\]FK=S)"*8!$B<_CMP76[DNMN8*'4J,K MI(E_PR,QNN!SHM7^ BUZXX?>W[_]\Q_HAM?IXSZ*&^[_Q>-8J.@\@-L#_ I; M!)X4^4U(W8T^N13C7Y]]4.$4S\J?M-KP7QSJGX M!?K)SE16?'-4N=UJ:D=G7?-1QO*&G-E@;WTNIQ$M2Y]'D8@B>$=LOTZS/LAQ+(06F@EGLS"2FCY^PF^%5DH82U0VN)XSSN*)5*,3E':8 MI]3T[Q,5S@0/V 7$$-B@=64:3'!OPKP)]WT1W.!&#[SX%IHTDC&I2/#\UAG= MJDVX0P&*4#'QS?.32-X*?\Y\>"*RW]_3MVFR+UHBR0NGN8Z'>24T6T8D->'! M[)9+:/LDO!.W*'DCQRQ*/ ^@.4Y\$FR:DS %'X^%I^U85"3AU])'L^,04K*. M:D@?L8Q#950BDABN^([MC(PQ,HY,PU#.27B3 *;0-^0WW? F^XL'_(;(^^^) MH) )HU#H!EP+7X+A)'V1VUUL*0I"Z1Y#W1Y(2)+[3%!K4CV299I A68!.)(Q M]V)(CA2YD3 24]0,%8X2+P;<0,>$J&]U)R/QR OQIER*P.E;V)\&[LL$R8CI M, =L^%ER9US)R.C^D J,@AJ JSG$0Z*T/,HU!&T "&VR/V)\RC3#^+\0$S*0 M!$@>I_IF:? "LB=DPE0/J1K4B/^U@ U/'X,M,/J2/DWE5L-8P#F/_ MZY^_72M?OL+_AU__"U!+ P04 " "NBV1)3;P+NY + (? $0 &5Y M97,M,C Q-C Y,S N>'-D[5U;;]LZ$G[>!?8_HX=MKN)DC.0:X'!M(F MB-W3?3N@)=HF*HL^I)3+^?4[0XFVKI3L.JVZW2RXEHP%S MR>2%C ;DAGN@K-Z2V]O++ID'P?*DUWMZ>CI0@VDD.G#$@G2[8.)4.7.VH 0J M]=59)Z'\='0@Y*PW.#SL]_[[\7:D]3J1XLDSF/E:I-X_/C[N::E1S6D^3Z1G M3!_U4#RABJTL@Y1;]+FO NH[*7TW6!5(*K_O1<*4*B]4_1"I8L[! M3#SV0 #Z_7?=PW[WJ&_40]6=4;I<%9E2-=&F8P$6^9 NX@O?#Q?%0-U ]H*7 M)>N!4A>TF.3.JEQUH70!]L+6@048PG<5G\T#; /:K\/C(VQC'ELP/[@1"'SX_#$O-H[QW)9P0?3WWW6L_X,'+$(S)A:ZD0[A[UK%J M8+7@A*[895/N<^W=8?37)UUBBB<_4M\ED2V2,';:RYI)& \5<^_\7_3GI60* MS.A"MW A+ABKE!1RJ.>$WF9EUJX4%HDO&,*W#<$%]; 3CN:,!2KB/'W)3O( MF!T!&2QF^1)J8#XXB9^4\+BKA[/8)(ELDC>??1JZ'"3_VO,.A-Q3"=#F+.#@ M<$$0TG)[1(Z^-2+D3:JZUD9H1:*ZF]XMF=0^QEVD1&:/S+MZD5G;)F)*UM;) MF[#UO2;)^Z58 +HY,,@?V:U0!:')J]@C]'Z;"*4J(5C+/E*92%$UO_'$4U&$ M5B)[9#YL%1DP3K3U?418[T[.J,__TJ[!Z3^C6LMKAQ/ MJ% R^)(TJ!=?QF1B;&MK3"ZHXM +[A.H1GSFPU+=H;#H=1P1PDK5G]U#"W67M+8GLZ15WPF);8['SA,DHOE(^MC)O;P&Y7/P5 M\S+RQJBW]@Y+028VIA//M()RL3V*N>RZ,%TC;R)CK64_FZ$EJ2^1V7G/I;TJVGMB3]2(TO5A4[\;G4NBQ/:7T@*G>&HO%7?<*6&_!'5G-#*5?, M'K!<\EYG@XF\B6LAJVI:&\>"=6A,3NDZUA7 MA""7\]M#0/K[(.0X'E0%85 1A%S:71&$P3X(.8XSDT@=17M0ZF;1^WFB+*%. M31)E0GL0:J74;9\>RK/E5 2JU:RQ.-HTJ]Z'I8+O?LVX5,SA1YOM8^_G\I(] M[>*)I)ZJ/4"U][SWLTGY7:G46%8FM,>A>E=\/VJ5,)OI%95:]D#D4O+R0.Q[ MPNI>8:H'9"_:"<]EVNN[A6UO\!DB,PV]5&KG.Y=6Y_C>M^NR&[7I1:M=QQZ% M7%Y=?JNV[;W SG._3C"JEJFYA+HR&BU>H=JI'M2)1\5=IZ-<;ET=C_;>>+)3 MG9DTZBI;X_,NGV]7QN?_<4[!?Y#*!S8E^GB!$WS7_:RC^&+IX6$ ^MI*V*]1?L[!0FM;U.0F0;[2E OU[7L M%#!TG4T!IWO;*^&]6E62A!L?]=!;G_40?\^>!W$*P(4,B)\[6\)V^$=T;,FM M<+0I2Q'\UC7ENGBIVQ]TC_H'S\I=>[J)$VL:-G/"E-O"">L1)"5>%);!#]UU MX;KU6\\SL=5?6+#'O$"9*]VUJ6V\PGO@ &[WTPH'SCRNV%(H'^%CT M73!G$A]8QR?DT5L''E@C\Q']TR<"F5-A0(K M MAF6:"MUT'?TNQ0R7<4*^K&)8(JP$XX8R?C,J@\9ED^_3&(=*A>CCC9 C)A^Y MLXY^&2?C(;)?!KA0LZDP[Z5P&'/5 MC12+_ OV$< *G9\!FAD8\50H-(2+DO4;JGF8%?J-A4Q?\,+=]!I27:$_C^DS MSAH>'L,S%K;Y9=O"VY/QRC/-:D]I=7-OS)Z#"P]0&,QVE0V011"B(R=/ F-C M!R!&U(-6J*F_ATR!W3,YFE.)_^-3<@9(M=KF8 #),BJ^6QR0>DV8A"_HH,(9 MD;E#?PR!4-1!P_T"5+4*;8PQTE"1S5VL;:A2=].X5=U%#[&8-A9Y'O<<='.] MZ-FP5/VEW?='^87A-^:>/S))9\P,%+I1;HJ]OJU-&8G;MB;W.S/R %DY+(7\ MV:7 AUR=(*3>+9^RNS! %_$4XFW(J6=VRPYBKC:/JOXKLN_/1 EML(/4=4,ZUZ\;)6B1=ZYT]4 MNO'R-@&Y1OSQB O M)B'T[HA*[R-#]E!0^PPQLX6\-S!0XA.\ 630S3*53IS])P"D7-0W 9 M0KM90!_P6=K_ D%SO1\_B6+O$X(&>S^7K(3]E*BY"&Y$*(L!)"4-]I\_E@0@ M*6FN_R/^7.Q^0M!@[_&&>(G_25%S$5SC8%^,("5J'H);.A%2[Z?A2R!+%*9Q M6!0:B*9H/:0R@*PZSHNC5MZ$^6P"F M^GO(.0:'_7X:4X52\U!=0L\ 2]&6'=,G5)J[)4)FVU\MW>9AQ#M$W&7G ;B) MN\\I4"7"YJ' WT,)/;PUDAT5LM>;YWLB8\?N4-!+2C/\"OWF837=(]I+#:4S MIZH 8J5:\Y#9?K/O//9V]5!@+=UOQQC?2\.[[+/==++HYX>2OSYD_>6IU>^K M91G8B:G&$52X)LY"KU!J'*C5NC&#(W^]<:X7;D"E=PX>A.?="(E;)M9M*TNI MGP.V;;N_+@FU;?R4E)1MQF[)3BUSC2-*M^^+Z@W'B^R&HUF&@"=A-(;C:PGC M.?7C="Q#CWX@_@H&_!O*I=X2*^"Y*=XT+DRQV]%3:-C]5J]0% B^V_,[I[WH MO1CX^#]02P,$% @ KHMD265S+3(P,38P M.3,P7V-A;"YX;6SM7=UOVS@2?S_@_@==]J4+U'6<=+O;HKU%FH\B0!H'<7I[ M;X4BT3:O,NDEI23>O_Y(2G(LB5]R+)$^7!\:V^*,?C-#S@R'%/7Q]Z=%$CP M0B%&GPY&;PX/ H B'$,T^W3P;3(XF9Q>7AX$- U1'"88@4\'"!_\_L^__RU@ M_S[^8S (3@D(4Q ']ZM@'H^&_OUY-HCE8 MA .(.*0(')14G(N,;O3^_?NAN%HV;;1\NB=)>8_C80EGS9E=A9KV&T@H_$ % MO"L!X].:)Q@>E 80&"4[ +9@&_.^WV\OU M72F(,(HIG,U3KO0AOSX\PU&V "@]0?$Y2F&ZND133!8"+Y-!,)P3,/UT %: MLON.WAV^/S[D=_W)AC9=+5DGH7"Q3)A.AML#_1PF7*^3.0 I-2&3-NX&RDU( MF KF((51F+3"):7<&>@32$1J]KIMP9R"N,9G> +"[1 Z I)K?\L@F?EFAGT,[_S%B(GH H M(S!E/=V$2M5^9X#^" D)+89PO=T.73N.?@QX/A7S.,*"B%7:8R#;75]B:I\) MUJ=)"!?<-9U0RORSE>.SH_;7L9<->W?P]1MWZ>COPOO$+**1L#.G;X=/3]5# M +"#:4O?F<>U@ZFGVKGWM0,E;]VU)[:TJPUQ?TEWWJ7H-==8RF8E+T["50R[ M=$S%/;?P3#7*'D".MD4]PK;MN2S8Z^%&81%DBR*_8]PH%>$H!BD%< M\N$BO'QIB_W,V1SF_T;!("BI-C^&* YR%D&%1Y?HY4M8%;A'#.-ZI8%]9AE9 MS-0/8OZ)X@3&8B6VX!3DK()7WU"8Q9!=^;E<-RPE2'!409WPA4M,JCV@ "U6 M)Z0]8PB2E):_B+XR.!P5*Y4_%3]_Y[6HE)YFA*^!E3=( MPGN0B-M^+]K5F@W= >;+.&J<^=4ZO(T><4*B ),8D$\':\<3DJC2#YJ+OD6+ M(9\;,+LM2OHIP0N=M@K-8 G23:6QFQP$CX!W/P'.H9+KB?I)>LK\QPJB MV;_") -J_1L)[4QSY-0TEM)[9[6BDDIY714^\+++-4C-0UM+96>O8Z?VLI'; M.V/QZ0YBO%<,J]HXU59VQGCKU!@RN;Q3_@T!RQ#&YT\\30(L,1FGA"N>'%EGA/7VKGVIV@2*A% NL'<.EL$E&8C;]# - MB6O7VL9*>K&[][$%A%/6DF_^O2,P3(IT2.5I]22N_:U9^689/!TE9V *F$3Q M+6 3C,SLQ53M74^BK,>'7N ^$I#\_E_XBD@!0IE^R)JZG@/9#0:=F-X-@O/% M,L$K &Y!PFO*;4*&!:F=P=ZY'QK6:O#.@&*59HX3IDF:+])>HBC)8K$SD@A- MIRF!]UG*,Y<[?(U1A%'*M,B@S"Y1"@B@&BOOBK_;XDP^(H4LAH*SM+'K1'6W M1FY6;53J\:ZWG^+% B,;.S9;NLYC.S6B2C'=1_7ZG4>*D"YIYSJY[<8B"F$] M'5$G<0RYI&%R$\+X$IV&2Y@^/[8HF2FJ"%SGP9V.+X.:NA]FUS@%&PM2=_@" M(K&/@$L]7G)LYT^ 1% ]TVS'PG6RW=W@W$:5_HW;*,H6F MB,=FKT$ZGMZ%3]K*3SM&KI/Z;L?Y=FKUKGO<\EU:",3G(4'\-(8-N=C\%$90 MD_+;T-IU@E_WLQ/8*\\[NV_,7$]0W-22U1J#@M+U+,A6MIHU]V@RS]-&F(JG M%9F$IU@\Q0C0YE.+\IF.DLCUI&=+FUDHPLYX#NOE;>3=L3O3JN;CL*Z9*_:] MKQVO\L-1*MM?CU^Z_35X5;G+S]UNZ#4.8:G>9R%N[CGP2A=<=B$9*#\,<9>FS M@#EA/D\7VFH-78H@KS=&8FUA(WT/5-\F7^L6I&S.N*$QDDPM1#)6W=3V6C1K7 M8/?4L4Z R <9V/QI@V?A-!%/0^,ZF[8=%&:YO3/5%X"8;+Q?G<0+UL=HFC]. M9[27D=!U'=[6:)8:\,YR++-Z+@2J[51KYD.DMX$M;>PZ.$I57NM.&BF]ZT+E MA#V'ND:NMHJ2P'40M;&,05KOK",*_]<8X6J/,GIF$YWK:&HUBJQD]ZS 9'=P M;*40\\LVA9@*[X S]Z0@(UFE,B_\:8GV/K[V':(L3% ;:O+AZ*4SE AW@0G# MA_(5E6AU1T)$PZ@XZTQ\*Y0?_R>C:?&PDU"'M*"=%VP-OK4_&*[#:OO>Y,1. M/L>!QNG<%?__;BO_SW@&@JDG?I\_ELXPW1#\ )FF/J^^,0DNT3K%.F&&?LA7 M/L426L9^:RY12'WKB_C^/WJT3\UV8,B]##!G@+FL"!9G"RT34/BFDP7W/W]5 M3O61/91C0^W:G7=BWC:*\\[JDSD+))]51VU+JI2*]A[,J79O6;UR>MW2?4EI MQB,_2R,F@#S 2+F[U$3DNBRY6TO92.SIT&,Q@0#6NS*T1%7[8.'B0)[RB53IP3QM3&_' MS_7>X)[Z1!OE[D-GJ1URL4T(6)/:=8'?]KT+*%2V'R&_=E9&2WLWJ.U,_OY_ MP.0*Q76?E]?1;'':2#L6EF61PSTQ:GL%[,UXKIWMT68P-T@MK;YGU3!KG?4_ MCAM05,]0VQ!:6F]?BEVV8GLZ4H46^%N7+S YP]E].LV2,FM0#U(]E:6%]ZSH M9:,I[\R[/ISVZO)BS+?FD@=P/IV"*!VC];*=SAE;D5L:?%]J9^V$]];R=9^D M/D.H3336<;'L!WM?5C-KTKONH-!,_@ZBBF9:K[I*>;@,:>%*K(C?X9/HSPP2 MH#S>5A/@6O#P=&U68]IZ9&NML%V6BQ0Y*,,0 1#3"R:NZA7/M>Q33^+I&JN% MF9G3D?+HJO^5IZWPYV=%I&!CHOYR:$U?U)-[ZCXT1E+U2QLU M=3]Y+;S9>)I':?[Y+GSB#Y^*8'V'6YQ(M"4O3UV-K4E?HD#_%A(V>ZA8!D<1 M2^&8]&%RD]TG,!JSG)YHGVYHP<+3_1X6IF\OJZ=1A\O/#^5@?WCB\A FXNWJ M##2.Z[F\VN;MN+AVXMO(W-R-MXNYTPM./>EPNW)GZM&E;UX> -.=*G0^QC8+8#RV^C-L_VX!O?>K_&7=F/_RM_ M+2>D48)I1@#[LLE'O*>SY!1LLNKV19T4TO'TA@#*]"VX3N ,P2F,^+0]+TV+ M YI8U,[/>^+[P"J7"$;L8Y0_0B"7_+>ZY.*^_'&#S3N_#C;N'3S?(2CO+G24 MW[]RN8:@2X5)7APO%_E]7>0*)1<]I^T2K'*2OXET=%A'*LB"G"ZH53XZ>:1% M^1)V.>!1'7#)H'I<5E#RZ!*[]$7L^!?(-_)QV4&6LF MF)TF(5QP#\ZW[5&J=M>C=XV>NF;R.LC9"%=<8;178:IL*)>_$:@[#%?!J[)Y MQT?X22+7'=_0I]!!(V1+XU?P*N?1,?9Z(-,!;P3>9CCK";4ZKFGP'S7"L3:Z M]21*/6CH!&B$YT;HZ ET&11T8!M!N23JJX_(0XH.AH]?PQ3P'>OBL/%LN4P,N\U,E*[76>3F4&T<-"C NZKX M&O@?F/S@#Y#A"%AUNEI[U\L][:PD%=9?VUSPHRCG(!9'.%O8IM;>]?I3.]M( MA?77-G:;J;TXLEV&666%JJF\U?[S$5$VXZ+2VAN/96$-B9B&73?]'W1ERL_D M,Y;C=JL#_IKI:(11^M%%O M,$K1N0O5RR$O !TW2@YF.;JN >GET ^.M\T"A%&>^F I8CG_CX-@O_P74$L# M!!0 ( *Z+9$F0@"M+VAD $[' 0 5 97EE&UL[3W;24?)NXRAZ[),]N\J2B24ABAB(< M@/)8^_4!>)%(D4V -$% 'N[#K"RA@;ZA&^AN '_\ZWGI6T^(4 \'7PX&;XX/ M+!0XV/6"^9>#[Y/#T>3LZNK HJ$=N+:/ _3E(, '__K/?_\WB_WWQW\<'EIG M!-DA>SV#I[];U]=FAM0C#Q\]'1S]__GQ#A[/XIS<.7EJ'AZR+ M/]C?/S[S?QYLBBR&2D _/U/ORT$&[N?)&TSF1\/CX\'1?]]<3YP%6MJ'7L!1 M#X>')X,TS=0]2647,)MA' M8S2S^/^_CZ\VHU+DX,"EWGP1/3)^HMWST&4^.FB-Z:ONI9"M(3D)V8SETJ&WL]M'1"*I"!E7#:4$ MN3.\?"1H@0+J/:%K3&OA" *K0=6FBTL?_ZR'XBY0:ZC=DKD=>']',F)S\'1% MO0!1*B]MZ0Y:G#K48SRY(X@R[D2#3+QYX,W8'&"&Q''PBEF28'Z'?<_Q$&58 MC9&#H]#VA%97#-D:DMDINF$:7,/DL9/CEH4J ]S= MHCM6*?J-7? ]J=UEU];=6)\K6!)**(0!3C9XT4V7A M6U_&2/(1:*X*'6F^B>!4K[1D[9,4=$?(BBV3''A'Z K]OR1X1^A*JV[-;JK0 MMXF34E#6.(L'D"=+TW4\0?8N0F_!NB#.Z@$=NMZ2YPEXI"89*,NB32]>$!ZQ MID=)FZ/2#M3CO1GLT,5+VZN)=!&Z XRCD0Z7:/F 2$UT\Z#J<;5]OQZ&$8!Z MO (V'W,9>Y'+ M/U'L>VY4LI'T9,5=6;]]#^R5Z[%?_MD= >69[APU)R^EQOHM-XI:Z@1I\AQE M;^4HVW9IX9FU[=3Z;=6-Q.32ZCG2WC4A+=>WQ3O70V(A+9\C[7TCTEB?5M1I M9R3)I_!SY'W@]LVCCH_IBB#V1[:?R."E/5G9KI0:#%6)^ASA'W<)C\;EPLN. M_+N5&=O:CF"EHT M130"LV(X*P%4:1W$90(Y? >[^*8=Y+V4E?:A$/7J"H(Y)![NXO"*4Z".%$2J;B*'<<$A0PZE&PJ:ET[DJ"IX;C2AC*[IB'S<2].T'Y$=C3Y/&96V/#$ ]4AD) MM)-VNRAO56M$4N23T*-D?#>.=WYFFA8R9;SPH]&^'% TYQ]2S&8$+X7\3'B' M*RG(,I@AW',<_1LU>F2ZQ5H5&K$BG-NX@DD&1+YYP7SSYZ85_(\)6AN[$)OY-DL K,)W#B<"FK0LBGU4L87*I M]N)Z**NT),V=ZACY/$!]9Y-P?<\6E=1VHF7+Z3K["V#;DT[J]&&HZ6] "6C# MC)$G:-I*J-7D.YKS'19<)TY&EX2,=$/JI*C&7[4CR(MGY*SX?NYV-O,<1$"G ME@"4M^_:FXDG#);$VDP#.%D]4,_U;+*>V#Y#.HH\5/NO"A"SW960UI(YHUFQ%#GI5: )CNW]H7!DZHQ4;"8 '!*Z=V!W7@!)E'988@(HN'MSP 1NO >[YBSX"F\ M.3I=QS5K\-RJTO M0^0@969&5NX(=A!RZ27CRA6E*YX4O26Q28N3C;"DQ;#&BU22!$,W$1G'L^+\ M8'\LF,6AG!+D7@491R2WX!'U8KP\:Q-C_ [DCK#]+#,P$1E24LQ![)/$BHA# MTGG;<@H P"&QZU &H!K*7,[+(@]Q_UVF#.)HARPVZ(].JZYV3VOF:B$*)8- MV57225_RT)<\&%[RT%Q*.=7G:G^Z/D6!LUC:1!!Y%$.:'8"4I=RTM7D1[Q1K M41!+#*DG!BDM"9$ RQEA7"!2G01-#D(JDK+)63:^G*)C](2"%?J&0E&2K;2Y MIAR;].0JKMM+23#3EM[8_XO)V8J&>(D(K?9W96W-]G P=:;%+.((>0Y?D2FL M -'CQ2JXC64Q-]1AM2D>DUW4RT78:5XL'?HV0)59L4([33Y%K/A8@'3;UDO MV/N?6(JQFW8*E%L=9_-8@PY:%6]9*SFUS;34EGOMN'T[3ZQ-X\V&'17Q-Z)]RS%W4T[79'U M1LS-8PV&U/6NR@M[P&U&>U B%6CGF(&:#HU-?TAC#PGKV,#\Q_;^QUP"I'#S M0'4"Q!KT*9 ^!=*G0/H4B"%ANSX%TJ= ^A3(7J1 DBMY*+^AQWOBMDB4!8$@ M]BL14D6%F4:USX7TN9 ^%]+G0OI$(??*^+P!<]62'$XTW+Z88\XO(LWQ.$/KRZ?-] D MIG;R>8,J89F8S]L^D);+YQ6NTA;D\X9]/J_/Y[W:?-X&]Z\(SXG]N.!O)0EN M48)!S YK"FDU+H#2/L60.J? >J? >J? ;KHGP%Z20ZS?P;(_&> M^/NX8<4:(/Y=5SF/M,?,H&G>"G/W==C*^Q6EGH?M+U?L%Y+[L9!L+J5+VR-_ MVOX*G:ZCV7WFVU1PLJ("Q- EIQAQ,]W&!N'8\-X@FULK]S88\V>4^?L+T8/D MWP/\0!&)CO!TU98R5VPTL2;OACNQTO?GX7QXB#,/%^AH](4'Q MDRS\WJP_)+A@VJ'/#BT9T#T2>N@)(UPG,9G,4$"I %NB*#;'C&;2'340XU'O(4Y4( MLV2!MMD\$9XT$>&)WG.DJD28)0LTI)H/.MET,0I<_C_^7-N3[>=HW\:F*XI8 M9+N8?C(\KU"/$O-2#Q/D(R=$[JGM\W?X)@N$PCAY4)6$.#G>34*D_5A)1U;4 MDQ5WDLE';.G40$OYA8TG@V;$]!N2/X$9%P?<>F0,A,'#=OCYR6 MT_4]&[LZZB$%;';(HP;]IL6L0-0YXJ)MKQ2PGMA&'9%("K/($>/"&:JE:7+H M0JG$.ZUUNK8?,.&MUQM,*HN

!.UIB$GI_1]^#A%94 +$*4Z<*8_RQU+O%D MN!OOY'U9O#,K[BC?RFB:Y;LN1G$881-]-.CNU@+LC.99J8[:0*M)A661PA*-+V M7",];J;(R!)&Y^DPSG_4Y;7)'J&&/$PV]3?VL[=<+87G7;+-=$78RU1\]Q6K M733!F:#7ZMPP7LFP/=M,5X1<@NT%-$%MU\OVS*KA'%&'>(_QC5"9Q8/4"A8" MUO6NA/S>7I(&,R/AV47?BC.$_;&P":)7E*Z0>Q74E:.PEWT2J!PQ9BYY,V3< M$<]!=XA$9$A),0>Q3Q(K(M[V&AFZMJ>&UI3=9!A=B%.G#W.ETHP4T+]IRR;P MC$>XGO 3OZQ+5'D#SO^)YL:WN7SP[ M_HI-ODO&D[B@*KDX],(F@1?,:6JR3]?E'53';I0.:G8TJ -^F[:R*<>8QRQ% M$7,QI)Y(5!="E%&;(@^-"WBI$[[)H3'S%*3;.O&RN@ZX,C*JL:X T91@D9YS M6)Z,MBTT((#O;.5,?C*$$?F+5[U4U1-S +"]KD!G$]Y7$P':QY99GPX]HA3S MVCKD_N6%BS/,%(*$'EL8G*.'ZE,3-7K0]8I,$_'4)0L26.,G9Z!'2/%RB8-H MZWL;Q0*KIPK47->#KTU$44D#Q/=6GO)X0>:,V5/B\1/-$=[?&5OI>/)=F$NK M M/U3%!=F4G3 LFNE8>$7A(*8.CR%0];7L55Q;X-OZB\V4Z!0&PQLU>"$Y(" M1PQ,W+I)KV-'2_Z*C;(X0-S]=&!L9+5],B6R4F9$707EVV_EPZ]]W78?B/T% M K%C%)W)N;-)N,XD6^CI.ON+H":N1A]FATGK<\.TJ&<63U&HJZRMIAJ[^GR' M!6=X:/)E$C(Y_*A BB97\)U[!#FL;]&.(M].4U2Q8H)@ ;9F&KK^P)'!M=W] M@2-92@QU4OV!(],/' %AY2CS0.2Y7/%]Q3;QC^HC=;!GC)2831)X\!U5& M;^KT8[QP&Y!CZ#JS^])WXV5;EQB)16K'X>,T*UQ9K/MN-UJ<0G5T*?,.DH+8 M]GLAMGU(NP]I_P(A[0WN<7*')[EPP&_V$T0'JL$,CQ#(T&R::]W!5;2O!)IK MB@5(,1S+$&!H"* -Z1B]T6]+@B;'J),U@"A$G6NF*4)=/3MP-;YM&SBH:(^_ MT7@[2X:_C>ML;UW 99NQWJ.=$+)E I7ZU.=)7"RAW@:T"+Q#:^ MZX=<^$[F\,%FRY=LM53EWN!#X>&3J)-3WHF5[:6K!UPJ:0!>;_E8FXC^X99^ MZ_"*MPZCGS9Q=U]'*"D@S#VM02I-I6X'X_-&N]1IQKS*/KV4_76_;W-EK M_EU$V9:\P.7UK3)GO-2,INE08*EX<0?T&KIOV7]5,GG7I$O=3-YD*3DCHFG5 MK])2U#E68FX^2,0AB$'?HHWNEDP8_4,1>^W4?Y@T/.C1Z).JX*Y M'6+1ZWAW;(9T_FW+MVXVI:O(T7"!R/W"3LBE?R&>AD'NZ D1>XXBGW3.-B^7 MMD>BE%?UABZZ ],(Y,S=ZAG&(TAE/^@WTX7L7Y%!#[L,2MCP#4X$A\Z5U4P=+#'>W;$?F@4C<597%AA6 M IE=;BA!KVE91@!E4>F7 $Q/.: ,^Z4$9GB5GPJ9F5QWU[)<32ZG.\,TO)WQ M0^;PE=A)VT)3365S(7U' =O)<]4;N MDK&7AO&E&I*2E *?#C2]Z]!$G#4H F6J^9F'D1]UCMSR,%5"2<6),"GXZ=#X M.^-KT ')TM2#O-7WY[P]KA^YZN_3Z2-8KS^"E9[FJ0Y9Y5N9':,JH\BT/9?L M 40S3J&63046W9='IA;9K>4.MA)&4PBH M^LRC%-9M&R*H&C9:.DWXTHF/7X)6)?-EP;4]D"261#T20+&\:UDP%\M''Z\1 MBA:>=ROB+-C:4R@/ =1T\,%4,4AA#G+_@^:8**\+$+R+LVUB]GJH0(MI)ZDB M!(6!YFPC3>_8%!A9PN@\'<8M@.KRVN2E3PUYF)P1NV&\7*Z6(J'DFNDZT%&F MXEB )C@3]%J=&_M9BNW99KHN[Y9@>P%-4-LU&_O^2;J&E( "-4:>_9-T1KK\ M_DFZU_$DW=G"0[.+9^1$C_[>SF:>@X3OTU4 Z2K,D'ZM3H0[)*?6JS 0"1F6 MZ8Z6GW4^8ZI*;/Z4'ES&%)4R2(!.->WAQ7*H10$DC<9;>4 :_-R[YZ)1R " M5%T-4]I66S6%',,K< ;#)8V+)B"-9U:46>:JR\4CW=AI-AT8:U)@=$&F-C8C M_76U+[RNMND-$?T=H_UUM4:MO?=?E4Q>__?7U79T7>W@DZ&W)G5U86W$ '"A M\&E?[U',O>\W6H4+3+R_U5P_!PPU'6I:,79P"VTER9 R&>ZO)(E]LCV?+P,O M,8F.1*O7J-T1?QW%*J<<-%;Z]>L%Y_"32Q4YN?G'AP8"#5,RYI[HF$+:S2PH MV)2>Q \0ET^TS94.$;WT'H>VG_V=G^#[AL/_0>$8.7@><-,=+0T2UL *U\GP MYNM>AVPP,S6FC 'QE57,WB=?\785!K!;/'YAQ:S@AZ&1KJIWW+/33.9FZMI] MF:\I36F"I/W.1&E'_KP=8<-=[:VL121!HGZO?YW=*'"R0R5T06+Z^QUA%E1% M1+()'GN@9!KX >9E]6NHC/;LDV0EN-[T!ET@49N/!4Q6A/!3M:34=G, L+W! M'); &^)VTXM9 6Y'SD">V5!SPWE=C3886-K3R&7I=4V(WM WHG2U3/?0CX@7>G"CK$+%A&.^ M8B63I!U4,\T1TJ8&NXKL/['/NO&]<#UFW%?@&^4'WQ/%ZX()H 8:'KBM0__8 MHS\N">*I>[9_IV&'^EK=0WZT/=$P)52#2F7 PVB%*577"NV)8 &\P0J]/0W7 M9T,C8QYW4Q&F+PZRKTKP F)!S3$@+/^2LNF1ZT8BL_T.SSW @[YBS9(E'M2T M/0V)GR/J$.^QB;.IU_LKUIT"E:"2&!#Z;D)@/!7B@K,T&JM 6\J&><5J Y,+ MZH\!);A1:KRL[K!TQ2XHRZS7V1[H0E.B0(GK#3*K.Q>QZ2D&VGU*5<>)%0%* MYFN?9M: .MPT3"VH(XSW^$GI%_9%982[S0V6IQAMD-=-P[( KY,ZD&UL[7W[<^0VDN;O%W'_ \X;<;8CU&YWMV?V[)W9C6H]/+I1 MMW0JM7T3$Q<.BD1)'+/(&I*E5OFO/SQ(%DD\R2*!+'DV-CSJ8B;P ?DA\4[\ MZ;^>UPEZPGD19^F?OWCSS;=?()R&612G#W_^XM/RU6)Y>GGY!2K*((V")$OQ MG[](LR_^ZS__^W]#Y/_^]#]>O4*G.0Y*'*'['5J^11=Q0G2+$W1U=?H*/9;E MYH?7KS]__OQ-\7;%/WT39FOTZA5)XD_DW[_^0/]S'Q08$2AI\<-S$?_YBY;> MYW??9/G#Z[???OOF]?_]<+4,'_$Z>!6G%%*(OZBU:"HRO3???__]:_:U%A4D MG^_SI,[CW>L:3I,R^1IKY%M(BOB'@L&[RL*@9#5JS 8I)>B_7M5BK^A/K]Z\ M??7NS3?/1?1%;0!6@WF6X%N\0JR8/Y2[#;%2$:\W"07%?GO,\4H.)LGSUU3_ M=8H?J!EI1M_3C-[\D6;T;]7/5\$]3KY 5/+3[:6R7-]WTJJ47KL&>X/S.(O. MTW&H^]J>X"_+("\/*$!;WWD1[K(R2$:!;VLZA_T1CZOQO9[[FB:^&X^KZ9;F M++!+$?+@ZI77:T)_O")_=2#BYQ*G$8YJD#0)C0=F.;".H4J[23T+.^DFU)MG M>;?L>(<+4KXW?_SV^W??LM+17WY9XC!+HV7\\%@N/\?E;SA/2,^Y#/+D U[? MXR815@*>BH7.ZSY"JKW(:YA!'AK*6DF\)AF%>%.^2GBM[W,7DX=T6KQZ"8$/M_\?7."F+^A?F<%I$J'[^Y?P9A]LR?L+7JU4< MXESJ:TS"+NAA!Y@R12_IG316\/K\:811)3V+!QE/HUN".-O$OG8X3=]C5*8>],LD4H#**)%,I6B,F!&C519,4M?L+I%I,9O';0 MI)!URB,=W Z'9()P^*-!)^-.@2KA$T3$@;FD4VJVM,S9:N]M7/SZ?O<>I^'C M.LAUGLFLYI)8MH5H<\RD X9NED#[S.NH(:J'&K5YAT.GVZ+,UCB_3K%Z,"01 M<^(2[SYG9)[2$G/L$ :#@$QH)[[;6PE+:^>UD/L%D:R)ET0-TQ-S; M6P0I6GPO \SF C"EU=^YLOH%*:;9Z&TIYS87(0HFWXO LKB 2VGP[YP9/'ZR M:.5M*?<&%R"*!F]$@!F\CTMI\#^X,O@R?C;;NR7DW-P"0,':C00L8_=A*6W] M1V#C^D489MNT+&YQB..GX#Z1>P2SN,LQO@ET>Z2ODO7.'TN ?2;5XF@O[\Q] MT,4P"P?2%G/O0D20HA/9RWBG@0&8TI'\NRNKG]-]&;/5.V+.K2X!*5B])0/+ MZB(PI=7_UZP'?YAGR7>\]ZC^T>\XJI]_(;"Z16I_<&%_$0BU^/Y7[S86H/2M M^NGCY=WY&5K>+>[.ES"& \LR*/$:I^6/.'O(@\UC' :);I]3+>]T?\H$N[-' MI1+VSAA;A'TBM<5FV.8V'Q4?O3?)TH0!. M/[BTY!Y(VY*G"S"6;* ($Z/%Q\79 L;8^4.6XMV'(/\5EQ?;-"JT"VDJ8:=; MY5K G>URJ:1W>EC!ZU.&"2,NC9@XL"79BR#.?PJ2+7Z_6Q0%+D^3H-"=N-#( MNV23$7:;4$IA,)PR(1369:D08E*@3IHVY;A,-]NRN,)/.'FC=4U:#2^,4D.7 MRZ) "E>FT83' M0!NXP@R(:""F6;!J]I-T5\%]EE/IW?D_M_&&KN"K-TXUPLZV3XV FTU4 MI:1W5EC!$PC1R*-& 9C/N_L&XZU3\5:\P0Q712DT9Z3)XAJ@QIAG69KXG5QKG=Q1FFWM\RTD+N7 MRZ2B8'BFQR=>)>/2Z"]!'GT.Y-D3VP#7 M+Z)J-5P2S )ZFV0:<3!$,V,4!UF5!FJK "/9Q39/XW*;8^*C+^)G^I>>8SH% MI^-X(_#.,%XI#89@1HC"XD.M<()J^6YG"8QJES?76F:UOKLDD@"KS9OF(QB: M]!$)IV1NKH'9_4/P'*^W:_WV7U?&[059";SNW=B6 !@>R% )6WM<']J+_]E@6J5 MN7O].I]%461A3".5_AR7CZ<9Z4GR,KY/\!F^UVS[#5)WQJ$1A6I8-4 7!L^& M ^XSK^':/@E$TT"M1!!-9?9+NMEZG:4LON7UAH79U=S45BX#;)M ;\; M5UNCX)UD0U"*T;-KG8IP3 L8W1@R.EK$:<&&BW3K6TLVK8;;J\9&Z-W+QDIQ M,#0S8Q1>$UAODFR'<46Q&X+FD3XH1A6!4>TLSG%(TM:RJR_DDE!R@&T.=27 MT$8*J\^4CUGZJF$++&94@S@M,7HR+GDAA=>F14< #"MDJ)3#9UB$:,(NT!WE MQLRT AB*2R**]7[,4!PV%*0<[M,4H%S.X!RIX0 M&(*HD(G3]:)DKX:P%R!@=5&7:9BM<>,2Z\=^-8Y$J^'TW)$9>NG5OD4:G=&;,QD[7G?^3">(^OB@5IJ.5X9LB]); M'S*I@6&A/5;)6A'39,*?=0*#B>\A,C7FJ1A$8^7[$*RF,9$<7WHF0/+"+C8*S;M0*>-.1:J6] M4\@:8I\W5 !5BU2-)L3=$PKI8[#6WC;NB#B]5BP!U[D_W/KNG2L:4,*-8,H# M*@-J4GCZ&./5H-?>M1I.%Z[,T#M+6&IQ,#0R8Q0.Q>?H?V=I4#X2\!:R:[.&\#.*TW@0L2$=[FM'G+>G>H>ZXDI6>N^G?@&+LYX$62MXI M-12I,#/DJJC19<.AEO;<#+O>ED42Q*P##X@I4DC>+*[&YS;S$I*:C M);VN0T?1DM&WVOSVNLYH,;0X#5UL%6'0:"!: MZD-O>LH95=Q-O.W [Z?>>GFGO'K"^7U6X"OE'-P*JY=3C HJG67AEFZUT%!1 MA,"T,:RR?,WW#^\+-G22E=1.SQFIAA2C89:-$@RW-0!IGURU*MLOXS*R[(0-44:'\#87D)(&5G065\6/DN#Z(X?5CN MUO>9K R][Z[L+(55&[KS$82E98B$U\"X#.)"/EOT#<[CC(QKHK.@U#7MGISK M-BZ%V6_L'2$07- A4S9_+DR&BQ&BXC[8L2! (@KF(@D>).7J?7?%!BFLF@6= MCR"L+T,D'$:O91 5\F'KTVV>4XQQ$0;)WW"0JYV!6M05 TQ@:S*HY$#PP@!. M?/>9B2,NCZB"5^? !Z8_XR3Y:YI]3I_4KU4*V(N*8_0OV4)=NT#/+=19S@O'_01"/GED *F%WB M](0 $4:.3$F41APQ>8\K$]P)WN)-EM-3G_3RQ%9-$I6XXW4*+>C>(F^U]$H<721;T-UL4,F[)(('7I4)+ ! 11%0*&G!!Q"0]]B_[:$XL M4&%!3ZZ404J7:=0N4:ODN*^Q*$"OQ]%H "*2!4S5TGDKY-8)XLJHI>USW8U/ MYOA2SP7Y33:4T:NB-N@;"*X;A2V_74!^20C2-$9<17FA' M/TFOJ+K;B#=TT;'HNLQ>B;22 M[NXO:J'N;RQ*Q=RPXGO.BA0_T&>F9,[&#%'8N*B$6QT3)+\C)4S_H_LN2-WW M0.QTM+T-)&M?Q<%]G/"W(%/^TM%CED0X+_@E?\."L+VZ2\8,+52;4[:Z8'JE M@8"%YW@O%^\OKR[O+L^7:/'Q#"WOKD__^I?KJ[/SV^67Z/S_?+J\^QLXJMKM M5N@4/-'18M]"+0V1RR2"T,BDA:AA$M4OED@@L&E M.A[.+4[85,.64Q9Z+KEE78PVQXQ*8+AFBU3%N;#UT.-D!%2L!%1YUF\'W.5Q MD%3KJ=+U +V\LU4!&]C-VH!.V#MI;!$JR5+IH)(J ?-79WB%">.C6_R$TZUA MX*02=OK4IQ9PY\E/J:1W.EG!$Q>;N##*N?1LJXX\FQ]I,*4*F'RA3";G<,51 M#;.UWB@*>3>^"9G2[@\LO-5$UI]K(F\]S_0]<;>;L,-:D;0>I'3WPEIS=1BT MH=>*XI+NG]0!LN/T :=A+ QGK#3P]:XCV!5>_ Z=EOA2[;56NZ K#'>Y%5GS##JSM%*)1V?+%)! M[9TDZHN!88X:F^2D4#5(*OA5U31#FR!'3U3G!+WY]N3;;[]%!;^_&FS+QRR/ M?\/1?Q"Y%*-LG@NMA_6/U85='<=$,=<]H0QDO_MKRX"AE@*8K*/+4CFI2$8J M5E4_Q30>4,0/!^PI]@/Z[NW)V^_^G?W^[@\GWW_W%@4E6I+J9J&RT;MO:>)O M_E@])QI6O[YAO_[AA,P B@T.:;3VY."8#\I'(+K5\T8VAY$(.7P&0@&P]0Y$ M3\([][2P=,Q#98;N<44G&!YJ$47L.F20W 1Q=)F>!IN83#E4Z_HJ::=[)7K( MG9T2N:AW!MGA$Q8A&VE$C].^BE,4.QQ2Q MMY\\) GOK#X,MV1KITZEOI/03@4K>4+^1E>Q6&L M6A*Q473)6?N"M&EJU@+#3&NH.C)&7!(&]\3%']+ DBV=!]W0J(99NBC+/+[? MEKR/^4A80%\\S-@SY9=IB4D=VR_9C4O<[_+>(16B7PH4>N&SL+L9^S&Z"W'[] MNRWN;Q%"=_+@AD=& .6A-'7\4IBHB;#/(";6#.KEO;*JBYD+:.X*%PV=?#IF01I_WC 8P%V*E[Y9!AI M@7XF8 !(/;W #;#X5DX3S]EP_E,I[3:.G!9R-Z2<5!0,G_3XQ$!S5!KM@V]# M"[.]#!*Z&\[N7OR895&ACMTD%W6ZR: !V]DRD,B!(9 &G'#. )>HH.(PN'*: M%>7UBF%>9HEZ:-23ZV."!A>R'&)?5/!(O@#HL6/>584-WFV4FZX M=R1R\BL#X/F 3:,!'T%3V4 626?KW!>4!OS=17B WC$XV\ M2Z888;=YHQ0&XTQ,"/MT:N2;.]Q ;J;!HK\5"3=(NC=T#GBO41!W=@""^Q0_T M2)'XQJ=.T-T- !W0_2T F91W>ABA":.92I9Q(F^D8;B>)6:G;4@Y^'L&>V^J M&MEK%)Q.DXS .Y,EI;1W/EE#%*Y:<@5&JW6M H-5/^*4=+6T=2RB-6$_[9;I MG2<]M8Q:3D?5=D7HC+3U*F"89H=3&(QS+4:WH*,'@W/":-!VU.AY#&XU]H8U M;$EK(W4T)J2@8!NGQB9L27!K%3!P&@=B5I8]9FG4; M@WY89%)RZHBL"M#Q25H-,.2R@BDL*+&K8YQ@Z*NJ=_L:T&-+'W%I[-QZ,B[9 M)(77)D]' -882 9-MK4%YRIA?3'M!N?LD,#[H(A#NK@5)]M2>0C(J.4TK*U= M$3I!;?4J8!R0'4X5P]@YQK ZTD'5T2MT3U/@"Y$\#= ''W_&\<,C ;EX(@[X M 7_E!(;Y!\'O-X@Z,13PU#J-HFB? M?R*0VV44PK2+[) M.%VR#B, 358)K9A!!Z?IO4E,7!#Q7$65,FHGO3^X5:#K%>JDCJX,PQK[(]\MCMAI0CSX@G2!L/ZB0LD MGVMWP[34,V]V,@C(60Y5-5R0"H@?4A[Z.=S=Y4%:D-+2RD@C]J^$+74NHG]L MB[)ZSI+%L-'4V4!3S(0!0I.394QSA MZ/WN$YE!7J;-!MR"AC/F[UJPIP2VY+?K9N?60,NI$G>\;3%AA?1FM!.D#*91 M3%HB&N2!3(GV(]^"AKDC "_)"V_N,MN,:5;G.#.DL%= M9EEKAK8U?[9N0T"[J<1N+.EY\P334AT55(QNW61+PPOG=6;LM#S;UR*_TK\I M(K2E*Y=Q"KFEGV$R7@QCYL#(WPFNID*+-9WN_,9^5YC 3M7M4WWVA>D^W&?6 M \/\ 6#%Q]WVJOQ8;$N'#NHV.:5JN6,?:3Q =A<$!E/K36:ZS;!_#%4UNE4( M.YTV: %W)@Q223",T\*3OJ?TZIY*=UZMA4$BU@,4!,Y%EI]EV_MRM4WJ-\(5 MI=>KN V[9@;?C;FFE@=#+@N0?8J]#^A5M?NR/IX-@UJ7Z1/QE5F^N[J\N*;7 MZO(G?+Y:X;"\3INU&^5)42M=M^=P!Q2G>RK70A$,_8:@[?/P_#G$9,07UTG0 MMY*H_OS/)-$X3'0!FK29)TU)(NZ=._88M>\LQ94: M6F4Y*BI%*+XLS#'IPL\P_]_65*EZ_<<GW MG*0I?J!GMW3;70,P2YXD88*MYY^@DK$><:B?GS;H^*6?!+Z>=RT%^(03P8K7 MM!H)J R[R3%]>N^LBDE=70E:I/P!J@7SW=8U8I>87TX.*;">K#8IP6?Q@%)( M(IE3U>;F,W]/EAUEXYT^5-+7/G@\PGG]UF! MQ_7K7<#*3GW#Q0!3+]^2-KH?"0^I"$'5.P$5A3%RL*=W%#248Y8PD0H"BPPMF,OHJ%BC[L"L, M=3BQNSP.$D6LFQ'ZSA8OQQ2K610P.+!A^IYIIR+.7* KPW-BU-IN7-V:F+H'1QH@H4 M&@V#JR01"XDZ%94@''E6M+9#$SV>(\XRYWA8BK NDDQ2%ME]8.,Q1]#-@Z[E M%H-.*(])"$ SL"BH!?4UJ8#9[QP-W71:/ZY3@'>&]R;8L1/)=]DB_.7V24W4&:T "3@^\#2Y8Y_B;M3:T%?W!R(55? +J,:#+][,= MZE4,@0G2$..HN""&_)"E>,=C0U]LTT@ZY]?+.QOVVL!N!KPZ8>^.T!9AGS)? M<1=)J?$UI0S3YZYO35.H(G:C%4T#AM^S]_4'=Q90>_'#>N^C&*2J<2L'I)LJ M"72_0U_1T>G7='@JZ\%!$_DB3H,TG.G"ZN#$ 32 D15BT3@&INS=R\]2'-,0 M>%6G"G (W.KPV'%<0K'+E" ,DIOM?1*'UZL5SM6AKP?H.[[Q,:Q8O>L?=LI@ MV#P4L:P#Z Y=_Y,\[#N,#7J^L-;V1I]'.0LU>43$,UO:Z7 MP;!-<:0#8YVB=\*-02N>E&H3K7S$"%>)T$E7QI,Y09^K5/CLJ]K&K6X ;*II M&MJ0E&N5N3C*YY37*[Z53/^^"Y[IFZ=L1_DN8U<9>.GKVI 3=EQ"[MA[2$'W M5!Z3"I1UA(-+('"=IT6)C9O44$F30SE/CUY\YZSF/&Y:P]&-L0\>:D$=*Q\V M'CZ*R:(:M]5D43;"A4'?ZD[BZOPY9!=R;DF;NTYI%9">BOX/71)\"A*LOL@\ M+ FG4?)'%*X3,G^ OO>QQP&@A0NH+ GFE:M$$)G98116=[:(%Z84A\%@>$!A.Z$*1Z0#AN$'@)2ER03*Z//O@X0N!Z&@ M1/?X(4[IVS-L=Y.E#;&.WWFHX_-4N['G;V^TR6&H<7JK##8*H,AZU#$PC@@2U]QENZ7 M$]((\@FR)HP-COI'U.4B;L-OB^"ZX;;WW\%P2 )*>!X@B'-$QIE;MF'07CLM M6&P@''4B Z&<],HXYT=M2;6EF#U;@#['Y>/4^UP3O2R2/P1I%5UR_WX3CU9Y M0V-E$7]._WF]JII7D.Q?=C*]SS--VDY? IFR.CHO?$R1,)B6,V5IA#=Y6FF? MH$[JS$6WTZ>-LLFA_>08N'#W0;G-V$*3 4%,)3<$Q MZ("RU@#GF^@;J,7UJNU7B1M?Q@]IO(I#>IA=*/4=?B[?$TB_*NKIL"1=4G2* MPK=)?$AZ8&@^02'$A2N2).VNVXF>M))$LJ9"W3*-*]?[G&OP]D7IOM,G%D/#!L'@)4\LKQ7I6Z4J@/AH713 M;M3I $CG (;O^(/S?E8PI1<*J/=C?[3TX#E :?$&>$%[??]TM/6'MLK 26KO M&=G52<3O3J(+.!7!*R M-Y.60-L<\8JH.H$JJU$%-S21;&:M%-V2CX)4L?N)XLM32H2%@V2%UQ M9L)][,T!Z_W'W,2M-I8I.2\[UN8P&$W6^EAG?G- BF]"VY2NE+Q-40 MU0,W7Y 7SWZ^,$#?/QTMYPO6RL!):C]?J!BZQ.$VG^3ND*(GK6^FZD9:HHRS M_E(%K^DB^P+>":!#U3=R+3:S;K M]KNMU?W?TZPH"_:R*WNKM0XY9A@K'9JHT]>@)ZF SCO1!Z7HW+JG012_@$L:2K%X+KQ,$-Z*SKZ'V[CDS#O(-3!=E^]%4PJ@')DSR^ M%J0MA_SI;*;2:4 P6@1]NS0NN2M((QY.Z@&G]"S%OCI,6W/#TG"[2SRB>-WM MX@$)@&'R&-2R5VVK-/CN7CL5U.H8H#GY*_P0)!^"LB3SO7[I3:[<4M40 Z\E6=DNN=A=OQ_UJ>D#0J M>S@+:5D@R:E'@R88=@Z":W62$08C#SJS"_%T[OASN$=VXO:@L[6&4[0PN/D1 M?VZ5K'."=XC?')Z,VSA?XPK9C?8U+ TP'!X)7#A_>Q3GO9?A(XZV"2[HY+)U M-O-Z14]FOM_1_UZ04726&_WNF)2<.N'Q1>UXY.')@*'V>.R"KZY2H@.(ZG6J MX@0%]2NZ.2%__$0?TD7_,UAO_@,]X.PA#S:/<8C"=LZP6@&I%NDQOCM:$ML& M8)N(#^X/*Z",]G8I@&/\(-@ZLD-]H&)?4'I8)B6Y[$ZW>*AFH@?>Z>?O*SAC7H:WX8V[RP.CX]/VYK9+'EWFE@8@"=T+@2Z'Q-]=Y( M'6-N!X[WS;&(]A&'UEL4116Z?S=PCC0^84\MX<"*4#2)D:E";!N'%4772#H/ ME1Q72[G%I-^+Z44_5A.?TICTA:311Y,VF\&Y0&I#(ZMH2(,:F,71M*YQY=(O M1-3JZ$T-^9&) SG VLJSC%+#JWJ9 M02_L$(!*&=)(P6-) M'YJ&*504,5D@=/D0IUE.AAR7:8GIT.3Z/.#WNYN [O H MJF%0"BX)-J)H;>8-4 =#R>&8A4B]M09][*12H2\!;IC2$7&6/EJ0I26ILH2^ M\7K@^*PK]F!VRQ([+JYK2F#+_+23!(JK[& T!=D+X=?Y,F#C9;9^ MJMY"-2KZ?ME=7A#3D^Y=+3!TM8:J?U<[KE01?0DCJ*8I="8$94,G:);Q/V[7 M]SBO5E8*_O;'97J7!V06Q9[J4(VK!B7A=,@ZHG"=P>P ?3#$'0%:> "(Z>VI M6C_GLMUD*7^J!=A++:TRW^1QB.M-;G,5]<0]L5,*6L'$CBQ$ULD "E,L^@UM MJ"3Z*DY11'KK("]H5\XYIWUU\H#P)"JP+TMV71;5&SXD5E*A\Q(C>WF52]!\@'YH2@E_O2Z=ZSDRO MXC4\N02\-BQY2]X[(P> %&Z1;PGWUL1_G=K>19C1*/1"L/RM>?[%\:$H757W M FOQ+#/0-JI]+@_?0?O)_H,WCY2@(I5]OK^HVIKBF6.JBU1AG(*;RQP>7!M M>))5#A\F?P MF="M$@?&M9^S_-?+E"U]%$:&]82]\$H*6,JFCB0\#LG@"4>)B0Q]=77#I8!Q MYR).X^(11S]F663D3D_8"W>D@*7:%*!Z"4(DS"*37*K P2W^YYQ)\0,-#&C%&A&C,*=+DNPSVQ6A#X3C9]HIL6M]V7U! M)5= M@%X#S&C!"J9D$U1R61=41[$(P^UZR^*=GN%-CL.8+=B1OQ-JZ6&=Y63V# MK:P&U;+69,D[?I5ZTDKIO6$]2=K0.KZ)RR5Y)KM.'D6M]%G3"EH)PVA6K>V< M,]*3Y_&&'^X>=(Y K>EI@]94%,5>K4H-C'.WQRK$2]^+L[VUO8*G@9O3PQY@ M[I0?A-[VW$>H[E\,2 ""@]<6J< AK&C8-M.=>B&A V1YQJ+#@]O]L[M'@3.AP0W>Z&HND/>6S)](G2A,4)D)1J:@K-)R[BB-30:INZ][8_' M+!S3I8F@ZQ6JDD'7U92DGL:03]4<^^^MU(!<_Y96P?6V+,H@C8@K5+A,LYK3 M\Z:6A>@<,S7H.&7HAG2D#.C4O#;OQF+IN_?E.IP2#@> MO)*->"_J@XV8_A='BR>8L9=U>IZ9.JS8!M[:)09XE#:L!/9C MMCI=5"6,ZI012_IHAG"="FD^-@%TE;< QZ7E?;!G6USC4,*4T-$,"RT+[]D &H=;HPAJ4#J\%NL&J9*!S&3UVDXQC8WN)U$%./ M2]]SIFN?VR"YBE=3C'&MD@8UW!U0&8-&OA;I'L\@V+XP!XR'FTQ0*Q=$LYEV M;#Q!KZ&J#_7RYCQ9@.Q+!E3.J&[%(GW(+>O00DTZKH;37J3'\*;/XUA;C'B8 M;^H,7F2;&3H9A3$I415LPOF)519'U5BFFK58I/]RFLK13&%:;?J2E"!.BSAD MP6^L:T:3@E^>&XNFI[%2'3!+39C%B\"5$'JB4JW'USH>',:JN>+U$ KW@<7J M?[_;B]P$._H3>_BG>FJK53GJ&?G&YJ1XTML]U0LV M[>Q0*S\:Y+PM5^6)6*8GJ,J6_-$:A;&Y/H*U$39AQ?*C6_,;L,[G2!MRMYIF M:L,\$X@;;W,54GB9@(O/MG8 H_G]R$8*ERD_?:T+TS%+3L?4!#55-64CE&3S M8GI1==GZK8])XH/G40YNH;2?@JWWP)1#TA$)@;F-HBVH]8T4:2IP"#X6>I^_ MS7<@##ZPX9(QYPK'Y9;4 @UV\KR)>6#LIBW/Y# L\CVF+L2Z&J?L4(R90@O% MXZK 0I!,KD'5'3-U_ 1/,T70!X8FN^0EI.&/ +6G]KK8G/.EF7Y'-, M;EY935.V/B&3E]?V5$54M3QQ'^;%M+R6&S*=PE^Y6A6W!G),;7=\1<_4M5JB M@#.%\E5T1ZOP)W;755[N,KW.*GXY\2(]C4?W\L*7_RV*_D(W!8I!Z[1S-/@I M$8!J]--7[:"&/UWVX&)L.B\Z[#V)0ZNC+K'79CX0Q%&U]%$5/&EC'X3@Q;7W M,:7_O6_C>!C;'X@)E$MP4?U.MX; .(PY5QRFJ(7?QUX2U'GJR]YWLBKZ[WLW MRD._99W[,?50 ZMTIOTL,+V.ZUVN U:D7O#>UR**8OI'D.R?\Q9"ZTYL%$.> MQ]2FK:IORI:LS?#%C!IM2CGGEM3@(!$0=Z3NS?5_/WB )+O125\O>:MC@FLD MSCV(GZH6_(I;&+"\C9>RN]["4KT[Y;P"Y*]7^8#A[@TL?Y6\?TG+/0;OK=QS MP8]U[G] 9:DG3;;NP"N28^K]#ZCJ*7O_$3"\^P7_9?\]+1=\S%)>//H8<[F[ M3,E<;,MV"MW$C1B>_U$L(XRMUDF6%(9F#JO).RSQ#$L-!,DK#@5Q+*@%Y@5' MIK"RP#SW7P9E_7*\QPRW9 ;D^Z*.N0XOMS!$..ZSK<,KICK7Y\X2389'WH)[ M%3=SNZUR>\D]?+>(PA.M5/GHCZ*I2V^,GC%KED?>%O41.6;,[\5$#[ O:[]A M_H2+XSD7/KSXRO-Q[BR@@7#D[=98N3.W8V7^+[F?-15:>9KS=1@0DB3'=Y;S M&*9A+^D4YYAR&R9BTZS1ZK9GQQ14+%_YB/.[QZ J?S_<-AOBGI%._"*(MZA^6]5X)7%S.L_(K+O8@!125!JCF"QN BBA=1P(@A MAKLX?,".'/'O3VS4;S383%N"0P PB\8N2_\[63JVN4 ^ MK.&[1'$4$^3#JGB^^,NP_, 4UZ9G*3[\I>H#W.)/7CMZZ]R/J9%MNNNEZQK\5B6SYF>?S;#,=UE/DTIB!-Z78>,L5A/.'.]B]D=8^-35=H<;;"?UXMK MBHH"&EMD5MTY>\BAQ4\]8)3:NI+7?:?9P3U3(<-C6@PP5]Q,MT9[N<%JGG,6 M45BK[>)-D.XR7.G^(0RSU9,V%DM5*PH7;[^VE6 ME!^S\F^XO,5A]I#2L4'[+3^%71SE[;+M.JW.=C-VDC&8%NVRM-*))MJF>:.$ MPO8AH) D2_OFJE-^X0(K@Y;L"7;'[ M/H'+TE:O\PJ^ENI]O3GL=NG<9CMG?!F,D MB$5GA'9+JZZU R*_1CE-1'@/Z/QO['DSB7D7T#DT[UT*S/I03([8KF))Y(!L M,HSVONP_]")$LX*AW>.?+(NC.'"CJ9Q)^G=)^K":X;2%DMV_H:>8^]?I*FWZ*W)B7K :WGP%%*ZUT%@63_74#-3.^>B: M: J]*(KMNEX;W>"05,PLSR589'@4[=&ZXB9ID<;W03EYA(DA.1_%X'1X54XR9K7/%E;K=5)6 M883;"*&<2+W QGL;%[]>Y)B>SL7$;J6KIBO/]V@;KJX:9VNVLDQ?9J/5E+3? M9*GHJQ61I8?&F?!+;;JU)SN+G^((IY'K7K>;[]$V75TUSM[CMC-]F4U74U+E MH#FJ9*&UW(-G]=VM^%D7$/I9'<7\U:*RIE]+ZN8#JQ7.4SCU?BP_ZEWM\(/: MU;=WR<>RMZ[<'N=GM)A=44C^?M";X@B&+^T]A5NZ?S?Y\PRR'(YB2**NFLFW MJ'CRL!SC M:''V53=I) 9U=L??(JW+V&^A'X+G>+U=H_3%1DII^:"I:[V3]%$T/4EE3-+& M6ND>?V,2"V/HUS;DXY&W$NXN^'6L>NM[ZGJ5YW$4[497/9,T(%D&Q]^2-*4R M7GJ(F1:09D7/25;O;XJ7%:7K!*JJ').2\UNIXXHJW$L=E@P+R!)DQ)7ZC]GI*A^CWA>1-0-VVIW$X+' 9, MH_== _)0/2D98%9+POJH/3-?&N5KV;P[7V:)]LZH*.O\RJ@*KG!CM"_HG8XV MZ"QW#U!!5&;B177Y@T&371]7"3EC@A)@0P%! H;M5;"$.'W5JWK,UJ/OD\_8 MO]WBA,;#O@GRP--%894P*FG*"%=) M>S'A&5[A/,<1FXO>XB><;L5^3"8$RV0:A"/;V6I%@Q[P2^LHYREZL1 9_*^S ME"T8B#>NY!*P;*."-\HP(4N,KVWP*U%>C$)F8+@@$S %:5Z?DEN"82FQ_G6?<0I'^_ MQ0_;A,YM=F+SE$G!LJL.XKAF6G=Q=)R2-TGZ=J!TFZ!Z0:!:A!%;IUXO17#?S$$9)9!;;%E7BGLC-=U:F'O#X'N_5NU@7YZ4.6XMV' M(/\5EQ?;-!);M$X8ECTMD(ZRY*:S^;>F*:,U2QJM:-K>;5B/!J]7U58$&6'\ M'.0LCIC6GCI%N+:U0'VXG>LQ;SNV&AUF?:XR\F-T?B3C>L4WN>C?=\$SG2RP M9Q\]QU^+M\3B (GM-*P;&\#5=B$?<2(I!GGI#N.BS#)BFW.FG:25UY MYF!*EMDIT$&]]F6-#EBR,< OJ M#:FMTF#-&EJ0L@;HR5C,1US3H3?QYPK[2&1@F40-4-AR1 4.MSF-MO% 6@AQ M<6P'^3%+(FH:9H@$\RZ,[IC\ MR7>^6TVF-63HM,ERUDQKNPOW$!(R'8IV*/NZD5CDL@,K>7.(?J7G%^CQ^?JH @K8GG>UMLR)5&SOBSB*@YQ0($>84(Y0 MBG>Z&+-5+QR$CY4^24RV-D:7Q@B'*3DHQ_BW!4_P[4)G'%::-(0YL5U04+/$.7?Z=+9$ZJXDIFGWXUYM=/ +M-0YG50:+-62@6DI$> + MLM05P9NS ROG9#*XH16BL)=2$I;53##-MDN:%-@$F27A>ZFC&_>JO@+<.O@N M'@08I W+AF.@RS8;A.6OW@I&M;(F7119X_(QB_9K(VQ9!<12AW3KI5"U6HTP M+*-;(-6N<\/:1&(/ GW.8P*HWGI16$@I"=_[K@BZ+(PIAN-_\K#Q$.);(90!]]M=O6V_8I\H:8*4;W>@8H/#>!77 M>QTGZ/-C3$95<8'6='3U2)HY3>8Q:*](\VV1@&]6LMT+>O>+=@"^C^96!V94 MXV*%("Q6&%!:C)#;K;HZV^/I9'M0%->KBN;7O-_I#CMNLR2YR')ZX5PTUR!U M8$8<@UULW3F]0KGB0K11!G3+B=1ZG,1!'=0I0)4=^/D]VB;O\4.N:3ADEL_PV%&[0YY];3>W[-CAE+]")AAPJX?@M<]=S,63XFIN2-?;9.$ MC;TW >E2Z'YT??>^42(NHRC)Q)G2)2CJ7N(^2/A%F4>,2Q21S@D0432/W0]V M*):)'0.)!I7D7\Z&T5]7::-=D&6BQ\"I4262N:O/50JO@BH@1#6*U'@<.L3D M;HS/:(AK"\E M#[/TSXJ5WD^>JPN?ZIN&=6':= ^-DUUB*?H>,V. Z0+B.RY M\I*X2KPO&2#FFM^UO8I7!SM"BW2/@;]C"_4O]RAK]ZKZN]XWH8,\I47ZQT"Z M0PO7)U^=$*I]9UXGQ78[JK3X$AWU?#+7=D(7?[Z\2?^6?DC/[M*_D/]9?HGX MW/&$GT][#M:;!)\0J3=_^\.'-^_.OB09-9<'*%_)/XD'I?Z5[K#0JR,I9N\5 MDA3B)TPO#Y6/Q0ESH^5C3$1Q2ESY#M#\<[QQ)#$3)L[@17-;M9WP+W)[(_=4 M UR+]%\>M9Q+4L=Q6L0ABQACQW"E^A$0 MV(1='KF-[M7R61;;'>!4(P1HOQ9.O[!]I&3';ENPI67\S*^3LH%L?9V4S^H4 MTRL_>_T'/H_5JE4+SR \GNT+ RR^^JN 0YUR==DU8#%Q?^=CCM'Q]<_9R8_+ MM"ASQA,AN'#/J"P"VUE0XN:A2-UR!@Q8 !L;HT&^R%>L^0W,L. >U3B/??#CHX?+.J-[$0:_ZL.'(0>B0LG ME, TK3#91MB/S>L60V\*$I]]0VKB[;=OWBBLKI6&97<;J.;C",U5R"H9]@J1 MG\;)0U[4$?1I7)5ZT)#ERD,C%DJPS#8 L!47L"3(VG/(P)E$A4\ MR?H$WZ4(FF7@)C!/T+[<%B28[;6QYE34JU+L L6+&#>\@_&8E"W,OAT->IY> ME.(O])SRG;2V2:0"CE^%DME CTM8O652)ZB2.[[GG8"0WH!.?,M;)NZ)XE=Q MHR0)5>:!V)G2K MJIL-JO/QWY")8Q&KS-"LI3J .& -5=/DV?83%_=DI!_SK"AN\FP52UMNZS.@ MJI>AZM( [*##!R#B _++,*0/0*[?]5-9D<;/4 &'0177,VNGL?YJE;_FIYXJ%- ^R3 M&)&&ATG++(_E/E"K -IL,IR6]FJI@K'338XW01S5CSE5OEP]%3XL)="6'50 M2Y-7:=9])!O]L>20UQFWVAO=!+OA'K=2 FU=%=:AOK;2AV0X^AY>:XIA;;N> M'G3SJ>#:6Y ]'-A* HP1ZZ7GZDFFP<94ZX,VJ@5L2^/6*:$J*8]69LNQ[MX% M!;+^/ JSRK@VB8!IN[UW,.T:;$\)="M58;5LFK4ZJO0A-,=I'F@%VO0T2$T- M3E3UU,P^XO(T*!YO\NPICG#T?O>IH %EFT6G!7_-C&ZW9"GY84M^JSYFJ;33 M/"Q%0 UTHH(()TIPB6BZJ$Z8GMG^BJ9-&O'7:+_T?HDV(/.. #VP53=)M5KU[^VM7B"]^&'@%FV,_ _M1)Z"A'8X-^QD:G\ M*MVQ&Z /R,:C8 M[>M3"M/ME?[32(7TSOZ\LF76!>>U@Y O:0#RR'4CAK(=. MZYC?R09B%1N(0I@.M0XHG]A$/=@#M7>($F7PWE"'>8 KI,D@?EMEGY"W!4*^ MR;MCQY'DJX%M"4 V4@ 3%XTJL1/$!'U7]"+ZQ[8HV2Q66]TM.8B5+H.GK'K4 MDO9U,2$,M^LMFTZ1EK1;N"QC^23)]608Y"\O$?=TV&QM%4 S;R:^_R]S+Y)D M8-7\91.NH]%D7K'XJ:B=%VIE1M>;VW)5AHCE2 8D/,_.R.0$\7R/E( 76;[" M<;G-V?VO\^=-7.UX7Z9\,78.0AHS!33'<5?6.0G;0L%G0WL<[$@W0W*D%&[U M O/Y4"&3%T11==GFI&0KUR/WH>K8VYW1RLQ=NR[KE]GA6Y78V3"@B9M>P>E- M=J!RNS#4-PM?W716D_-[NNR/R2'/4.HQ/"]LB<[Q[$<*1\MV^Y[0M2>WS/J8 M6#YQB9T-1EX8MS]FU1$K M%^J*KMOIM(L6%OF]!*\\I)CN>=M@\,G6 ]YG^IBE/*JI\748)7>=Y [-$[LM M])Q#C :.9(#!("&*J77NZ]C\LLW<90#=W4%X"=[[P)+/27R+R2,X_D_A=KH; M +X]_V TT%J%WTIPTC/4/Z$&X#&T%?V2",A5"XN%!>565S+3(P,38P M.3,P7W!R92YX;6SM7=]SXS:2?K^J^Q]TLR^YJG5F[)G-9K8VMR7_FG.=QW99 MGN3N*463D,P=BM2"I,?*7W\ *,H420 -BA":&N4A<6P [/Z^1@-H-("__^-E M'HV>"4W#)/[ES?&/[]Z,2.PG01C/?GGS97(TGIQ=7;T9I9D7!UZ4Q.27-W'R MYA__]>__-F+__/T_CHY&9Y1X&0E&C\O1Y&1T&4:L;OKGT?7UV='H*TO"7-Y5ZW][_ MF-#9VY-W[X[?_N_GZXG_1.;>41ASD7SRIJS%6VFK=_SQX\>WXJ]ET4;)ET<: ME=]X_[849]TR^VNH*%^1) W_E@KQKA/?RP2BVL^,I"7X_QV5Q8[XKXZ.3X[> M'__XD@9O2@($@C2)R#V9COA_O]Q?K;^:$C^)@S2)G0NY&4ZB :?*)G^\H8L2_S3NX_OW_&O_@E2-ULNF)&D MX7P1,4S>=A?TU(LXKI,G0K)4)UEK83NBW'F40?!$LM#W(B.Y6FOV)N0D8]V0 MLY/>3F\7A I6M,"I:UD1[BR9+RAY(G$:/I/K)#6245K9CJA>^G09)=_,1*Q7 MZDVT6SKSXO /P1'K@Z=Y&L8D3>%L@QOHL>ND(:'6Z^IK M]B;D=1+/'@B=7\7/),T2>L__K)-/6:DWT2[^E;,A>D+\G(89LW2=5++RO0GT MFT>I!^C"]7(]NO;$_WK$YU,!'T?8( *:]FBJ]6=+#/:9:/HL\L(Y=TWC-&7^ M&>3X8+7Q.O:RX,X=?/W#-AW]@_<8Z5745K3F]&'RJ6OM8 " B0FM;\WCPL14 MU^K=^\*$:B]MVQ,#>854WMVDNS"I](8CEK%5R=:3<%F#-AW3ZIL=/%.MY@Z$ M/.XNY?$.Q3SI+N;)#L4$VZU!$];&)Z"9:JKM8(0""@IN8':4']$ZCVCH35>R98 M]1V)JQW_@=5W)"[8= V;48F_J"SBK]DO-JJ0EXS$ 0G*AK@.V^]ML5_S9MX5 M_QR/CD9EK>J/7AR,BB9&U396PI?B1XF_(7'$]_T2J@.0_^9WE:SCQY1-L_QU M2##R'DDDFO^=UX55?=M%V!6Z8B>20?SC+'E^&Y#P+9/_ _^!*_+AZ-WQ:A_R M3^Q7OQG+1(SHJVEZP+6C6*,?5'"0T(98R5;7K4WS"%YM;I MJL3;A=AP._*?PFAM15.:S$VA7,&6:!2IHLM$V#D%9V)V'EVQ3O/R/V2IXJ!1 M%$C",3X6)%J[H*'4XX$UVX[^9@D@Z">80&_3T076#]3C62J3Y?PQB=K!KA4! MHOT>$]JM6KHT[3M"PX2I$)Q[F<;&:T6!\'_ !+]2:Q/$4M5[(AJP$DY2,^4M08N.-&V,@9#F:D4AC*!\K5N$3U%C;^_K:AW37[ACH]'ZP #[ M^8RU0N*4!/RG-(G"0!RH6K4T*IH:_? E]O(@9'_YST[[$%5CFWKIHR N3X]F MGK?@%O?36Q)E:?D;L6-1,;W5KW]?RWT[O0QC)E_(>D:2AIIMBU5U6.VM^U)W M]7C&;);J%:F7<[6'883K9H>2:-*_9]N6C=4D'DI*H[BSK0TUPFTT2%3%P08_ MUR0'O_BKLQT-$(Q)B\28$*ZGK8VS,X_2)9L%_NI%>5O4<5536]'9WD<'7H H MX*!L=:@@Y4<,PF>>@7Q#LI6>"D^EK.5LIZ0#61#]<3#%T_YBUO:2"2AG9K.4 ML\V3#DRTZ8<#^3M*%EX87+SP7"'")OVWV1.A&[K)"0%5=K:_TH$G S1PT ZV:M;T!91$$EA9]LM()!5DG?M M.!^+CA.3&0]\N.\Z4MHV$'*Y'6.^M-P7MW8=>H]A),X:,/,3,?.G)&(XI\51 M!'V8 -Z"NPV?[>,ZICCAF&M4I :'?51UW&T*=:5!RB+JV%"Y#+SSEGP-"%X MU\N[VR>" ]Z^ &[7' T[-&=NOJ&;DB!9%7=[1UMPI-8?!TT7\T64+ FY)Y&8 M!QG0!:@*IEF;S*[,Y8R7YC6T/E(V^JV6[;$ZOK@*EP%J< DZ! M7AE,/>=\-9&])\\DSO7#CZP\E"!K40OC/J+6W-HRM_CH)W[V:?5EZ2*WK2@4 M9VN!!+..H-(71PB,@Y1*5JR&D69)*!W6X@B=?%R;MI:F@RPNVE(-B:VW] M#\=6H@$F*Q\'@0CG>M&=%P97\9FW"#.O[41S&PP M&QW]D&.X:J,(PJZ%U*_6I!5S.Y>7ZA M1RX-1U_7$U;)(9=3,DTH>?!>6A/DBUQ>0+"_MR\XVV>S:QU]4X#;L"Z9/N$L M+BZG\)0$7^Z_,((N8K7,<4Q,Y>B-EO3G3[1%9')[?;H#0%GD],S&8!K5/"1MMSDGQWXJRJYOZ0&?2P&VXSH6T.NLW!Q.K$32?_#2AOZTV M@LQ)4VYTY,I!&O[S:$UMRR%*>46YIAJ&+,V^K: %EWVD?_6D:?E,0NO3IB9V M 6L/0ZIHWP9C@N0^6E+M-:TN \NZ*H;,55O#2@V?SON,SX0^)BE!:@JU1[L, MK:%1&T.RJP6#D*"TCS8A?Q',Q#94K6!(ENW;1O2HN;052<2AKD:'Q]C,FG#^ M/EYWYLV5=4^[+1=1>Q#-Q"\TJCI_K\^",Y#@,P /T)!=]F8)I*+SE_[Z[>UR M;(;?Q[<+R]E*7D+PB*'MS)<>4!_ZR3L)"CRNDYJFS71IR_F[C/VEQ@$PPQ'Q M9FMKL2?TD(S]?^4A)4P39MC9\B[RXFPP3$J27#*;/24R6Q:TQEWD^O YLCMZ0"_ND?76H:\*6SDMYEA:2FYJ2I'^;(AOV2ZT"$.?O,H?_@= M,OJKJSM_H=,.G68@V*6RF('>3HN8-__YP7OA%S*+T/=#8O#(9\>VG+_V:9'D M;= =_G8U'-@^Y@,('A6UZOW-T1SZ7'.5M#N]>/&?O'A&[IE9W\8[>,70A,NM.5H(ZMG7:38$IGX_@7.UBP<+ M3;CBLO?"UD6,8#8^R1>+2*#@124*5_$TH7,/^+@MM $HWYAB;X;HX!A$RU-8 MZW!S'*R7 ^)H%B#>"F\"2JN]EQ$-.4JZ:HJ)X_71-Q*TY>^L+;Y:"LJ4O;B9 M,=:)0ATI'0YN>+JE,R]>W17 M#K-TS F::I[8>^OHZ/1>9CZ49+FE+#_J;8S M\N)@5+94>5?/X;U.5?%>[Z,J=+ZK(%IY0?'UIBK U8_]-._2]7H9([+M:<46 M']M2UO$-3KWR6W>T4FAP=&%^$W)Z.ZVJ.0EG<3@-?9YU49P888[JCH'B\SU@ M_E213S;^1).8_>@7>+1W^9_K75Y\E]_B5OWRGT>5;X]>OS JORZ<0_']C3]O M2N#P6J4F7OH+D11U'/;I%L-@W"MMXX&9WRD3Z:MU:=>PG].S6.G\?&.)P M$\PM\DY'5W[P/DR_MG?TC_6.OE&3=WA1U^$K?^SSW(M]86+1S MC6/ZEIIK3 M*UU[9P&C5PD@T,5JU<5BOHEVO5F-G&^ROV87,9,U;A M/1 Z+V)S";WG?V[O_2?UWL_KCGCE45E[5%3O,2.M53[-DSB:.GTFS+5^2E#= MWG&DXKW6SU ZZ"5\4,^6$^+G=#.E:J.#O*]WD*+:J%+/ M\<;!4Q(QXTD+N6Z2#)!%HZOG>B^D(9K1O-2@">>7[$/X:]LX,4$(QZ#4R';> MZ&8?ZMUL7;Q'QUZVJ1EJFL7Z'%W*UF$F794'E06W ]4<3 #J#G\H$5WRZ%%Z M"_6&J?^EL> 2M<4=UJ.-Z@YOJ%_+5SP&5(JTRFH_2](L%3=O"YW+,Z[Z@6?; M=EU>V@\5_;0J.F"XVKIAQX-8/[92O\>_'[1Q#'W7;)XX*]:HD1?.>.?&@NS=2-_'A7-B&W#:D-.'TB;A\6UT3QD)DX^S$C,MWY>E0#$2\V: M<>@-KLG,BSY[6<8F8751 7T>6-UUV+0+J[6.; 04CN[:>_) 6;"]IS?RABPF M$8Q^*(N[?%%N__():M(MBW_#,P>T]0>:(P#$!4D:YI99(#WG>U@[UF!,YM:I M'4X.IGY3NF-X%S5OR?53;<8$=P4+QWC=DL7SP&^"EHRWC:2]UER>T0]%&R[' MR;U+ZIGX3R3(&:I\4=<@[73)_WW)A$PHQ-UV:6R *3];@(:C?]8S@%2=LY%H MU\P#PM S]S AJ#2SXCQ54T@!ND&WA+;C>HW;)36H&U8X>J,\/TC1+T\:^7G* M+"$,7?20+@3N\.O7],YRRKN,>5?7M;#/:4*&,.)8'DEO(070#JGK>HUKDW$X M=C@\?CW11>7G&]F@C707#+Y]'_->UFYDS!8%01CE6?A,7F&_>/&CG-'.+Y/C M&V)Y:;\7'HW9JIW?%R(VQ(S\=G_?&F0FC37,<73\,O="U>$;":!EI>WZ.8H, MG+Y[9KN1E<+>%HF2H$AQ]R8QY_MLKQVFWB-)ZE%UID:RJ"RU!\,@>LCQ477U M=6Y)587*79[IZB[&I?EBJ7O;^YCITQ_F.%96.GWN"8,CY*$3H=F7.&00??-H MT+=!&7_(]9K-B7EUI .;K97O&4X(?0YY5*]-UW$D9"GV#MB0-V,K9 :DN+], MH&MD=;U_TO6VJ67[LT01CLF2]LZD(C"/L^3Y;4!"3L '_@/'_4,%=_:K(L'X(F;N<3E^"=L M9Z4:A8: =)OS+TP;H=WLX1C;-M@:P"[*?'KN=1]GZ MA7IL;NF+F=+ILOH7B5\I4Y4,VAB"V^F@5F7!@81,J;=JT0Z)W^J NY:XGAQ< M3T^8O!!?;!S=3J=L74>E7G!505;>=?A%;F?UMTB4"N/P@)/\,0V#T*/+B;?> MB5 [/$45'%T(-H&5:[%^^\(M,Z]BW7AS]F/%&^C<&Z0N$JYT]E>G#:"9G>F< MV(,K7Q54SN!:2X(?7+$%--BQ1EAB&:WWV)"TZ=P M<42< DG<7HT:<)W#(8@RUGM(!F0%1RF_53^*,X1;QA^-$D2T) M;F_2]6RC7[Y5L.%@O^UAUUM:>*\B-4*9<*FMZWKS!,PG' @[3'!R-.EZO!IS7I/7DF<4YN2*;;]) 4=QV%@%IARSQ:JCR. M]4#K"M+(X^!')Y;>+CV+HM(M(;\NF\FZ(*#DKDAM5X M(U"JB9V=C/(KMS%1[F.TE'/MA[2&4EU12O6TM'POO_?P+0'A6BGG.BK9"=>& MGK9Q9:5@%KM1TG60L!NV35TMHWN9Y/*4C*IHU8*N(WJ=L&UJ:AO:\!EFM]6" MKJ-VW:!M:&H9VDGX D*V4@X([$^H@&WHB6/VW%@7O&XV*EYH5]<:R@8[1'?L MT>I703?"U8U+U=7AZM'Q(6!]"%@? M:'@/4A8'T(6!\"UH,.6*\NN$[Y$PGA M,S=(7!(5LM"<3VK[BP;>IJ&=T+'ED&H;M1$HCNSZC0;=$5Q\KO ML.LR[%V7D_9=E\8#EYI=EY/#KLMAU^6PZW+8=;'*PB>2S*BW> I]+])<#"*O M,D1.FEK@V&"9D%E=/.U](/(JR)B165N=)+E"/6ZBE#?DB=T NBPH6OU/G9W5 MKW__,FFA8?5'_C?7<4BM]91(5V3N?^[;!=FK!SFR_&^NPPZFR+[JXQK9AWLY MLOQO0&0_8D'V51_7R%XJD+V$(WML[P8#0V@OT4![?B&'EO\-"JVUB(XIM*\* MN8;V;"R'EO\-NN>#9A![5>@0P#D$<+8/X&ANYX>^G([J.OY#0.<0T#D$=+ ' M= [7XA^NQ3]_4JRRYS] M57E]V,?ZA%+4'A751Z(^BKO#SKSTB.F%]%\><38S^,0H%Z53O=MJ*]+^*P M"ZVMRTRD=SQ0G RK3UETY\)DY5UO@=KN*/7#2TK8<,SX*Y:^_O&_0T*97$_+ M:_),-*D?T/HX^K6IOU>JA.,A[ MC^4LFBWZWF.DKSTDLA;_-/Q9;MC%8-C41+HZ(1 M%&'97I]B;W:'GIIWZ!.NXF> M9@(( -\;I5VOD7;">@L^YMQ_++B/R8P_4XZ(_1NBF$1NEG)]EF+V/& MQ@-Q"R[JZ?*!?5N] PNJ/"">0/K@2+R1BLH%U>VX@BKCX,W /J%D5I6TDV[. MYD8)Y:67ZX\J\\P5Y5T'?@SLK)I[KD4 1SC@+)DO\HQ0/4WEEH6L@NO 3@>> M="IA(NJ:>"EY2J+@:KZ@R7,Q[]&1I:SD.J+3G3 %CA(N\QI'&9LC<74NPQ? M^$]:SE1U7(=CNE.F1P('8U(-->%27;VA[$C#],?!U=CW\WD>\7C;.6& ^D6* M*/LY(JN5XWB>T&RUJI2J)F>UOR^XGL7 3VWU#.KP(ZE2%961574MUY.E[?U! M>QC583#T.HEG#X3.>: W9:9PS_\,NCGB_4D]'LK;&O'&1F5K(]%<;Y='R)9- M;3HH8I=BH:&N@R&^-:R ) #40Y019?0*<91QDC^F81!Z=#GQ(G([G62)KWE' M35%E2)S(M< 11ZR(5=Q7_D"].&7=G,]Z=#=\ NHBX4IG?W7: )JA.)5Q=7>K M6U%7BCB?AH.-K;Y]75<3QQ+LWHMGFBV22A$D70'BMBI2XSAJ)@326?I&(1QH M-RRD#>A29!0>Y;/W$L[SN?:<[68QU]'4%OMH/.?7HA<.-_(YC$&0;Q9S'0T% M0-ZF%P[(*R/1.4E]&BZ*[(K*@ 2:]\@K#R7D:8 $.NIN&"3I59KF M)+B*33D$M.)\XM2!33 X/9^JJBYJ#UZK8[B M[*(@@N^P$YH6$MXD&=%GT>KJ88B##BL:#03V$)%&&49 ')$>QUD8A%'.-[%> MO<_%BQ_ES/U=,G6+O*A5UO6%1^,PGJ7E('NZ;&] '0RR^M$!V855''#$U=LE MY%%/751=7Q,'TSOH02"SJ2)C*9VW;3M4GLDFW4%%:WZEF O/S9.TX3G09'@MS![.DN8 M = L9-[]G#RJ\]J-6G!]_+(+-1T@LD06\[7S)!;SY%L1P5-W$7EQ( W67K#J M0H-.>1R!RWOF-VG(#YH*2;_$89;>3[YH=[74U5R_DV?*%TPK3+P) ?E;&.-64EZ/B/9@( 40H395O.3<=S_H2;M75 IE['2VV.'?)/<^B2+67[]Y-)"(:-J(JR&J'"/7#5+)K(@52T8BS9*KM6>^B[N#H)_S? M)!@_$^K-R$H7(@X+=1S(P4TZ.YRZU;ANB!CB47Y#]/4?T]5?T[;#52I'J&_. M6?9>;V0"Q@,HJGL\9=BQ81E,+G[::],:\OQ#!=>6LQ)PT\[26OLVHOX@&9PY M;2IV3_A. )N:GR6Q&.9S+[H.ISU-;4"M XWJ9]2S' ,<;>6N&YBS3%KU4M:T MTX"^XBSSV@:S';V+ 1W#,![9M0/]?P8<0?O.[4=UWP$6 ^IW%@/ZBKLS! ,P M'_4\!\_FDR;?_"?M+I2EFYAWNQ_U72>&0Z9RASQP+)EX>// UZ(5QPKXB9PD M)MRHU!F2ZFI#Y*9=$QP)WC79=,F1DN+(6%%97(TDB4(HDKM77EB7VUTKYCH5 M2VE1-?1;-=SEM+HRK;]B$[8P3D/_5R_*C6;-BD;0)SQV40K3_%4D?!T]>BD) MJN> E;E4?VV\MRP:.>6-C*JMH+C[[572VVE5N%6.ZEF2KC:'!0AWWA+XPO*V M[;J<6HC[>NJ574\HWJ?4KF+K!JU.[3E^CJVW5I39["1&,N68#%TID2\ M@IORIQ1?%B$5+:P[B#U7!OBTZ^IN7/0KN$M5T,E+%;$%>()CJ-!.BFJH_&+J7M,"-_ MB-N-M;58N!O:+1W0V+U&LK/U3B2!6K&U3;2=6K$SF/?)=* OT371+!%]QCPF^Q=UQ$W25Q,ZXM[,ZYBIG(N8-S9*75S M$=!?:[%[2+X?8[1VTL+HZ^C=8.^FM4O3/IQU!R$FLC>59Y M?G.P)]_Q]H : MGWOKS2&GYZU^=;#G[/':KNJ0_O=VU%F.DC3#<:<]02'%8(_]X^T96L[WUL\C MF[4/^O@_7OM&>TF *M&C"P1-S;,G0A^>O!4R]=O8Q73NG(UEEUY(Q>65^K=8 ML CG['T@<(P%$UKH_/@6V_NLHS^3E*FNA,H>)#$X?'4)F@/TF>IA;PG<> MJ8$ M<2GEHWA@45'#]>7#1B1HM<'4@28D8FW.F)R?/?J59.QG8._1UW1^Y5J7O@,% M! =]GTC,EOS "A@-;@P$?.N"9]W\6^VB*+$'E[=^;VO>AY,L;!$R<5\$25+ M0L1\]2ZG_A.;%VB9T-9R?M\CH"/ -!]^ZLH]STI0C\Z5(CC&"-#07)&Z.&)G62,C4+=S:RN(@Q]PD%<3A2A%X"LGTXH7X.9^ WTZGH4^H-EE 5L0DS46_Z2LLZWC6%@*S6U9>?,1>91YL69VJ8;Q:"8.G0B[8)CFD=]IU<- M?SA<-7RX:OAPU?!V5PV?N'OG^W#7L-$50N)VH-NI^&LZSK.GA(9_V+D%4/JI MH23H6$-YOXSHV0LC/NQ>)E2W:SE<[U6YMTDE03B,4W2;JS3-27">,R\^*V0NY@[5/@6Y!KQ#6ZZ#^O#Q MLC-0PT]YD>@NAOM^;$35%-!$K"6?;6LB>IB0N(+. 92:7K*;\\J_WU'F96V$ M'KO)@?_V7$? H#-.B.&8D6KO@6PC4F6 [WR\D.RW;884)CD3*6;XM3IZ7D%1 MWO419MA=U5J%+6ULBK$"CK.\N+O[+8UPUNF+R/GT=I_L)YJD-IX047W,W76. M.PM[ZK'>@XEX:]"NOGGPA?>ARH23[VFE&V.[2..L1/#:[_*3O1!_HC%># *Z MNVZQGT"L,TX'[G'%O_@-Q.OEEVXCH+>O.,_7LN]C%>@BLINM[ZXN1X_UO:$6 M-Y/D7X3:D_L JFW4!VY;:X7&:9K/RZ7X@O $$NY[;5@7X)O.406 MUL4OJ_3\-8E8,U&8+>\9W!8&0Y./.S]);'^,-.=B#XWO/DR_7E+"4P/8)N?=GYPWZV_:^,!D=EM/67= M#!/;7B34OP8U+H>Q=*OZH[.G1O.+Q'3X#J/80F_+86R= MQ6MR/4T;@YH!@JAT=ZQPD&WO+,:ZI:)2_.Y#T\YYLY3\5L[# MBM7^*B94)HLRHY05;RD&!=1C.E$B.R>]*+OT: MSY.G(,"\. ]LP %0 @ $WD0 97EE&UL4$L! A0#% @ KHMD29" *TO:&0 3L65S+3(P,38P.3,P7VQA M8BYX;6Q02P$"% ,4 " "NBV1)H-J:W;,K #3$0, %0 M@ &L_0 97EE&UL4$L%!@ & 8 B@$ )(I $ 0 $! end